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The relationship between metastasis-inducing S100 proteins (MIPs) 
and matrix metalloproteinases (MMPs) in rat and human breast cancer 
Morteta H. Al-Medhtiy 
Abstract 
Breast cancer metastasis is the most common cause of death amongst 
females worldwide. The presence of metastasis-inducing proteins such as S100P or 
S100A4 in primary breast tumours has been reported to be associated with a 
reduction in patient survival times in vivo and these proteins enhanced cell migration 
and invasion in vitro as well. However, the pathway of S100P/A4 in inducing 
metastasis or cell migration/invasion is still controversial and not clear. To investigate 
the role of matrix metalloproteinases as mediators of S100P/A4-stimulated cell 
migration/invasion, human HeLa and rat mammary 37 (R37) and S100P/A4 
overexpressing cell lines (R37-S100P/A4) were used to demonstrate levels and 
activities of matrix metalloproteinases (MMPs) using antibody arrays, zymography 
and Western blots. siRNAs to specific MMPs and direct addition of S100 proteins 
were used to measure effects on cell migration and invasion. Primary tumours from 
183 breast cancer patients were immunohistochemically stained to investigate the 
association between MMPs and S100 proteins and their effect on patients’ survival 
times using relative association and Cox’s multivariate regression analysis. In vitro, 
R37-S100P/A4 cells significantly (P≤0.035) produced only MMP-2, -9 and -13. In 
addition, MMP-2 and MMP-13 showed significant (Student’s t-test, P≤0.031) 
proteinase activity (active and pro forms) on specific substrates, but MMP-9 showed 
only the inactive proform. Knock-down of each MMP significantly reduced R37-
S100P/A4 cell migration and invasion (P≤0.037). Extracellular additions of S100P/A4 
to R37 cells caused significant increases in these same MMPs (P≤0.026) and in cell 
migration and invasion (P≤0.025). RAGE receptor levels were expressed significantly 
higher in invasive carcinoma R37-S100P/A4 cells compared to control R37 cells. When 
the RAGE receptor was inhibited, it caused a significant reduction in R37-S100P/A4 
(P≤0.037) or S100P/A4-treated R37 wt cell (P≤0.007) invasion. In vivo, the presence 
of one of S100P, S100A4, MMP-2, MMP-9 and MMP-13 showed significant reduction 
in patients’ survival times. There was a strong association between MMPs and 
S100P/S100A4 and both S100 proteins partially confounded the MMPs effect on 
patients’ survival times and death-risk. Since manipulation of the levels of S100P/A4 
and the three MMPs caused changes in cell migration/invasion, the three MMPs are 
probably some of the S100 downstream effectors, particularly for cell invasion. 
Moreover, there was more association of one S100 protein with a particular MMP in 
cultured cells and in human breast tumours, suggesting that different S100 proteins 
are likely to promote selective enhancement of individual MMPs. This conclusion may 
explain the observed synergistic effect (Wang et al., 2006) of the combination of 
S100P and S100A4 on early patient demise in breast cancer.
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 Breast cancer  
 
The most commonly diagnosed cancer, which causes death among women 
worldwide is breast cancer (Moravkova et al., 2016). The three most common cancers 
are breast, lung, and colorectum, which collectively represent one-half of all cases; 
breast cancer alone accounts for 30% of all new cancer diagnoses in women (Siegel 
et al., 2018). Metastasis is the greatest cause of breast cancer mortality in females. 
Breast cancer is a malignant tumour, which begins in the cells of breast tissues. This 
type of cancer is able to invade and spread beyond its original location (metastasise) 
and to populate other organs in the body, such as the liver, brain or bone (Cancer 
Facts & Figures, 2014). Unfortunately, metastasis can occur early in the development 
of cancer. Therefore, there is an urgent need to stop and/or reduce metastasis in 
breast cancer at an early stage, before it becomes life threatening.  
1.1.1  Breast cancer subgroups 
 
Previously, breast cancer has been divided into two main groups: 80-90% 
ductal carcinoma and  5-15% lobular carcinoma, both typically initiated from the 
terminal ductal lobular units (de Silva Rudland et al., 2011; Wellings et al., 1975). 
Recently, by using microarray gene expression profiling  techniques, breast cancer 
has been divided into five subgroups; two luminal-like (A and B), one ERBB-2 type 
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(HER2-overexpressing), one normal breast tissue-like and one basal-like category 
(Sorlie et al., 2003). The luminal type subgroups present some similarities to the 
expression of mRNAs which exist in normal luminal epithelial cells and both are 
positive for estrogen receptor α (ERα) using immunohistochemistry (IHC).  The ERBB-
2 subtype produces large amounts of the c-erbB-2 receptor, this protein is identified 
by IHC and by amplification of its gene using FISH (fluorescence in situ hybridization). 
The normal breast tissue-like subtype expresses genes entirely typical of normal 
luminal epithelial cells and contains less ERα compared to the Luminal A and B 
subtypes. The basal-like subtype produces the stratified epithelial cytokeratins CK5/6 
and CK14 which are usually found in basal epithelial and myoepithelial cells of the 
breast (Moll et al., 1982; Sorlie et al., 2003). The basal-like subtype lacks other 
markers, like smooth muscle actin/myosin which are usually observed in completely 
differentiated myoepithelial cells (Rudland et al., 1993). Researchers have found that 
the protein markers CK5/6 and CK14 of the basal-like subtype are associated with 
high grade breast cancer and poor patient prognosis (de Silva Rudland et al., 2011; 
Fan et al., 2006). But what actually kills patients is the process of metastasis. 
 Metastasis 
 
Metastasis is a complicated process and is still the greatest challenge in the 
management of cancer (Figure 1.1). In fact, metastasis may occur after many years 
from first diagnosis, or before the first diagnosis of primary cancer. There are several 
hypotheses to explain the metastatic process, but none of these entirely explain the 
biological and clinical events (Nguyen, 2004). In general, a cancer cell is required to 
follow a sequential series of steps, before it establishes itself at a secondary cancer 
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site. Usually, but not always, these steps involve detachment from the primary 
tumour, invasion throughout the adjacent tissues, access to, survival in and exit from 
circulatory (blood and lymphatic) systems or even in the peritoneal space, and finally 
survival and growth  in a secondary target (Al-Mehdi et al., 2000).  
Patients with only a primary tumour have a better prognosis compared to 
those with an additional metastasis (Nguyen, 2004; Stetler-Stevenson et al., 1993). 
The initial steps of metastasis are believed to occur as an early event, often even 
before the diagnosis of the primary tumour (Schmidt-Kittler et al., 2003). Therefore, 
metastasis is the most important aspect in the clinical management of cancer after 
removal of the primary tumour. The next step in the description of metastatic cancer 








Figure 1.1: Illustration of the most common steps which metastatic breast cancer 
cells follow to migrate and localise in a distant organ. This figure was modified from 
Nguyen (2004).  
 
1.2.1 Metastasis-inducing proteins (MIPs) 
 
Metastasis-inducing proteins (MIPs) have been discovered in experimental 
rodents and these proteins can induce the metastatic process. These MIPs include 
S100A4 (Davies et al., 1993) , osteopontin (Oates et al., 1996), anterior gradient-2 (Liu 
et al., 2005) and S100P (Wang et al., 2006). The metastasis-inducing proteins (MIPs) 
also occur in normal tissue, but much more is known about them in relation to cancer 






1.2.2 S100 protein family 
 
The name S100 is derived from the ability of most members of this family to 
be soluble in 100% (w/v) ammonium sulphate at neutral pH (pH 7.0-7.5) (Deloulme 
et al., 2002; Moore, 1965). The first member of the S100 family of proteins was 
identified in bovine brain (Moore, 1965). This family has 25 members in humans 
(Moravkova et al., 2016), which consists of 16 S100A (S100A1-S100A16) as well as 
others, such as S100B, S100G, S100P and S100Z (Gross et al., 2014). They are 
characterized by being low-molecular-weight acidic polypeptides (9-13 kDa) 
(reviewed in Donato, 2003; Gross et al., 2014; Bresnick et al., 2015; Moravkova et al. 
2016). The most common feature of all the S100 proteins is a pair of calcium-binding, 
helix-loop-helix domains which include EF hand, calcium-binding regions situated 
towards the protein termini; they are divided by a hinge region (Gross et al., 2014). 
S100 proteins have been reported to possess a wide spectrum of substantial 
intracellular and extracellular functions (Moravkova et al., 2016).   
The presence of some of these S100 proteins, e.g., S100P and S100A4 in the 
primary breast tumour shows a strong correlation with early death of patients and, 
therefore, a poor prognosis in cancer patients (Rudland et al., 2000; Wang et al., 
2006), in part, due to their ability to induce migration of cancer cells to a secondary 
location (Jenkinson et al., 2004; Wang et al., 2006). Increased expression of certain 
S100 proteins has been reported in several types of cancer, such as those of the 
breast, lung, bladder, kidney, thyroid, stomach, prostate and oral cancers (Salama et 
al., 2008). A recent study has suggested that expression of S100 proteins in cancerous 
tissues and serum of patients might be used as a diagnostic and prognostic marker 
and as a target for therapy (Moravkova et al., 2016). When introduced into 
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experimental syngeneic animal models, overexpression of S100A4 can enhance 
metastatic potential of a benign rat mammary (Davies et al., 1993) and bladder 
tumour (Levett et al., 2002) cell line. Moreover, overexpression of S100P can promote 
tumour growth in many other tumour models, such as those from the lung, prostate, 
colorectum, pancreas, as well as tumour cell proliferation in certain animal cells 
(Bresnick et al., 2015; Wang et al., 2006). In contrast, other members of the S100 
family can cause tumours to be suppressed,  for example S100A2 in malignant 
melanoma (Maelandsmo et al., 1997), in prostate (Maelandsmo et al., 1997), lung 
(Feng et al., 2001) and in breast cancer (Liu et al., 2000).  
1.2.2.1 S100A4 protein  
S100A4 (11 kDa protein with 101 amino acids) has been reported to be a 
biomarker for poor patient outcome in cancer prognosis, such as breast (Rudland et 
al., 2000) and colorectal cancer (Gongoll et al., 2002). The nuclear expression of 
S100A4 is also reported to be a prognostic marker for colorectal cancer (Boye and 
Maelandsmo, 2010). The association between patient survival times and expression 
of S100A4 has been reported in many types of cancers, including pancreatic cancer, 
non-small cell lung cancer, stomach cancer, ovarian carcinoma (reviewed by Boye and 
Maelandsmo, 2010). S100A4 can increase cell motility and invasion in cancer cell lines 
of the breast, colorectum, pancreas, lung and esophageal squamous epithelium 
(Jenkinson et al., 2004). In vitro, S100A4 expressed intracellularly can regulate cell 
motility in renal proximal tubular epithelial cells via epidermal growth factor (EGF) 
and TGF-β1 stimulation, which can lead to more elongated cells (mesenchymal, 
fibroblastic morphology) (Okada et al., 1997; Strutz et al., 1995). In vivo S100A4 can 
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induce invasion of epithelial cells into the mammary fat pad by branching 
morphogenesis via TGF-β-related pathways (Gross et al., 2014), possibly mediated by 
matrix metalloproteinase-3 (MMP-3) (Andersen et al., 2011). Overexpression of 
S100A4 in tumour cells in vitro led to significant changes in the cells’ architecture, 
producing a more mesenchymal behaviour of the cells (Davies et al., 1993). This 
change occurred via reorganization of the cytoskeleton and motility-related 
protrusions, with significantly  increased numbers of lamellipodial projections, some 
to focal adhesions on the leading edge of the cell (Li and Bresnick, 2006). These 
changes are caused predominantly by the binding of intracellular S100A4 to non-
muscle myosin IIA. Addition of S100A4 to cultured cells could also enhance cell 
motility of the smooth muscle cells of human pulmonary arteries (Li and Bresnick, 
2006). The enhancing activity of exogenously-added S100A4 may be due to the 
release and stimulation of MMP-13 (Vicente-Manzanares et al., 2007), perhaps via 
specific cell surface receptors such as annexin 2/plasmin (Semov et al., 2005) and/or 
RAGE (Lawrie et al., 2005).  
1.2.2.2  S100P protein  
S100P is another member of the S100 protein family and consists of 95-amino 
acids. Its overexpression has been associated with drug resistance, metastasis and 
poor clinical outcomes (Arumugam and Logsdon, 2011). It was originally  purified 
from placenta, hence the P designation (Becker et al., 1992). S100P has a unique 
location on human chromosome 4q16, while most other members of the S100 
protein family are juxtaposed together on human chromosome 1 (Schäfer et al., 
1995). S100P has been reported to be associated with poor clinical outcomes in 
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several types of cancer, such as breast, colon, pancreas, prostate and lung cancer 
(reviewed in Arumugam & Logsdon, 2011). 
S100P, in common with S100A4, enhances cellular motility in several various 
diseases, such as cancer (Du et al., 2012) and is increased in endometriosis 
(Hapangama et al., 2012). In pancreatic cancer, S100P is one of the most frequently 
overexpressed genes which might make it a useful histological marker (Schäfer et al., 
1995). In breast cancer, activation of c-ERB-B2 enhances breast cancer cells to 
express S100P (Mackay et al., 2003). Overexpression of intracellular S100P in a 
human breast cancer cell line is able to enhance cellular motility (Zhou et al. 2012). 
In vivo, upregulating the level of intracellular S100P by overexpression from 
transgenes enhanced cell invasion and metastasis (Barry et al., 2013; Wang et al., 
2006), while down regulation of expression of S100P leads to a reduction in both cell 
migration and formation of secondary lesions (Jiang et al., 2011). S100P protein is 
associated with a decrease in patients’ survival times in human breast cancer, and 
when overexpressed, induces metastatic properties in otherwise benign rat 
mammary tumour cells (Wang et al., 2006). Like S100A4, S100P also can directly 
interact with non-muscle myosin IIA to cause an increase in cell motility (Du et al., 
2012). Moreover, expression of S100P intracellularly in cancer cells has been linked 
to promoting destabilization of DNA methylation patterns by hypomethylation of 
specific genes (Sato et al., 2004).    
Addition of extracellular S100P has been reported to activate intracellular 
signalling via binding to extracellular receptors of advance glycation end protein 
(RAGE), and in this way it might also increase tumour growth, drug resistance and 
metastasis in pancreatic and colon cancer cell lines (reviewed in Arumugam & 
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Logsdon 2011). A further study on MKN45, and Kato III (human carcinoma cell lines 
derived from the stomach) has shown that when S100P was overexpressed in isolated 
tumour samples, it can function both via intracellular and extracellular pathways 
(Namba et al.2009). This latter study also found that up-regulation of S100P could be 
caused by addition of non-steroidal, anti-inflammatory drugs (NSAIDs) like celecoxib.  
This up-regulation of S100P was suppressed by silencing the activating transcription 
factor 4 (ATF4). Silencing this factor resulted in a suppression of the cells’ invasive 
ability, which may happen due to suppression of the S100P-RAGE interaction, cell 
growth and level of MMP-9 expression (Namba et al.2009). Thus, the S100 proteins 
are important in promoting the process metastasis and the next step is to investigate 
their main downstream targets, one of these is the family of proteases known as 
matrix metalloproteinases (MMPs) (Berge and Mælandsmo, 2011; Mishra et al., 
2012; Saleem et al., 2006). 
  Matrix metalloproteinases (MMPs) 
 
MMPs are family of zinc-dependent and calcium-containing endopeptidases, 
which are able to degrade most of the components of the extracellular matrix (ECM) 
such as elastin, collagen, fibronectin, laminin, gelatin and vitronectin (reviewed in 
Liotta et al., 1980). This family has 26 members, some of which can be produced by 
the cancer cells themselves; for example MMP-2 and MMP-9 are secreted by cervical 
and ovarian cancers, respectively (Roomi et al., 2010). Some MMPs are secreted by 
the cells immediately surrounding the tumour. For example, MMP-13 is expressed by 
stromal cells immediately adjacent to the tumour cells, as well as in the cancer cells 
themselves in breast cancer (Leeman et al., 2002). Therefore, the reactive stromal 
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cells round a beast tumour may participate in degradation of the extracellular matrix 
and basement membrane (Salamonsen, 1996). Thus, MMPs from both cancer cells 
and host stromal cells may play a significant role in remodelling and degradation of 
the extracellular matrix (ECM).  
MMPs are classified according to their substrate specificity into matrilysins, 
stromelysins, gelatinases and collagenases (Table 1.1). The MMPs in general have 
four prominent domains: the N-terminal pro-domain; the catalytic domain which is 
approximately spherical with a diameter of roughly 40 Å and is almost the same in all 
types of MMPs; the hinge region; and the C-terminal hemopexin-like domain. The last 
domain may be responsible for interaction with tissue inhibitors of 
metalloproteinases (TIMPs) and appears to be regulating the enzymic activity of most 
of the MMPs, except MMP-7 and MMP-26 (reviewed in Verma and Hansch, 2007). 
Additionally, the membrane type of MMPs (MT-MMPs) have transmembrane and 
cytoplasmic domains (Cathcart et al., 2015; Sela-Passwell et al., 2010; Skiles et al., 
2000; Verma and Hansch, 2007) (Figure 1.2). 
In pathological processes, MMPs have a crucial role in cancer cell invasion, 
migration and tumorigenesis (Liotta et al., 1980; Stetler-Stevenson, 2001, 1990). 
MMP-2 and MMP-9 are reported to play a critical role in invasion and metastasis in 
breast, cervical and ovarian cancers (Freije et al., 1994; Roomi et al., 2010). MMP-2 
and MMP-9 are gelatinases (gelatinase A and gelatinase B, respectively) that cleave 
relatively-unwindable collagen fibrils of both collagen I and III, which themselves have 
been previously cleaved by other collagenases, e.g. MMP-1, 8 or 13. Moreover, 
gelatinases are able to cut other types of nonfibrillar collagens and extracellular 
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matrix elements such as collagen IV, small-diameter fibrillary collagen V, epithelial-
anchoring collagen VII and elastin (Birkedal-Hansen, 1995). 
 
 
Table 1.1. Subgroups of MMP family with their respective substrates a. 
 
 
a Schmidt-Hansen et al. 2004; Snoek-van Beurden & von den Hoff, 2005. 
b Matrix metalloproteinase.  
c Membrane type of matrix metalloproteinase.  
d Xenopus laevis matrix metalloproteinase is an additional insertion of approximately 30 
amino acids between the pro-domain and the catalytic domain of MMP (Ahokas et al., 2002).  
e Cloned matrix metalloproteinase from cultured primary chicken embryo fibroblasts (Yang 
and Kurkinen, 1998). 
12 
 
Another MMP often reported in human cancer is MMP-13. MMP-13 (54, 60 
kDa) is a member of the collagenase subfamily. MMP-13 is reported to be secreted 
by reactive tumour stromal fibroblast-like cells, e.g., myofibroblasts (Crawford and 
Matrisian, 1996; Engelholm et al., 2001; Nielsen et al., 2001), as well as by the tumour 
cells themselves (Nielsen et al., 2001), e.g., invasive breast carcinoma cells (Balduyck 
et al., 2000). MMP-13 produces a single cleavage in a small section of unwound triple 
helix of fibrillar collagen I, II and III. This cleavage allows comprehensive denaturation 
of the native, tight, triple helix form of fibrillar collagens which, in turn, allows further 
digestion by the gelatinases into small soluble peptides (Armstrong and Jude, 2002; 
Stechmiller et al., 2010). How this digestion process occurs is described in the next 
section. 
 
Figure 1.2. The structural form and domains of MMP members. Abbreviations: 




1.3.1 Molecular activation of MMPs 
 
Activation of MMPs is regulated at several levels, starting with gene 
transcription and the synthesis of proenzymes. Moreover, their activity is usually 
terminated by TIMPs which can inhibit the active MMPs and underpin substantial 
regulatory processes (Springman et al., 1990; Van Wart and Birkedal-Hansent, 1990). 
MMPs are first produced as an inactive zymogen, which requires activation. The 
propeptide domain possesses a cysteine residue (Cys), which acts as a stabilizer of 
the proMMP. The catalytic domain has a Zn2+ binding site which binds to the Cys 
forming the pro-form of MMP. Activation occurs when the bond between Cys - Zn2+ 
breaks, and this mechanism is called “the cysteine switch”. After the cysteine switch, 
a water molecule binds to the Zn2+ ion to replace the cysteine residue and converts 
the noncatalytic zinc to a catalytic zinc, leading to creation of an intermediate active 
form of enzyme. In addition, full activation occurs when the propeptide becomes 
removed by autolytic cleavage or by the action of other enzymes. Usually the 
molecular weight of the cleaved part is about 8-10 kDa , which results in an active 
enzyme with lower molecular weight compared to the proenzyme form(Park et al., 
1991; P. A. M. Snoek-van Beurden and Von den Hoff, 2005). 
1.3.2 Cellular activation and inhibition of MMPs  
 
Activation steps can be accomplished by endopeptidases, catalysed by other 
MMPs and by several inorganic compounds. MMP-13 (collagenase-3) assumes a key 
position in the MMPs’ activation processes and results have been obtained from 
more than one human cell line (Leeman et al., 2002). MMP-13 is formed first as a 
zymogen and activation occurs by cleavage of the N-terminal propeptide by 
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autoproteolytic activity, as is the case for other MMPs and by other inductive factors 
such as circulating hormones. In normal physiological conditions, tissue inhibitors, 
TIMPs are capable of inhibition of MMP-13 in a 1:1 molar ratio, but this ratio can be 
changed in pathological conditions (Leeman et al., 2002). Stromelysin-1 (MMP-3) is 
able to activate proMMP-13 in a concentration-dependent manner (Knäuper et al., 
1996). MMP-2 (gelatinase-A) and membrane-type metalloproteinase (MT1-MMP) 
are also able to activate proMMP-13 to a fully active form (Knauper et al., 1996).  The 
activation process for proMMP-13 by MT1-MMP is enhanced by the presence of 
proMMP-2, thereby demonstrating a distinctive new activation cascade involving 
three members of the MMP family. During the activation process of proMMP-13 by 
MT1-MMP, the latter also generates active MMP-2 which, in turn, contributes to 
forming active MMP-13 (Knauper et al., 1996).  
Fibroblasts express MT1-MMP when stimulated by concanavalin-A. 
Fibroblast-derived plasma membranes are able to activate an intermediate form of 
MMP-13 to full activation in the presence of proMMP-2  (Knauper et al., 1996; 
Matthew F. Leeman et al., 2002). Plasmin activates MMP-13 by cleaving the N-
terminal propeptide domain. In addition, autoproteolysis occurs; this leads to release 
of the rest of the propeptide domain at the N-terminus and results in active MMP-13 
(Knauper et al., 1996). Active MMP-9 (gelatinase-B) is generated when MMP-2 and 
MMP-13 are activated (Knauper et al., 1997). In a human chondrosarcoma cell line 
SW1353, MMP-1 (collagenase-1) and MMP-13 (collagenase-3) were shown to have 
separate independent mechanisms for activation. Activation of MMP-1 is 
independent of the activation pathways of MMP-2, MMP-9 and MMP-13 (Cowell et 
al., 1998). Finally, hormones such as parathyroid hormone can influence the ratio of 
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MMP-13 degradation and activation (Leeman et al., 2002; Orgaz et al., 2014), 
presumably indirectly by influencing gene transcription and thereby protein 
degradation. 
 Breast cancer metastasis and the relationship between matrix 
metalloproteinases and metastasis-inducing proteins S100P and 
S100A4 
 
There are several barriers that cells must pass through to reach the secondary 
tumour site during the metastatic process. One of the major barriers is a continuous 
collagen-containing structural barrier produced around and in response to the 
tumour; this barrier also exists naturally in several organs of the body. Thus, invasion 
and spread of tumour cells within the primary tissue need degradation of the 
extracellular matrix (ECM) and other insoluble proteinaceous molecules by a 
sufficient number of degradative enzymes (Barsky et al., 1983; Kim et al., 2012). 
Moreover, intravasation and extravasation processes require the breakdown of the 
ECM and basement membrane barriers which underlie endothelial cells, before the 
cancer cells can enter or leave the circulatory systems, respectively, prior to their 
deposition at secondary sites. In addition, tumour-associated host cells, particularly 
the surrounding  stromal tissue and tumour- infiltrating immune cells, may also play 
crucial roles in producing some of these degradative enzymes (Barsky et al., 1983; 
Chambers and Matrisian, 1997). There have been many studies in the past that have 
shown that malignant tumour cells can produce enhanced proteolytic activity which 
is efficient in degrading collagen in vitro (e.g. Salo et al., 1982). The development of 
biochemical and molecular biological techniques have helped to identify individual 
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proteases in the tumour and many may play crucial roles in these digestive activities 
(Salo et al., 1982). The major classes of proteases which have been associated with 
malignant tumours are serine, aspartic, cysteine, threonine and metalloproteinases 
(Brünner et al., 1994).  
Perhaps the most important proteases in cancers are the MMPs, since they 
are able to degrade the ECM and basement membrane, the principle components 
through which the cancer cells have to pass. Type IV collagen is the main structural 
protein in basement membranes (Kalluri, 2003; Tanjore and Kalluri, 2006). MMP-2 
(Gelatinase A) or MMP-9 (gelatinase B) is responsible for degradation of type IV 
collagen; they possess molecular weights of 66 - 72 kDa and 82 - 92 kDa, respectively. 
The most common three subgroups of MMPs found in cancers can be identified by 
their substrate preferences: the collagenases (e.g. MMP-13, 54 - 60 kDa), the 
stromelysins (MMP-1, 10 & 11), and gelatinases (e.g. MMP-2 and MMP-9). The 
collagenases digest fibrillar collagens, stromelysins degrade 
proteoglycans/glycoproteins, and gelatinases digest nonfibrillar collagens (gelatin) 
(Table 1.1) (reviewed in Chambers and Matrisian, 1997; Stechmiller, Cowan and 
Schultz, 2010) Thus, one promising target for the treatment of cancer are the matrix 
metalloproteinases or MMPs. There is also a strong association of specific MMPs e.g., 
MMP-2, MMP-9, MMP-13, MMP-1 and MMP-7 with malignant tumour pathologies 
(Verma and Hansch, 2007). Therefore, there is an urgent need to examine the 
production of active MMPs and their relationship with other major players that can 
induce metastasis, particularly the most widespread proteins in metastatic cancers, 
the S100 proteins, S100A4 and S100P. 
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The direct relationship between S100 proteins and the MMPs has been 
established in two different ways. Firstly, by overexpressing the S100 proteins 
intracellularly in tissue cultured cells and secondly by directly adding exogenously the 
S100 proteins to noncancerous cells (Bresnick et al., 2015). Thus, when S100A4 is 
overexpressed in a transgenic adenocarcinoma of the mouse prostate (TRAMP) 
model, its overexpression is associated with metastasis (Saleem et al., 2006) and with 
the level of gene expression and proteolytic activity of MMP-9 and its tissue inhibitor 
TIMP-1. There is also a positive correlation between overexpression of S100A4 and 
of MMP-13 in a breast cancer cell line MDA-MB-231 in vitro and in vivo (Wang et al., 
2012). Thus, upregulation of S100A4 can cause an increase in MMP-13 and this 
increase led to increased cell migration and angiogenesis in the MDA-MB-231 breast 
cancer cell line. However, although downregulation of S100A4 by siRNA treatment 
lead to the anticipated downregulation of MMP-13, it produced cells with little 
significant effects on cell migration and angiogenesis (Wang et al., 2012), suggesting 
involvement of other factors. These studies suggest that the invasion process may be 
regulated, in part, by intracellular S100A4, in turn regulating MMP-13 levels, at least 
in model breast cancer systems. Furthermore, genetic studies in a Drosophila model 
have shown that overexpression of mutant Ras Val12 and S100A4 increased the 
activation of the stress kinase JNK and the level of Drosophila MMP-1; all these 
components in that order were required to enhance greatly invasion and metastasis 
(Ismail et al., 2017). 
When S100A4 was added extracellularly to the human pancreatic cancer cell 
line BxPC3, it stimulated the IκB signalling pathway and MMP-9 secretion, which in 
turn lead to stimulation of cell proliferation and invasion  and mAbs against S100A4 
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block these activities (Dakhel et al., 2014). Moreover, when Zhang et al. (2011) added  
S100A4 extracellularly to endothelial cells, it stimulated angiogenesis by the  
paracrine  production of MMP-13, and thereby facilitated cell invasion into the 
surrounding tissue (Ambartsumian et al. 2001; Schmidt-Hansen et al. 2004; Sack & 
Stein 2009; Donato et al. 2013).  
It appears that S100 proteins may function both intracellularly and 
extracellularly in the same system. Thus, when intracellular S100P was induced from 
a transfected transgene in Rama 37-T25 or HeLa-A3 cells, substantial changes 
occurred in cytoskeletal organisation in vitro in both rat mammary or in human 
cervical cancer HeLa cells. These changes, in turn, created a disturbance in the 
formation and stability of cellular focal adhesions (FA). The combination of the 
changes in the cytoskeleton and FA was responsible, in part, for the observed 
increase in cell migration (Du et al., 2012). However, when 100 nM S100P was added 
externally to uninduced Rama 37-T25 or HeLa-A3 cells, it failed to produce a 
significant increase in cell migration, but instead caused   a very significant increase 
in cell invasion through a collagen I artificial matrix (Du et al., 2012). This result 
suggested that extracellularly-added S100P stimulated an unknown product which 
could partially digest the artificial collagen I matrix in the Boyden chambers, most 
likely a protease like the MMPs. Thus, intracellular and extracellular S100A4 or S100P 
from both tumour and host stromal sources, respectively, can mediate breast cancer 
progression and metastasis in a model system. The types of stromal cells which 
contribute to S100-mediated cancer dissemination are not well described. But both 
reactive myofibroblasts and endothelial cells produce S100A4 and additionally 
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endothelial cells secrete MMPs (Bresnick et al., 2015), so any one or both these cell 
types could make such a contribution in vivo. 
Zhang et al., (2011) found overexpression of S100A4 mRNA and increased 
levels of MMP-9 proteolytic activity in specimens from 16 osteosarcoma patients who 
had lymph node or distant metastases. Moreover, in specimens of human breast 
cancer, the levels of MMP-2, MMP-9 or MMP-13 alone correlated with patient 
demise from metastatic disease and these MMPs were produced in the same cells as 
those expressing S100A4 (Ismail et al., 2017). The most frequent reports of links 
between S100 proteins and MMPs concern MMP-13 (Uría et al., 1997; Wang et al., 
2012), followed by MMP-9 and MMP-2 (Dakhel et al. 2014; Freije et al. 1994; Roomi 
et al. 2010). Finally, studies by Yammani et al. (2006) have shown that S100A4 can 
bind to a receptor called RAGE and its binding can stimulate the expression of MMP-
13 by a signalling cascade in human articular chondrocytes. The RAGE receptor would 
appear to be one of the main initial targets for surface-acting S100 proteins (Leclerc 
et al., 2009).   
 Receptor for advanced glycation end products (RAGE) and S100 
proteins/MMPs 
 
1.5.1 RAGE receptor  
 
The receptor for advanced glycation end products (RAGE) is a receptor 
capable of binding to advanced glycation end product proteins (AGEs). RAGE occurs 
at the cell surface and is defined as a single transmembrane multi-ligand receptor of 
the immunoglobulin gene superfamily (reviewed by Chuah et al. 2013). This receptor 
is capable of binding to diverse ligands, these ligands lack sequence similarities due 
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to RAGE’s ability to recognize three-dimensional structures instead of specific amino 
acid sequences (reviewed by Chuah et al. 2013). The RAGE receptor consists of an 
intracellular tail domain, transmembrane domain, two C-type domains (C1 & C2 type) 
and an N-terminal V-type domain. The V-type domain is the active site responsible 
for interaction with potential extracellular ligands  (Bopp et al., 2008; Chuah et al., 
2013; Schmidt et al., 2001).  
RAGE receptor was discovered in 1992 and since that time it has been 
reported to be involved in a broad spectrum of human diseases such as diabetes, 
chronic inflammation, Alzheimer’s disease (Leclerc et al., 2009), cardiovascular 
diseases, osteoarthritis and most importantly cancer (Xie et al., 2013), particularly 
breast cancer (Radia et al., 2013). In breast cancer, the role of RAGE in tumour 
development and cell proliferation is still unknown, but its expression levels are 
associated with the degree of severity of the disease (Radia et al., 2013). This receptor 
has been reported to be highly expressed throughout normal development, 
predominately in the brain, but its expression level falls in aged and mature tissues. 
Thus, low levels of RAGE have been found in neurons, uterus smooth muscle, kidney 
glomerulus mesangial cells, mononuclear phagocytes, hepatocytes and cardiac 
myocytes, while in lung and skeletal muscle tissues with appreciable turnover rates, 






1.5.2 RAGE-S100 protein interactions and MMPs 
 
As stated above RAGE can be stimulated by many ligands such as advanced 
glycation end products (AGE) (Schmidt et al., 1992), β-amyloid peptide (Deane et al., 
2003), amphoterin (HMGB1) (Hori et al., 1995), and members of the S100 protein 
family (Hofmann et al., 1999; Schmidt et al., 2000). The specific S100 proteins that 
can interact with the RAGE receptor include the following: S100B, S100A1, S100A2, 
S100A4, S100A5, S100A6, S100A7, S100A8, S100A9, S100A11, S100A12, S100A13 and 
S100P (Leclerc et al., 2009). How S100 proteins are secreted extracellularly is still 
controversial, due to their lack of a signal peptide for secretion via the traditional 
Golgi apparatus-mediated pathway. Also, the reasons for their occurrence 
extracellularly is still controversial, particularly whether they are secreted somehow 
from living cells  or are released from dying lysed cells (Bresnick et al., 2015). 
Nevertheless, studies by Perrone et al. (2008) showed that secretion of S100B could 
occur in secretory vesicles and this process required phosphorylation of caveolin-1 
and depended on endocytosis of the RAGE receptor. Recent studies by Leclerc & 
Vetter (2015) suggested that RAGE receptor and S100 protein ligands have crucial 
roles to play in the progression of pancreatic ductal adenocarcinoma (PDAC), and this 
study indicated that the potential RAGE ligands, S100P and S100A6, were highly 
expressed in pancreatic-tumour compared to their control samples. An investigation 
by Arumugam & Logsdon (2011) revealed that, when extracellular S100P bound to 
the RAGE receptor and stimulated cellular signalling, it could also stimulate drug 
resistance, tumour growth and metastasis in pancreatic cancer cells. Moreover, when 
S100P was added extracellularly to SW480 human colon cancer cell lines, it enhanced 
cell growth, migration, and both Erk1/2 phosphorylation and NFκB activation 
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(Fuentes et al., 2007). Moreover, when S100P was added to SW480 cells, they 
showed an increased expression of RAGE protein, which may indicate that the RAGE-
S100P complex was the key to simulating activation of NFκB and phosphorylation of 
Erk1/2 (Fuentes et al., 2007). Conversely when the S100P-RAGE interaction is 
inhibited, this led to significantly decreased NFκB activation, cell growth and invasion 
in pancreatic cancer cells (BxPC-3) (Arumugam et al., 2006). However, experimental 
evidence to support individual pathways has not been reported. Moreover, the 
S100P-RAGE reaction could control oncogenic miR-21 levels in SW480 human colon 
cancer cell lines. Thus, when S100P was added extracellularly to SW480 wild type 
cells, this led to upregulation of miR-21. In contrast, silencing S100P in overexpressing 
SW480-S100P cells reduced level of miR-21. Finally when the RAGE receptor was 
blocked with anti-RAGE antibody, this caused a decrease in the inductive effect of 
S100P on miR-21 (Mercado-Pimentel et al., 2015). The oncogene miR-21 also reduced 
the level of the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) in 
U87MG glioma cells (Chen and Tseng, 2012; Gabriely et al., 2008). RECK is a gene 
responsible for inhibiting tumour and metastatic activity and can inhibit many matrix 
metalloproteinase such as MMP-2 and MMP-9 which are usually upregulated in 
tumour formation, angiogenesis and metastasis (reveiwed in Noda & Takahashi 
2007). In summary, exogenous S100P added to human colonic cancer cell lines could 
supress RECK protein levels due to upregulation of miR-21 (Mercado-Pimentel et al., 
2015) and RECK’s involvement could also be one reason why  several MMPs were 
upregulated in different cancers.   
In common with S100P, the S100A4-RAGE receptor interaction has been 
implicated in progression of many cancer, such as in human colorectal cancer (CRC) 
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(Dahlmann et al., 2014). This report showed that interaction of extracellular S100A4 
with the RAGE receptor in cultured cells enhanced their motility and metastatic 
potential. Moreover, the S100A4-RAGE receptor interaction may have a role to play 
in promoting metastatic activity in human melanoma cells (A375) (Herwig et al., 
2016). This study showed that when extracellular S100A4 was added to the A375 
human melanoma cells stably transfected with the vector for RAGE cDNA (A375-
hRAGE), the resultant cells showed enhanced cell motility, adhesion, migration and 
invasion. Extracellular S100A4 promoted cell migration in human umbilical vein 
endothelial cells (HUVEC) by interacting with RAGE. The S100A4-RAGE interaction led 
to signalling through  activation of  ERK1/2 and thence NFκB pathways, and activation 
of MMP-9 to enhance the migratory response in HUVECs (Hernández et al., 2013). 
Moreover, the stably transfected human melanoma cell line overexpressing S100A4 
(A375-hS100A4), was shown to secrete S100A4 extracellularly by an endoplasmic 
reticulum-Golgi apparatus- dependent pathway. The use of this secretion pathway 
by S100A4 was proven by using different types of inhibitors. Thus, Bafilomycin A1 was 
used to block a vacuolar H+ - ATPase, which defined the type of vehicle-carrying 
protein; Brefeldin A was used as a blocker of the conventional ER-Golgi secretion 
pathway; Cytochalasin B was used to block the actin filament-dependent pathway; 
and Nocodazole was used to depolymerize microtubules and inhibit the tubulin-
dependent route. Another study in a melanoma cell line showed that S100A4 and 
S100A9 could be released extracellularly from the surrounding stromal cells and by 
signalling through the RAGE receptor and the extracellular MMP inducer EMMPRIN, 
respectively, they caused a stimulation of NFκB. NFκB, in turn, enhanced indirectly 
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cell expression of cytokines and MMPs which, once again in turn, boosted  cell 
invasion and metastasis (Bresnick et al., 2015).  
In summary, S100P and S100A4 have been reported to be involved in 
metastasis in a variety of cancers. Also, the RAGE receptor has been correlated with 
the activation of MMPs, such as MMP-2 or 9 in human diabetic plaques; MMP-3, 9 & 
13 in an arthritic mouse model for rheumatoid arthritis, and MMP-9 in human 
pancreatic cancer cells (Cipollone et al., 2003; Hofmann et al., 2002; Takada et al. 
2004). The active linkage is unclear.  
 Hypothesis  
 
“S100 metastasis-inducing proteins induce migration and/or invasion by stimulating 
the production of a subset of MMPs”. 
 Aims 
 
To investigate what role the matrix metalloproteinases (MMPs) have in the 
S100A4/S100P stimulation of cell migration and invasion in breast cancer. 
This aim will be accomplished in four experimental chapters with individual aims as 
follows: 
1- To identify the MMPs stimulated by S100P and S100A4 in suitably-
transfected, overexpressing rat mammary cell lines. 
2- To examine the effect of siRNAs to specific MMPs on the cells’ migration and 
invasion of S100P/A4 overexpressing cell lines. 
3- To examine the effect of exogenously-added S100P/S100A4 on specific MMPs 
and migration/invasion of parental rat mammary cell lines. 
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4- To examine the relationship between specific MMPs and S100P/S100A4 in 










Chapter 2  
 
 
Materials and Methods  
 
 Reagents and equipment 
 
All chemicals and equipment used throughout the current study were 
obtained from our laboratory communal stocks or purchased from Sigma-Aldrich Co. 
(St. Louis, MO, UK), R&D system (Minneapolis, MN, USA), Gibco (Thermo Fisher 
Scientific, Waltham, MA, UK), Cell Signalling Technology, Inc., (Davrrers, MA, UK), 
Fisher Scientific UK Ltd. (Loughborough, UK), Bio-Rad Laboratories Inc. (Hercules, CA, 
USA) or Santa Cruz Biotechnology (Santa Cruz, CA, USA), unless otherwise stated. All 
cell culture equipment such as plastic ware was purchased from Corning Inc. 
(Corning, NY, UK), unless otherwise stated. Most buffers were prepared manually 
using ultra-pure distilled water, unless otherwise recorded. 
 Cell culture 
 
The culture medium used in this project was purchased from Gibco, unless 
otherwise indicated. Cells were seeded in Dulbecco’s Modified Eagle’s Medium 
(DMEM), which in all cases contained 4.5 g/L D-glucose, non-essential amino acids 
(NEAA), 3.7 g/L sodium bicarbonate and phenol red. DMEM was further 
supplemented with 4 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL 
streptomycin and 5% or 10% (v/v) foetal calf serum (FCS) from Sigma. This solution 
will hereafter be referred to as full supplemented media (FSM). Monolayer cells were 
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kept at 37°C in an incubator of humidified air with 10 % (v/v) CO2. All steps for tissue 
culture were performed in a laminar flow tissue culture hood using sterile materials. 
2.2.1 Cell lines 
 
Rat mammary (Rama) 37, a non-metastatic benign rat mammary tumour-
derived cell line (this cell line will hereafter be referred to as Rama 37 wild type 
(R37wt)) (Dunnington et al., 1983), and HeLa cells - epithelial, human cancer cells 
firstly obtained from cervical cancer from "Henrietta Lacks" (Scherer, 1953).  
Rama 37 cell line was cultured in FSM with 5% (v/v) FCS, 10 ng/mL insulin and 
10 ng/mL hydrocortisone (Clarke et al., 2017). HeLa cell line was cultured in FSM with 
10 % (v/v) FCS (Du et al., 2012). All cell lines were incubated in the same conditions 
(Section 2.2).  
2.2.2 Transfected cell lines 
 
The Rama 37 cells had been transfected previously with Piggy Bac-S100P and 
Piggy Bac vector alone (empty vector) as a control (R37-S100P, R37-EV), respectively 
(Clarke et al., 2017). The benign rat mammary cell line (Rama 37) had also been 
previously independently co-transfected with the human cDNA for S100A4 with 
pSV2neo (S5-R37) and PSV2neo (neo 1 – R37) vector alone (empty vector) as a control 
(R37-S100A4, R37 EV), respectively. These cell lines had been well characterised in 
previous publications (Clarke et al., 2017; Lloyd et al., 1998).   
HeLa cells were transfected to give overexpression of S100P using a 
tetracycline inducible system. This system consists of two plasmids. The first one is 
pBTE plasmid which expresses the regulatory element rtTA2(S)-M2, that is 
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responsible for doxycycline switching, and the second is pTRE-ins, which is 
responsible for expression of the S100P protein (Lamartina et al., 2003). The inducible 
clone derived from HeLa is called HeLa-A3. One µg/ml of doxycycline was sufficient 
to induce HeLa-A3 cell line to produce S100P protein (Du et al., 2012). This antibiotic 
was prepared by dissolving 5 mg/mL doxycycline (Clontech Laboratories Inc., 
Mountain View, CA, USA) in distilled H2O (d H2O) as a stock solution. HeLa-A3 cells 
were seeded in 10 cm diameter Petri culture dishes for 24 h with 2 µL of doxycycline 
stock to give a final concentration of 1 µg/mL.  When-long term inductions were 
required, the medium of the HeLa-A3 cells was changed to doxycycline containing-
FSM every 48 h. 
All stably-transfected cell lines (R37-S100P, R37-S100A4 and their vector 
alone controls) were cultured in FSM (Section 2.2) with the addition of 1 mg/mL 
Geneticin 418 disulphate (G418) as a selection agent (Davies et al., 1993; Ke et al., 
1998). These cell lines were used to investigate the presence and relationship 
between overexpression of S100P and S100A4 proteins and matrix 
metalloproteinases in their invasive ability. These cell lines have been successfully 
established as model systems for investigation of their metastatic phenotype (Rama 
37-S100P ; Clarke et al., 2017) and Rama37-S100A4 ; Lloyd et al., 1998) in rat breast 
cancer, and HeLa in ovarian cancer (Du et al., 2012).   
2.2.3 Thawing and sub-culturing cells 
Cells were quickly thawed in a 37°C water bath for about a minute and then 
quickly seeded in 10 mL FSM of Rama 37 medium in 10 cm diameter Petri culture 
dishes. FSM was changed to new medium every 24 h.  
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Usually, cells were passaged after 2-3 days, when they became about 70-80 
% confluenct. Monolayer cuboidal Rama 37 cells were washed twice with phosphate-
buffered saline (PBS), then incubated for 10 minutes at 37°C with 1 mL Versene 
(0.02% w/v EDTA: ethylenediamine tetraacetic acid in PBS). Versene was aspirated 
and replaced with 1 mL Trypsin (0.05 % w/v with Versene) at 37°C for 3 minutes or at 
least when almost all the cells had detached. After that, cells were collected in FSM 
and replated in FSM at a ratio of 1:5 to 1:10, as needed.   
  Thawing and passaging for HeLa cells followed the same steps as for Rama 37 
cells except for trypsinisation, they were incubated for 10 minutes at 37°C with 
Versene.  
2.2.4 Freezing cells 
Rama 37 or HeLa cells were collected when 80-90 % confluent as reported 
above. Cells from each 10 cm diameter Petri culture dish were centrifuged for 5 
minutes at (1000 x g) at room temperature, and then the cell pellet was resuspended 
in 2 mL freezing medium (80 % (v/v) FSM, 7.5 % (v/v) DMSO and 4 % (v/v) FCS). Each 
1 mL cell suspension was collected in a cryovial tube (Star Lab), and then all cryovials 
tubes were quickly packaged into a Cryo freezing container (Nalgene) for 24 h, at - 
80°C (to maintain a cooling rate of about -1°C per minute). After 24 h, cryovials tubes 
were moved to -135°C for long-term freezing and storage.  
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 Cell lysate 
2.3.1 Cell lysate (CL) for SDS-PAGE 
Cells were lysed in 10 cm diameter Petri dishes on ice at 4°C by adding 90 µL 
RIPA Buffer [50 mM Tris-HCl, pH 8, 2 mM EDTA, 150 mM NaCl, 1% (v/v) Tergitol® (NP-
40, nonyl phenoxypolyethoxylethanol-40), 0.5% (w/v) sodium deoxycholate, 0.1 % 
(w/v) SDS] and 10 µL protease inhibitor [10 µg/mL aprotinin (Sigma-Aldrich, A 1153), 
2 µg/mL leupeptin (Sigma-Aldrich, L 9783), and 4 mM benzamidine (Sigma-Aldrich, B 
6506)]. The contents were mixed well with a scraper, and the mixture collected and 
transferred to an Eppendorf tube. Eppendorf tubes were placed on end-over-end 
mixer for 1 h at 4°C. Samples were vortexed for 2-3 minutes and then centrifuged 
(Eppendorf 5415R refrigerated centrifuge) at 16000 x g for 20 min at 4°C. The 
supernatant was then transferred into a new tube and frozen at -80 °C for further 
use. RIPA buffer was made in dH2O and then kept for up to 2 weeks at 4°C. Protease 
inhibitor reagents were individually prepared in dH2O, aliquoted and kept at -20 °C. 
Protease inhibitors were added to RIPA buffer immediately before use. This protocol 
was adapted to fit in with the work plan (Köhrmann et al., 2009; Toth et al., 2012a; 
Toth and Fridman, 2001).     
2.3.2 Cell lysate for Zymography assay 
Cells in 10 cm diameter Petri dishes were lysed on ice by adding 90 µL Lysis 
Buffer [25 mM Tris-HCl, pH 7.5; 100 mM NaCl plus 1% (v/v) Nonidet P-40 (NP-40)] 
and just before lysis, a cocktail of protease inhibitor (Section 2.3.1) was added; the 
contents were mixed well with a scraper, and the mixture collected and transferred 
to an Eppendorf tube. Eppendorf tubes were placed on end-over-end mixer for 1 h 
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at 4°C. Samples were vortexed for 2-3 minutes and then centrifuged at 16000 x g for 
20 min at 4°C (Toth et al., 2012a; Toth and Fridman, 2001). The supernatant was then 
transferred into a new Eppendorf tube and frozen at -80 °C until further analysis. Lysis 
buffer was made up in dH2O and then kept for 2 weeks at 4°C.  
 Conditioned medium (CM)   
The CM contains Opti-MEM® I Reduced Serum Medium which is a 
modification of Eagle's Minimum Essential Media (Gibco) containing 10 ng/mL 
hydrocortisone, 100 units/ml penicillin, 100 µg/mL streptomycin, 4% (w/v) amino 
acids (Gibco), 25 mM D-glucose, 3.7 g/mL sodium bicarbonate (Gibco), and 1.8 mM 
calcium  dichloride (Clarke et al., 2015). The Opti-MEM medium with all these 
supplements and after incubation with cultured cells will hereafter be referred to as 
‘conditioned media’ (CM). 
One million cells of Rama 37 or HeLa cell lines were counted using a Z1 
Coulter® particle counter (Beckman Coulter., Brea, CA, USA), and then routinely 
cultured in FSM in 10 cm Petri culture dishes for two days (Section 2.2 and 2.2.1). 
After this time, cells were approximately 70-80 % confluent. Cell monolayers were 
gently washed 3 times with Opti-MEM, and then incubated for 24 h in 7 ml CM. Next 
day, CM was collected and centrifuged for 5 min at 1000 X g at 4°C. Supernatants 
were concentrated to 0.25 mL using a centrifugal filter concentrator with 10 kDa cut-
off (UFC901024, Merck Millipore Ltd., Co. Cork, Ireland) at 4000 X g at 4°C for 20 min. 




 Quantification of CL and CM protein concentrations 
 
The concentrations of proteins in cell lysates were determined using the 
bicinchoninic acid assay kit (Pierce™ BCA. Protein Assay Kit, Thermo Fisher Scientific 
Inc., Waltham, MA USA). A standard curve for bovine serum albumin (BSA) was 
created using BSA dilutions in cell Lysis Buffer (0 - 2000 μg/mL) according to 
manufacturer’s instructions. All samples were diluted 1:5 using Cell Lysis Buffer. 
Triplicate 10 µL of BSA or sample lysates were pipetted into a 96-well plate (Thermo 
Fisher Scientific, Waltham, MA, USA). BCA reagents (50A:1B) were used and 200 µL 
from the mixture were added to each well of a 96-well plate. The 96-well plate was 
covered, rocked using a plate shaker, and then incubated at 37°C for 30 min. After 
the incubation time, the absorbance of each well was measured using a Spectramax 
plus384 (Molecular Devices, Ismaning, Germany) plate reader at 562 nm. The linear 
standard curve of mean absorbance (three values) of BSA was used to measure the 
concentration of protein in the samples. 
The CM samples were concentrated (Section 2.4) and standardised before 
loading firstly, by seeding the same number of cells at the start of the experiment. 
Secondly, by estimating the total volume of the CM based on the BCA results of the 
cell lysate. This amount of total protein in CL was used to adjust the volume of CM in 
µL applied to the gel, so as to standardise CM input with respect to total CL protein. 
 Trichloroacetic acid (TCA) preparation steps 
 
One million cells from R37-S100P, R37-S100A4 and their empty vector control 
cell lines were seeded at a density of 70-80 % in 10 cm diameter dishes with FSM then 
changed to CM as described in CM. The method was performed according to 
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Nandakumar et al. (2003) with slight modifications. The 7 mL CM from 2 plates were 
collected and proteins concentrated using TCA precipitation. TCA precipitation 
involved the following steps: 0.1% (w/v) (final concentration) N-lauroylsarcosine (N-
LS) and 7.5% (w/v) (final concentration) TCA were added to CM samples. Samples 
were mixed and kept at -20 °C for 2 hours. Samples were thawed at room 
temperature and each 1.5 mL fractions were sequentially centrifuged in an Eppendorf 
5415R refrigerated centrifuge at 10000 X g for 10 min at 4 °C. The centrifugation 
process was repeated using the same Eppendorf tube for the whole sample volume.  
The remaining pellet containing the precipitated proteins was washed in 1 mL 
of –20 °C, ice-cold acetone two times, then centrifuged at 10000 x g for 10 min at 4 
°C. Acetone was removed and the excess acetone allowed to evaporate for 5-10 min 
inside a fume hood. Ten µl of 200 mM NaOH on ice was added to the pellet for 5 min 
to help protein solubilisation (Nandakumar et al., 2003). Ninety µL of 1.1 X 
Solubilisation Buffer (50 mM Tris-HCl, pH 8.0 and 2% (w/v) SDS) was added to the 
samples, and the contents were mixed and sonicated for 10 min in a water bath at 
room temperature twice. Samples were heated to 95 °C in a heating block for 5 min 
and then incubated for 10 min in a sonicating water bath at room temperature. 
Finally, samples were centrifuged at 13000 rpm for 1 min to pellet any insoluble 






 SDS-PAGE technique (Western blot) 
 
2.7.1 Sample preparation 
 
Cell lines were cultured routinely in FSM (Section 2.2 and 2.2.1). CL was 
prepared (as mentioned in Cell lysate (CL) for SDS-PAGE) and cell extract protein 
concentrations were quantified by BCA (Section 2.5). CM for detection of MMPs were 
prepared, collected, concentrated (Section 2.4) and normalized (Section 2.5). CM for 
detection of external S100P/S100A4 was concentrated using TCA (Section 2.6) and 
samples normalised following the same procedure as that in Section 2.5. 
2.7.2 Reagents for SDS-PAGE Western blot 
 
 Sample Loading Buffer (SLB) (3 X) consisted of 187.5 mM Tris-HCl, pH 6.8, 6 
% (v/v) SDS, 30 % (v/v) glycerol, 300 mM DTT and 0.625 % (v/v) bromophenol blue. 
Running Buffer (RB) consisted of 50 mM Tris, pH 8.3, 192 mM glycine and 0.1 % (w/v) 
SDS. Transfer Buffer (TB) was 120 mM Tris, 192 mM glycine and 20 % (v/v) methanol. 
Tris buffered saline-Tween 20 (TBS-T) was 20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 
0.1 % (v/v) Tween 20. Blocking buffer was 5 % (w/v) fat-free skimmed-milk (Marvel) 
or BSA in TBS-T.  
2.7.3 Gel preparations for SDS-PAGE 
 
Resolving gel buffer contained 750 mM Tris-HCl, pH 8.9, 0.1 % (v/v) SDS, 8 %, 
10 % or 15 % acrylamide (30 % acrylamide:bis-acrylamide 37.5:1), 0.06 % (w/v) 
ammonium persulfate (APS), 0.015 % (v/v) TEMED. The Resolving Solution was 
poured into 1 mm-thick, 7.5 cm-wide and 10 cm-high glass plates for polymerisation 
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in a vertical casting apparatus (BioRad). Two hundred µL butanol to stretch the gel 
surface and avoid drying out the gel was overlaid above the Resolving Solution and 
then the solution was left to polymerise for 1 h at room temperature. When the 
Resolving Solution had set, the butanol was removed, and the surface of the resultant 
gel was gently washed 3 times with dH2O. The Stacking Gel Buffer consisted of 250 
mM Tris-HCl, pH 6.8, 0.1 % (v/v) SDS, 4 % acrylamide (30 % acrylamide:bis-acrylamide 
37.5:1), 0.06 % (w/v) ammonium persulfate (APS), 0.015 % (v/v) TEMED. This Solution 
was poured over the set resolving gel. A 10 or 15 well comb was inserted directly into 




Gel surfaces were gently rinsed for up to 3 times with 1 X RB to remove the 
unpolymerized acrylamide and were then placed in vertical gel electrophoresis tanks 
(BioRad) and submerged in 1 X RB. For the cell lysate (CL) samples, 10 µg of cell lysate 
protein were mixed with 3 X SLB (volume made up with RIPA buffer to 15 or 21 µL). 
Samples were mixed by vortexing for 2-3 minutes, heated to 95°C for 5 min in a 
heating block and then briefly centrifuged in a bench top centrifuge before the 
supernatants were loaded onto the gel wells. Gels were run at 200 V for 60-75 min at 
room temperature, until the bromophenol blue dye reached the bottom of the gel. 
The CM samples were all normalized based on the BCA assay of the cell lysate 
proteins (Section 2.5). Sample volumes were made up to 21 µL with 1 X SLB before 
being loaded into the gel well. All the remaining steps for SDS-PAGE are the same as 
those for the CL samples described above. Precision Plus Protein™ Dual Color 
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Standards protein ladder (BioRad, cat. no. 161-0374) consisting of 10 different 
proteins of molecular weight (250, 150, 100, 75, 50, 37, 25, 20, 15 and 10 kDa) was 
loaded onto the gel, followed by samples using gel loading tips. 
For Western blotting and transfer, all electrophoresed gels were gently 
detached from their casting-plates into a tray of cold, fresh transfer buffer for 15 
minutes. Immobilon-P PVDF membranes (Millipore) were activated by immersing 
them in 100 % methanol for 1 min and then in TB in a tray. A sandwich cassette was 
set up as follows: a bottom layer of sponge, 3 layers of filter papers, the gel, the PVDF 
membrane, 2 layers of filter papers and then another layer of sponge. This sandwich 
was evacuated to remove air bubbles, fitted into a plastic cassette cover and then 
placed vertically in a transfer apparatus (BioRad). This apparatus was submerged with 
TB in a transfer tank. The tank was covered with ice and electroblotting was 
undertaken in a cold room at 100 V for 2 h. 
To check the transfer efficiency, a membrane was immersed in an ATX 
Ponceau S stain (Sigma-Aldrich) for 2-3 min, washed with TBS-T to remove the stain, 
and then the next steps of the Western blot process could be continued.   
Membranes were removed from the transfer cassette and rinsed with reverse 
osmosis (RO) water. Membranes were blocked with Blocking Buffer (BB) for 1 h at 
room temperature on rolling mixer to remove nonspecific absorption sites. After the 
blocking step, membranes were incubated with primary antibody (Table 2.1.) in BB 
overnight in the cold room on a roller mixer. Next day, membranes were washed 3 
times with TBS-T for 10 min each, and then incubated with secondary antibody (Table 
2.1.) for 2 h at room temperature. The membranes were then washed as before and 
blotted dry with blue roll tissue.  The bands of immunoreactivity on the membranes 
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were then visualised using 1 mL of Amersham ECLTM substrate (GE Life Sciences, 
Buckinghamshire, UK) for 2 min following the manufacturer’s instructions. ECL 
reagents were removed with blue roll tissue and membranes placed immediately in 
an X-ray film cassette and exposed to RX X-ray film (Kodak). Exposure times varied 
from 30 sec. to 15 min. If the bands were hardly detectable using ECL substrate, 
membranes were washed for 5 min with TBS-T and then ECL selectTM substrate (GE 
Life Sciences) was used and the membranes re-exposed to X-ray film for 30 sec. to 7 
min.  
 








Protein signals on X-ray film blots were scanned using a flatbed scanner (MP 
C3004ex Ricoh, Tokyo, Japan). Density of protein bands was measured using 
ImageStudio Lite software version 5.2 (LI-COR Biosciences, Java).    
 Purified S100P and S100A4 proteins 
 
Recombinant (r) S100P and S100A4 proteins were obtained from Dr. T. M. 
Ismail, University of Liverpool. The wild type S100P or S100A4 was produced in E. coli 
BL21 (DE3) cells (Thermo Fisher) using bacterial expression vector PET15b (Cat. No. 
69661-3, Novagen, London, UK) (Ismail et al., 2010, 2008). The His-tagged 
recombinant proteins were purified on HisTrap columns (GE Healthcare, 
Buckinghamshire, UK). The His-Tag was removed by reacting with thrombin-agarose 
resin (Sigma). The cleaved native proteins were passed through  HisTrap columns 
again to remove the his tag, and then protein in the run through was purified on 
Superdex 75 gel filteration columns (GE Healthcare). The preparations of rS100P and 
S100A4 gave single bands on 15 % (w/v) SDS-PAGE gels of apparent molecular 
weights of 7.5 kDa and 8.6 kDa, respectively, (Section 3.2.1), in agreement with 
previous reports (Clarke et al., 2017; Ismail et al., 2010, 2008). 
 Activation of recombinant MMP-2, 9 and 13 in vitro 
 
Recombinant rat MMP-2 (rrMMP-2) (R&D Systems, cat. no. 924-MP), 
recombinant human MMP-9 (rhMMP-9) (R&D Systems, cat. no. 911-MP) and 
recombinant human MMP-13 (rhMMP-13) (R&D System, cat no. 511-MM) were 
purchased as the proforms.  
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2.9.1 Working buffers and reagents 
 
 TCNB buffer (50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij35, pH 
7.5) was prepared manually. P-aminophenylmercuric acetate (APMA) (Sigma, A-
9563) was prepared by dissolving APMA in DMSO to yield a 100 mM stock solution.  
2.9.2 Methods  
   
Following the manufacturer’s instructions, rrMMP-2 was activated by diluting 
rrMMP-2 stock to 40 µg/mL with 1 mM p-aminophenylmercuric acetate (APMA) in 
TCNB, and then the mixture was incubated for 2 h at 37 °C. Five ng of rrMMP-2 
treated with APMA (active form of rrMMP-2) and 5 ng of rMMP-2 untreated (proform 
of rrMMP-2) were loaded on 10 % (w/v) SDS-PAGE gels and both forms showed bands 
at 68 kDa and 62 kDa (Song et al., 2013), respectively, using Western blotting (Figure 
2.1). Recombinant human MMP-9 (rhMMP-9) (R&D Systems, cat. no. 911-MP) and 
recombinant human MMP-13 (rhMMP-13) (R&D System, 511-MM) were diluted to 
100 µg/mL in TCNB. RhMMP-9 and rhMMP-13 were activated by adding APMA to a 
final concentration of 1 mM. The activation mixture of rhMMP-9 was incubated at 37 
°C for 24 h, but only 2 h for rhMMP-13. Using Western blotting, proform and active 
form of rhMMP-9 were detected at 92 kDa and 67 kDa (Shin et al., 2016), respectively 
(Figure 2.2.) and proform and active form of rhMMP-13 were detected at 60 kDa and 
50 kDa (Ozeki et al., 2014), respectively (Figure 2.3).  The molecular weights were 




Figure 2.1. Proform (Pro) and active form (Act) of recombinant rat (rr) MMP-2. 
 Five ng of both forms of rrMMP-2 were loaded onto a 10 % (w/v) SDS-PAGE gel (as described 
under Activation process) and the resultant bands were detected using Western blotting 
techniques. Exposure time for the X-rays was 20 sec. Molecular weights were estimated from 
mobility on the gel compared to known standards (Bio-Rad, cat. no. 161-0374). The pro 
MMP-2 at 68 kDa and act MMP-2 at 62 kDa have been reported previously (Munesue et al., 
2007), consistent with the loss of a 4 kDa propertied. 
 
 
Figure 2.2. Proform (Pro) and active form (Act) of recombinant human MMP-9 
(rhMMP-9).  
One ng from each incubation time of 2, 4, 6, 8, 10, 12, 24 h or pro rhMMP-9 were loaded on 
a 10 % SDS-PAGE gel and bands were detected using Western blotting as described in Figure 
2.1. Exposure time for X-ray was 1 min. Molecular weights were estimated as in Figure 2.1. 
showing original proMMP-9 at 92 kDa and 2 cleaved products at 87 kDa and subsequently at 
67 kDa. The first peptide released from the N-terminus is 20 aa and the remaining protein 
would be 89 kDa. The chemical cleavage for the 20 pro-peptide occurs between Ala-Pro 
residues (Ogata et al., 1992; Okada et al., 1992). On further analysis, there is only one other 
Ala-Pro sequence in the proMMP-9 at 463/464 residues. Cleavage at this site would produce 
a second fragment at 65 kDa. Literature reported that for proMMP-9 at 92 kDa (Takino et al., 
2003), the cleavage process resulted in either MMP-9 with molecular weight at 82 kDa (Ogata 
et al., 1992) or alternatively at 67 kDa (Okada et al., 1992). These calculations and literature 
reports are consistent with my results for the generation of 2 smaller fragment of proMMP-







Figure 2.3. Proform (Pro) and active forms (Act) of recombinant human MMP-13 
(rhMMP-13).  
Three ng from both forms of rhMMP-13 were loaded on a 10 % (w/v) SDS-PAGE gel and bands 
were detected using Western blotting (Section 2.7). Exposure time for the X-ray film was 10 
min. Molecular weights were estimated as in Figure 2.1. The proMMP-13 at 60 kDa and 
actMMP-13 at 52 kDa have been reported previously (Ravanti et al., 1999).  
 
 
 Relation between amount of protein loaded and band intensity 
 
The whole CL of Rama 37 empty vector was normalised to constant protein 
concentration in BCA. Different amounts of proteins (5, 10, 15, 20 and 25 µg) were 
loaded on a 10 % (w/v) SDS-PAGE gel. Western blotting techniques were used to 
measure glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein’s band 
intensity using ImageStudio Lite software Ver 5.2 (LI-COR Biosciences), to confirm the 
relationship between the amount of protein loaded on a gel and band intensity (Bell, 





Figure 2.4. Western blot for different amounts of GAPDH loaded on a gel. 
 Different amounts of protein (5,10, 15, 20 and 25 µg) were applied to a 10% (w/v) 
polyacrylamide gel, the gel samples electrophoresed, and the resultant blot exposed to X-ray 
film. The GAPDH was used as a target protein to show the relationship between the amount 
of loaded protein on a gel using Western blotting and band intensities when measured via 







Figure 2.5. Histogram of amount of GAPDH protein loaded against its band intensity 
on a Western blot. 
 (A) The GAPDH X-ray film from (Figure 2.4) was scanned, subject to densitometry and the 
area under the same band in each track was plotted against the amount of GAPDH protein 
loaded per well in µg. (B) Linear relationship between the amount of protein loaded and 






 Simultaneous screening for different MMPs  
 
Whole CL or CM of R37-S100P, R37-S100A4, HeLa-A3 or their control samples 
from vector alone transfected cells were screened simultaneously for detecting 
different MMPs using a semi-quantitative human MMP antibody array (ab134004, 
Abcam, Cambridge, UK). This kit has membranes pre-coated with polyclonal primary 
antibodies to 7 different MMPs (MMP-1, 2, 3, 8, 9, 10 and 13) and 3 different TIMPs 
(TIMP-1, 2 and 4) as dual spots for each target (Table 2.2.).   
The membrane in Table 2.2 can detect 7 different MMPs and 3 different 
TIMPs using kit supplied by Abcam following the manufacturer’s instruction (Baig et 
al., 2016). All steps were conducted at room temperature except membranes were 
incubated with samples at 4°C. The membranes were placed in a tray and incubated 
with 2 mL 1X Blocking Buffer for 30 min. After this time, Blocking Buffer was removed 
by aspiration and replaced with 1 mL of concentrated CM or 200 µg/mL CL proteins 
(volume made up to 1 mL with 1X Blocking Buffer) from any selected cell lines. The 
membranes with solutions were placed on a plate shaker overnight at 4°C. 
Membranes were then washed 3 times with fresh 1 X washing buffer type I (WBT I) 




Table 2.2. Human MMP antibody array membrane a. 
 
a This array aims to detect 7 MMPs and 3 TIMPs simultaneously in 32 different wells labelled 
(A to H x 1 to 4). This shows the arrangement of targets on the arrays. 
 
 
After the washing steps, membranes were incubated with 1 mL of 1 X biotin-
conjugated anti-MMPs for 2 h at room temperature. Membranes were then washed 
3X with WBT I for 5 min and then 2X with WBT II. Two mL of HRP-conjugated 
streptavidin (1/1000 of 1X Blocking Buffer) were added to each membrane for 2 h at 
room temperature. Washing steps were repeated as above.  
MMPs spots on the array were visualised using chemiluminescence. Equal 
volumes (1:1) of Reagent C and Reagent D (Abcam kit) were mixed well and 0.5 mL 
of this reagent mixture was used to coat the membrane for 2 min. Finally, all 
membranes were quickly placed in X-ray film cassettes and immediately exposed to 
Super RX X-ray film (Kodak) for 30 to 60 sec in a dark room to detect the 
chemiluminescent signals from the MMPs’ spots. Positive control spots were used to 






Developed X-ray films from human MMP antibody array were scanned using 
a flatbed scanner (Ricoh). The intensity of protein spots was analysed by 
densitometer and spot recognition analysis software (imageStudio Lite, Ver 5.2 (LI-
COR Biosciences)).    
 Zymography technique 
2.12.1 Sample preparation 
 
R37-S100P and R37-S100A4 and their control cell lines were cultured 
routinely in FSM (Section 2.2 and 2.2.1). CM was prepared, collected and 
concentrated (Section 2.4). The processing was performed as described by Toth and 
Fridman (2001) and Toth et al. (2012) with some alterations to improve its efficiency 
under our conditions. 
2.12.2 Reagents for Zymography technique 
 
Four times (4x) Sample Loading Buffer (SLB) (250 mM Tris-HCl, pH 6.8, 40% 
(v/v) glycerol, 8% (w/v) SDS; and 0.01% (w/v) bromophenol blue) was used to mix 
with the samples. Gelatin (gelatin from porcine skin G1890, Sigma-Aldrich) or casein 
(casein from bovine milk C5890, Sigma-Aldrich) 0.25 % (w/v) was prepared by 
dissolving the gelatin or casein in 10 mL dH2O and then the mixture was heated with 
stirring at 60°C for 30 min. The mixture was left to cool down at room temperature 
and was always freshly prepared. Running Buffer (1x) (RB) was prepared by mixing 
25 mM Tris base, pH 8.3, 192 mM glycine, 5 mL 20 % (v/v) SDS (added freshly) and 
the volume was made up to 1 L with dH2O. Renaturing Buffer (1x) (RNB) was made 
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by mixing 2.5 % (v/v) Triton X-100 (Sigma-Aldrich) in dH2O, stored at 4°C. Developing 
Buffer (1x) (DB) was prepared by mixing 50 mM Tris-HCl, pH 7.8, 200 mM NaCl, 5 mM 
CaCl2 and 0.02 % (v/v) Brij 35, stored at 4°C. Staining Solution (SS) was made by 
adding 0.5 % (w/v) Coomassie blue R-250, 5 % (v/v) methanol and 10 % (v/v) acetic 
acid in dH2O. Destaining Solution (DS) was prepared by mixing 10% (v/v) methanol, 
5% (v/v) acetic acid in dH2O. 
2.12.3 Gelatin or casein - acrylamide gel preparations 
 
Gelatin or casein – 10 % separating gel was prepared by mixing [10 mL 1.88 
M Tris-HCl, pH 8.8, 17.8 ml of dH2O, 5 ml of 0.25% (w/v) gelatin or casein, 16.6 ml of 
30% (v/v) acrylamide-bis-acrylamide (37.5:1), 0.25 ml of 20% (w/v) SDS, 150 µl of 10% 
(w/v) APS, and 30 µl of TEMED] for preparation of eight gels. This mixture was poured 
into the 1 mm gap between glass plates in a vertical gel-casting apparatus (BioRad). 
Two hundred µL butanol was overlaid on the surface of the mixture to avoid drying 
out of the gel. The Separating solution was then left to polymerise for 1 h at room 
temperature. The butanol was removed after the separating gel had polymerised and 
the surface of the gel was gently   washed 3 times with dH2O. Stacking gel (4%) was 
made by mixing [11 mL of dH2O, 2 mL of 30 % (v/v) acrylamide-bis-acrylamide 
(37.5:1), 2 mL of 1.25 M Tris-HCl, pH 6.8, 0.1 mL of 20 % (w/v) SDS, and 75 µL of 10 % 
(w/v) APS] sufficient for 8 gels. The stacking mixture was poured on top of the 
separating gel, a 1 mm comb (BioRad) (10 or 15 wells – comb as required) was gently 
immersed (to prevent any air bubbles) in the Stacking Gel mixture and then the 
mixture was left to polymerise for 30-60 min at room temperature. All gels were kept 





Gelatin or casein-containing acrylamide gels were gently washed up to 3 times 
with 1 x RB to remove any unpolymerized acrylamide. Gels were placed in a vertical 
gel electrophoresis tank (BioRad) and submerged in 1 x RB.   
R37-S100P, R37-S100A4 and their control samples under reducing conditions 
were made up to the same volume with 1 x SLB and then mixed with 4 x SLB in a 3:1 
ratio. Samples were mixed by vortexing for 2 min, briefly centrifuged and then the 
supernatant was micropipetted into the gel wells. Gels were run at constant voltage 
(125 V with 30-40 mA stable current) for 100 min at room temperature. The gel was 
then incubated two times for 15 min each at room temperature with gentle agitation 
in RNB to remove the SDS and allow the enzymes to refold. To reactivate the 
proteases, the gel was incubated in 1 x DB for 30 min at room temperature, and then 
with fresh DB for 48 h at 37C°. To detect the digested area in the casein or gelatine 
gel, the DB was decanted, and the gel was incubated in SS for at least 1 hour. Finally, 
the gel was destained with DS until areas of gelatinolytic or caseinolytic activity 
appeared as clear, sharp bands in a dark blue background of stained gelatine/casein.   
The method to detect the MMP-13 activity using casein as a substrate rather 
than gelatin was the same as that for gelatinolytic activity, but with simple 
modifications. The renaturing step was achieved this time by washing the casein gel 
two times with 2.5% (v/v) Triton X-100, 50 mM Tris, pH 7.5 at room temperature for 
20 min each to remove SDS, and then two more times with 50 mM Tris, pH 7.5 plus 
5 mM CaCl2. The rest of the experimental steps were the same as those in the 





Gelatine or casein gels were scanned linearly using an Image-Scanner III gel 
scanner (GE Life Sciences). Intensities of protein bands on gelatin or casein gels were 
measured using Image J software (Hu and Beeton, 2010).    
 Migration assay 
 
Boyden Chambers consisting of 6.5 mm diameter polycarbonate membrane 
inserts with 8 μm diameter pores (Corning Costar, Acton, USA) were used, as 
described previously  (Du et al., 2012), with some alterations to improve efficiently in 
our conditions. Warm DMEM (serum-free medium) was used to hydrate the chamber 
membranes by adding 250 µL to the interior space and 500 µL to the exterior space 
of the chambers (to the bottom of plate’s wells), and then the chambers were 
incubated for at least 2 h in a humidified tissue culture incubator at 37˚C, 10 % (v/v) 
CO2 atmosphere. One day prior to the experiment, cell lines were cultured routinely 
in FSM (Section 2.2 and 2.2.1) in order to achieve 80-90 % confluence on the day of 
the experiment. After the hydration step, DMEM was aspirated from both sides of 
the chambers, 500 µL of FSM with 5 % (v/v) FCS was pipetted into the bottom of each 
well, and 250 µL of FSM with 1 % (v/v) FCS containing 7.5 X 103 cells were pipetted 
inside the top chamber in triplicate wells. All chambers were incubated for 24 h or 48 
h in a humidified tissue culture incubator at 37˚C, 10 % (v/v) CO2 atmosphere. After 
this time, the non-migrating cells on the top surface of the membranes were removed 
by a gentle wipe using cotton buds.  The migrating cells on the lower surface of the 
membranes were fixed and stained by using a REAstain Quick Diff kit (Reagena., 
Siilinjärvi, Finland). Migration experiments were recorded from 3 wells repeated 3 
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times with different batches of cells (n=3) or recorded from 3 wells repeated 2 times 
with different batches of cells (n=2).  
All migrating cells were counted manually using a light microscope with 4 x or 
10 x objective. The procedure for cell counting was to use a zigzag pattern to avoid 
double counting of a cell (Figure 2.6). 
 
Figure 2.6. Zigzag pattern followed to count migrating or invading cells on bottom 
surface of transwell membranes. Bar = 20 µm. 
  
 Invasion assay  
 
The BD BioCoat Matrigel Invasion chambers with 8µm diameter pores (BD 
Biosciences, Two Oak Park, Bedford, MA) were used in this experiment (Clarke et al. 
2017). These chambers were shipped and stored at -20°C before use. The 
experimental protocol was the same as described in the Migration assay above, 
excepted the incubation time for rehydration was at least 6 h, and the number of 
cells seeded on the Matrigel invasion membrane was 15 X 103 cells / 500 µL of FSM 
with 1 % (v/v) FCS.  
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 MMP small interfering (si) RNA transfection 
2.15.1 Rat MMP-2 siRNA 
 
A pool of 3 target-specific 19-25 nucleotide siRNAs (sc-108049, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was purchased to knock-down gene expression 
of MMP-2 in the rat cell system. The manufacturer’s instructions were followed, but 
with modifications (Lin et al., 2014) and some alterations in protocols were required 
to make the assay work efficiently. Lyophilized duplex MMP-2 siRNA was briefly 
centrifuged and the pellet was resuspended in 330 µL of the RNAse-free H2O (D 2916, 
Santa Cruz) to give stock of 10 µM in buffer (0.01 mM Tris-HCl, pH 8.0, 20 mM NaCl, 
1 mM EDTA). The stock was aliquoted and kept frozen at -20 °C.   
2.15.2 Rat MMP-9 siRNA and Rat MMP-13 siRNA 
 
MMP-9 and MMP-13 siRNA were purchased as an ON-TARGET plus Rat MMP-
9 (81687) siRNA-SMART pool (L-093919) and ON-TARGET plus Rat MMP-13 (171052) 
siRNA-SMART pool (L-100431) (Dharmacon RNA Technologies, Buckinghamshire, UK) 
to knock-down gene expression of MMP-9 and MMP-13, respectively, in the rat cell 
system. The protocol was the same as that for Rat MMP-2 siRNA, except that for the 
10 µM stock, 5 nmol of MMP-9 siRNA or MMP-13 siRNA were mixed with 500 µL of 1 
X siRNA buffer (60 mM KCl, 6 mM HEPES, pH 7.5 and 0.2 mM MgCl2) (B-002000-UB-





2.15.3 siRNA transfection for all MMPs (2, 9 and 13) at the same time 
 
In this case, the same amount from each stock of siRNA for MMP-2 for MMP-
9 and for MMP-13 were mixed together to examine the silencing of 3 MMPs in 1 
transfection experiment on expression of these proteins and on the biological activity 
of the transfected cells. 
2.15.4 Control siRNA-A for knock-down experiment 
 
Control siRNA-A was purchased as a non-targeting 20-25 nucleotide siRNA (sc-
37007, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and was designed to be a 
negative control. The lyophilized control siRNA was resuspended in 66 µL of the 
RNAse-free H2O and mixed with Buffer [0.01 mM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM 
EDTA] to give 10 µM stock. The stock was aliquoted and kept at -20 °C.  
2.15.5 Working reagents and solutions 
 
Different doses (2, 4 and 7 pmol or µL from 10 µM stock) of each siRNA for 
individually knocking-down MMPs were tested. Seven pmol dose was found to be the 
optimal, in agreement with the manufacturer’s instructions (data not shown).    
Solution (A), 70 pmol or 7 µL of MMP-2 or MMP-9 or MMP-13 siRNA stock 
were mixed with 100 µL Opti-MEM Reduced Serum Medium (Gibco), freshly 
prepared. Solution (B), 5 µL of transfection reagent (sc-29528, Santa Cruz) was mixed 
with 100 µL Opti-MEM Reduced Serum Medium, freshly prepared. In the case of 
knock-down of all 3 MMPs, which means silencing MMP-2, MMP-9 and MMP-13 at 
the same time; Solution (A), 3.5 µL from each MMP’s siRNA were mixed together and 
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Stably transfected cell lines (R37-S100P and R37-S100A4) were seeded at 4 x 
105 cells/well in 6 well tissue culture plates in antibiotic free-FSM and incubated at 
37°C in 10 % (v/v) CO2 for 24 h in order to achieve 80-90 % confluence. Next day, 
solution A and solution B were mixed together cautiously and incubated for 30 min 
at room temperature inside a laminar flow tissue culture hood. During this time, cells 
were washed once with 2 ml of Opti-MEM Reduced Serum Medium, the volume of 
the mixture of solution A+B was made up to 1 mL with Opti-MEM Reduced Serum 
Medium and then 1mL of the mixture was added to the washed cells. Cells were 
incubated at 37 °C for 6 to 8 h, based on observations of cell detachment/death due 
to the toxic effect of the transfection reagent and serum starvation. After the end of 
the incubation period, cells were supplied with 1 mL FSM containing 2 x FCS and 2 x 
antibiotic and then re-incubated for a total of 24 h. After the first 24 h incubation, cell 
medium was aspirated and replaced with fresh FSM for another 24h, the latter was 
changed every 24 h. For Western blotting of samples, cells required a 72 h incubation 
period. After these periods of cell culture, the cells and medium were collected 
(Section 2.3.1 and 2.4). For migration and invasion assays, the cells were incubated 
for just 24 h in fresh FSM after the time of transfection, and then cells were routinely 
trypsinised, counted and seeded in the required numbers into Boyden chambers as 




 Effect of extracellular addition of S100 proteins on MMPs 
2.16.1 Effect of different doses of S100P on levels of MMP-9 
 
Rama 37 wild type (R37 wt) cell line was seeded in FSM at 4 x 105 cells/well in 
6 well tissue culture plates and incubated at 37°C in an atmosphere of 10 % (v/v) CO2 
for 24 h in order to achieve 70-80 % confluence. The next day, cells were washed 3 x 
with Opti-MEM and 2 ml of CM was added to each well with different concentrations 
of purified S100P protein as follows: 0, 0.001, 0.01, 0.1, 1 and 5 µM. Each 
concentration was added in duplicate wells. After a 24 h incubation period, the cell 
lysate (CL) and conditioned medium (CM) were collected and normalized to process 
for Western blotting (Section 2.3.1 and 2.4). 
2.16.2 Effect of 1 µM S100P or S100A4 on levels of MMP-2, 9 and 13  
 
One million cells of R37 wt in FSM were routinely seeded in two 10 cm dishes 
(Section 2.4). One µM of S100P or S100A4 was added to CM of each plate. The CL and 
CM were collected after a 24 h incubation period and then normalized as described 
above in Section 2.5 to process samples for Western blotting.  
 Detection of RAGE receptor in cell lines 
 
R37-S100P, R37-S100A4 and R37 wt in FSM were seeded in 10 cm diameter 
dishes. Cell lysates were collected and quantified as described in Section 2.3.1 and 
2.5. Samples were processed to examine the presence of Receptor for Advanced 
Glycation End Product (RAGE) in cell extracts using Western blotting. The identifiable 
RAGE band at   4̴5 kDa was confirmed by mixing 2.5 µL of anti-RAGE antibody (ab3611, 
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Abcam) with 5 µL of Rat RAGE-blocking peptide (ab41778) in 6 mL Blocking Buffer 
(BB) for half an hour at room temperature on a rolling mixer, and then the blot was 
incubated with the mixture (6 mL BB + RAGE antibody + RAGE blocking peptide) 
overnight at 4 °C on a rolling mixer (Figure 2.7), under these conditions the band at 
45 kDa was eliminated. The band at 39 kDa remained after blocking and hence was 
considered unrelated to RAGE protein.   
 
 
Figure 2.7. Western blot for RAGE receptor in cell lysates of R37 wt, R37-S100P and 
R37-S100A4.  
(A) Blot was incubated with 2.5 µL / 6 mL anti-RAGE antibody in blocking buffer overnight. 
(B) Blot was incubated with 2.5 µL anti-RAGE antibody + 5 µL Rat RAGE blocking peptide in 6 
mL blocking buffer overnight. 
 
 
2.17.1 Effect of inhibiting RAGE receptor on cell biological activities 
promoted by intracellular/extracellular S100P or S100A4 
 
R37 wt, R37-S100P and R37-S100A4 cell lines were cultured routinely in FSM 
(Section 2.2). Cromolyn sodium salt (C0399, Sigma-Aldrich) (Arumugam et al., 2006) 
and anti-RAGE antibody (ab3611, Abcam) (Dahlmann et al., 2014) were used to 
inhibit the RAGE receptor. Cromolyn is an antiallergic drug which can bind to S100 
proteins and inhibit their binding to RAGE receptor (Arumugam et al., 2006; Okada et 
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al., 2002; Oyama et al., 1997). These experiments were repeated twice under the 
same conditions.    
2.17.2 R37 wt with 1 µM S100P or S100A4 added extracellularly for 
migration and invasion experiments 
 
R37 wt cells were seeded in each Boyden or Matrigel chambers for migration 
or invasion assays, respectively (Section 2.13 and 2.14). For the Boyden or Matrigel 
chambers the 24 well plate was divided into 3 groups with 3 chambers for each group. 
Group 1: R37 wt cells were seeded alone as a negative control. Group 2: R37 wt with 
final concentration of 1 µM S100P on both sides of the membrane. Groupe 3: R37 wt 
with final concentration of 1 µM S100A4 on both sides of the membrane. Boyden 
chamber migration assay were carried out as described in Section 2.13. Matrigel 
chamber invasion assays were carried out as described in Section 2.14. 
 
2.17.3 R37 wt with RAGE inhibitors for invasion experiment 
 
R37 wt cells were seeded in the same way as described above (Section 2.14). 
The 24 well plate was divided into 3 groups as follows: Group 1: R37 wt cells were 
seeded alone as a negative control. Group 2: R37 wt with 1/200 µL anti-RAGE 
antibody above and below the Matrigel membrane. Groupe 3: R37wt with 100 µM 
Cromolyn above and below the Matrigel membrane. Matrigel chamber invasion 




2.17.4 R37 wt with 1 µM S100P or S100A4 added extracellularly with 
RAGE inhibitors for invasion experiment  
 
R37 wt cells were seeded in the same way as described above (Section 2.14). 
The 24 well plate was divided as follows: Group 1: R37 wt with final concentration of 
1 µM S100P or S100A4 on both sides of the Matrigel membrane. Group 2: R37 wt 
with final concentration of 1 µM S100P or S100A4 and 1/200 µL anti-RAGE antibody 
on both sides of the Matrigel membrane. Groupe 3: R37 wt with 1 µM S100P or 
S100A4 and 100 µM Cromolyn on both sides of the Matrigel chamber. Matrigel 
chamber invasion assays were carried out as described in Section 2.14.  
2.17.5 R37-S100P or R37-S100A4 with RAGE inhibitors for invasion 
assay 
 
Stably transfected R37-S100P or R37-S100A4 were seeded in the same way as 
described above Section 2.14. The 24 well plate was divided into 3 groups as follows: 
Group 1: R37-S100P or R37-S100A4 cells were seeded alone as a negative control. 
Group 2: R37-S100P or R37-S100A4 with 100 µM Cromolyn on both sides of the 
Matrigel membrane. Groupe 3: R37-S100P or R37-S100A4 with 1/200 µL anti-RAGE 
antibody on both sides of the Matrigel membrane. Matrigel chamber invasion assays 
were carried out as described in Section 2.14.  
 Human patient material and information 
 
Specimens from 183 breast cancer specimens were collected between 1976 
to 1982 from patients in the Merseyside Region of the North West of England. All had 
been treated by simple mastectomy and none had identifiable metastases at the time 
of presentation. None had any further hormone or chemotherapy. Information 
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regarding patient follow up, tumour pathology and ethical approval was obtained as 
described previously (de Silva Rudland et al., 2006). Specimens  were originally fixed 
in buffered formalin, embedded in paraffin wax and stored at room temperature until 
further use, as described previously (de Silva Rudland et al., 2011). 
2.18.1 Immunohistochemistry 
 
Four to seven (4-7) µm sections from the stored paraffin blocks were cut and 
placed on 3-aminopropyltriethoxysilane (APES)-coated slides. Sections were 
dewaxed in xylene and rehydrated through graded ethanol to water mixtures 
(Warburton et al., 1982). Endogenous peroxidase activity was blocked by incubating 
them in 100 % methanol containing 0.05 % (v/v) H2O2 for 20 min at room temperature 
(Streefkerk, 1972). Sections were then incubated overnight at 4˚C in a humidity 
chamber with mouse monoclonal anti-MMP-2 (#MAB 13431, Millipore, 
Hertfordshire, UK), rabbit monoclonal anti-MMP-9 (#137867, Abcam, Cambridge, UK) 
or mouse monoclonal anti-MMP-13 (#MA5-14238, Thermo Fisher Scientific, MA, 
USA), at dilutions of 1:40 (MMP-2), 1:100 (MMP-9) and 1:60 (MMP-13) in 1 % (w/v) 
BSA/PBS.  Indirect immunohistochemical staining was then carried out using a 
commercially available enhanced Horse Radish Peroxidase (HRP) labelled polymer 
system, the DAKO EnVision + System peroxidase (Dako Ltd, Ely, UK) (Sabattini et al., 
1998), prepared according to the manufacturer’s instructions.  The labelled polymers, 
which bound to the sections were finally visualised by incubation with 0.05% (v/v) 
H2O2 and 3,3′-diaminobenzidine (DAB) to produce a brown precipitate. The sections 
were washed in running tap water and then the nuclei were counterstained with 
Mayer’s haemalum. Sections were dehydrated in graded ethanol to water mixtures 
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and cleared in xylene. Coverslips were mounted on the slides in a mixture of 
Distyrene, a plasticizer, and xylene (DPX) (Merck, Poole, UK). Positive and negative 
controls using 1 % (w/v) BSA/PBS to replace the primary antibodies were used with 
each batch of about 20 stained sections. In most cases when positively stained, 
cytoplasm was the target. Controls using antibodies previously incubated with 
immunizing peptides to the proteins gave no specific stains. The purchased 
antibodies yielded a single band on Western blotting of the correct molecular weight 
according to the manufacturer’s data sheets.  
2.18.2 Scoring of samples and data analysis 
 
Sections were scored by two observers independently (Prof. Philip Rudland 
and Mrs. Angela Platt-Higgins) using a light microscope and a 20 x objective (Leitz 
Laborlux 12). The percentage of tumour cells stained was estimated from counting 
10 fields of 100-200 cells each across the whole section. The stained sections were 
subdivided into 5 categories as described in Table 2.3. and any differences between 









Table 2.3. Categories of immunohistochemical staining for breast cancer samples. 
 
 
a Only staining of the cancer cells was recorded, that due to host stroma/blood vessels etc was not 
included.  
 
Data analysis was performed by Mr Morteta AL-Medhtiy. First of all, the 
cumulative proportion of patients surviving for the different staining groups was 
plotted against time in the form of Kaplan Meirer plots, to identify the two most 
significantly different categorical staining groupings for each of the three MMPs. 
Usually the cut-off between two categorical staining groups was at either the 1% or 
5% level of stained cancer cells (de Silva Rudland et al., 2011). For MMPs the cut-off 
was 5%. The significance of the difference and the relative risk between staining 
groups was computed by Wilcoxon-Gehan statistics and Cox’s univariate analysis, 
respectively, as described previously (de Silva Rudland et al., 2011). Kaplan Meier 
plots and statistical analyses were performed for the two categorical groups for each 
MMP. Further analysis was undertaken with data already collected for staining for 
S100P and S100A4 (Rudland et al., 2000; Wang et al., 2006).  
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The significance of the association of paired stainings was computed from 2x2 
tables using Fisher’s Exact test (two sided) with the Bonferroni correction for multiple 
tests to reduce chance associations  (de Silva Rudland et al., 2011; Rudland et al., 
2000). Computations were undertaken for staining for MMP-2, -9, -13, S100P and 
S100A4. Logistic regression was carried out on staining for combinations of MMPs 
and S100 proteins. Cox’s multivariate analyses to show significance of association 
with patient survival on staining sets containing combinations of these groups were 
also carried out to show significance of association with patient survival. All statistical 
analyses were performed using the IBM statistical package for the social sciences 




Chapter 3  
 
 
Levels of matrix-metalloproteinases in S100P and 




Overexpression of S100P /S100A4 has been correlated with increased 
metastatic activity and with promoting expression of MMPs in many cases of cancer 
(Berge and Mælandsmo, 2011; Bresnick et al., 2015; Mishra et al., 2012; Saleem et 
al., 2006). MMPs act as molecular scissors to cut and digest components of the ECM, 
e.g., collagen I, gelatine, and elastin fibers, and this destruction leads to remodelling 
of the ECM which aids the route along which dissemination of tumour cells occurs 
(Singletary & Connolly 2006; Rizwan et al. 2015). 
Amongst many means to examine cellular activities, estimation of the levels 
of specific proteins is considered to be one of the most fruitful (Jones, 2014). Usually, 
cell functions are directly accomplished by proteins, and only indirectly via DNA or 
RNA. Moreover, experimental analyses have shown that a dissimilarity between 
mRNA levels and their corresponding proteins can exist under certain conditions 
(Mahmood and Yang, 2012). Therefore, an analysis of proteins is crucial to an 
understanding of intracellular and extracellular pathways. In this chapter Western 
blotting is used to detect specific proteins from entire protein mixtures using specific 
primary and secondary antibodies (Mahmood and Yang, 2012).  
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For the MMP proteinases the development of sensitive methods for their 
detection and activity are vital to determine their role in tissue degradation 
(Fernández-Resa et al., 1995). One of the most popular and reliable techniques is 
zymography for quantitative measurement of MMPs’ activities (Lombard et al., 
2005). In the past, ELISA has often been used to estimate levels of specific proteins in 
serum or urine samples (Avrameas and Ternynck, 1998) and immunohistochemistry 
for biopsy specimens (Hornick, 2014). These two methods are time-consuming, 
expensive and do not help to identify the molecular weight of the active enzymes. In 
contrast, zymography provides a cheaper and quicker screening method with the 
added advantage of visualising the MMP’s molecular weight. To detect MMP-2, 
MMP-9 and MMP-13’s activities in biological samples, zymography is used with 
gelatin or casein as substrate;  it is a very sensitive assay for these enzymes (Hu and 
Beeton, 2010; Schmidt-Hansen et al., 2004; P. Snoek-van Beurden and Von den Hoff, 
2005; Toth and Fridman, 2001; Yu and Woessner, 2001). This assay visualises their 
enzymatic  activity in biological samples using sodium dodecyl sulphate (SDS) 
polyacrylamide gels impregnated with gelatin (Toth et al., 2012b) or casein (Schmidt-
Hansen et al., 2004). The latter substrate is used for MMP-13, which only introduces 
a single cuts ( ¼ and ¾ fragments) in its target, collagen I, but cuts casein in many 
places leading to a more complete digestion (Snoek-van Beurden and von den Hoff, 
2005; van Doren, 2015; Zitka et al., 2010). The biological samples are electrophoresed 
under nonreducing conditions, which maintains their proteolytic activity. Triton X-
100 is then used to remove the SDS from the gel (renaturing buffer), a procedure 
which allows the enzymes to refold again. Calcium-containing buffer is then used to 
activate the enzymes, which can now degrade the gelatin, leaving a protein-cleared 
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zone, which can be observed as a unstained band after incubating the gel with 
Coomassie Blue R-250 stain (Toth and Fridman, 2001).  
3.1.1 Chapter aims 
 
To identify the MMPs stimulated by overexpression of S100P and S100A4 in stably-
transfected rat mammary cell lines. 
 Results 
 
3.2.1 Expression of S100P/A4 proteins in stably transfected rat 
mammary (R37) S100P/A4 cell lines 
 
The R37-S100P / A4 cell lines were analysed for the presence of S100P/A4 
proteins compared to the R37 empty vector-containing cell line. Thus, 20 µg of 
protein from each cell line estimated by the BCA method were run on SDS 
polyacrylamide gels. There was a (mean±SE) 21.9±0.9-fold increase in S100P (Figure 
3.1.A1) and 127±30-fold increase in S100A4 in cell lysates (Figure 3.1.C1), and a 
34.3±3.0-fold increase in S100P (Figure 3.1.B1) and a 75.94±12.89-fold increase in 
S100A4 (Figure 3.1.D1) in conditioned media. The amount of protein produced per 
20 µg of total protein was estimated to be 16.6±3.8 ng and 18.1±0.5 ng for S100P and 
S100A4, respectively, in cell lysate, and 8.6±2.3 ng and 8.0±0.4 ng in 10 µL of loaded 
volume for S100P and S100A4, respectively, in conditioned media. Thus, 
approximately 14.4 % of the total S100P and 13.1 % of the total S100A4 was found in 
the conditioned medium. The molecular weights of S100P and S100A4 by comparison 
with standard recombinant proteins were estimated to be (mean±SE) 7.4 kDa ±0.24 




Figure 3.1. Overexpression of S100P and S100A4 proteins in transfected rat 
mammary cell lines. 
Representative Western blots for (A1 & C1) 20 µg protein cell lysate (CL) or (B1 & D1) 10 µL 
of conditioned media (CM) were run on 15% (w/v) SDS-PAGE from the following. (A1: CL) Cell 
lysate (CL) from stably transfected Rama 37 with empty vector (R37 E.V.) or Rama 37 with 
S100P (R37-S100P) cell lines. (A2) Mean band intensity of S100P in (CL) of R37 E.V. (mean±SE: 
114±20.5) or in R37-S100P (mean±SE: 2300±197.3) cell lines showed a 21.9±0.86-fold 
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increase. The amount of intracellular S100P protein was estimated to be (mean±SE) 
16.59±3.77 ng in 20 µg of loaded protein by comparison with similar gels run with 
recombinant S100P (rS100P). (B1: CM) Conditioned media (CM) from R37 E.V. or R37-S100P 
cell lines. The level of protein in the CM was adjusted and normalized based on cell lysate 
BCA readings. (B2) Mean band intensity of S100P in CM of R37 E.V. (mean±SE: 34.46±4.45) 
over that from R37-S100P (mean±SE: 1156.66±49.10) cell lines showed a 34.32±2.99-fold 
increase. The amount of extracellular S100P protein was estimated to be 8.58±2.32 ng in 10 
µL of loaded volume by comparison with similar gels run with rS100P. (C1: CL) Cell lysates 
(CL) from R37 E.V. or in R37-S100A4 cell lines were run on similar SDS-PAGE gels. In controls, 
recombinant 5 or 10 ng purified S100A4 (rS100A4) were also run in parallel. (C2) Mean band 
intensity of S100A4 in CL of R37 E.V. (mean±SE: 24.30±6.90) or in R37-S100A4 (mean±SE: 
2706.67±243.40) cell lines showed a 127.95±29.77-fold increase. The amount of intracellular 
S100A4 protein was estimated to be 18.11±0.51 ng in 20 µg of loaded protein. (D1: CM) 
Conditioned media (CM) from R37 E.V. or R37-S100A4 cell lines. The level of protein in the 
CM was normalized based on cell lysate BCA readings. In controls, recombinant 10 ng purified 
S100A4 (rS100A4) was run alongside. (D2) Mean band intensity of S100A4 in CM of R37 E.V. 
(mean±SE: 7.53±0.90) over that from R37-S100A4 (mean±SE: 550.33±46.17) cell lines 
showed a 75.94±12.89-fold increase. The amount of extracellular S100A4 protein was 
estimated to be 8.03±0.41 ng in 10 µL of loaded volume. All in all, the percentage of S100P 
and S100A4 detected extracellularly were 14.4 % and 13.1 % respectively. Appendix 1 shows 
the full length gel for overexpression of S100P and S100A4 in CL to confirm only one band 
being present.    
  
 
3.2.2 Multi-screening for MMPs in conditioned media of 
overexpressing S100P/S100A4 cell lines 
 
Conditioned media (CM) from the S100P-inducible human cervical carcinoma 
cell line HeLa-A3, the stably transfected rat mammary R37-S100P, R37-S100A4 and 
their empty vector control cell lines were used to investigate whether these cell lines 
produced MMPs, and if so which MMPs, using a general human MMP antibody array. 
This multiplex approach offered fundamental advantages for screening a defined set 
of proteinases in the CM at the same time and the human MMP antibody array used 
was capable of detecting the following: MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, 
MMP-10, MMP-13, TIMP-1, TIMP-2 and TIMP-4. By visual inspection, the S100P-
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induced HeLa-A3, R37-S100P and R37-S100A4 cell lines showed on increased 
presence in their CM of MMP-2, MMP-9 and MMP-13 compared to the control cell 
lines (Figure 3.2). The levels of MMP-2 (mean fold increase±SE: 1.09±0.23, n=3, 
Student’s t-test, P=0.76) in S100P-induced HeLa-A3, (1.07±0.07, n=3, Student’s t-test, 
P=0.48) in R37-S100P, and in R37-S100A4 cells (1.12±0.04, n=3, Student’s t-test, 
P=0.33) were all nonsignificant increases compared to control cell lines. Also, the 
levels of MMP-9 (mean fold increase±SE: 1.2±0.2, n=3, Student’s t-test, P=0.39) in 
S100P-induced HeLa-A3, (1.11±0.04, n=3, Student’s t-test, P=0.24) in R37-S100P, and 
in R37-S100A4 cells (1.04±0.02, n=3, Student’s t-test, P=0.81) were increased, but 
again were not significantly compared to controls. The level of MMP-13 was also 
increased, but not significantly (mean fold increase±SE: 1.50±0.15, n=3, Student’s t-
test, P=0.08) in S100P-induced HeLa-A3 cells, but was significantly increased in R37-
S100P (mean fold increase±SE: 2.40±0.02, n=3, Student’s t-test, P=0.002) and in R37-
S100A4 (mean±SE: 3.6±0.3, n=3, Student’s t-test, P˂0.001) cells compared to 
controls. The remaining MMPs: MMP-1, MMP-3 and MMP-8 showed no significant 
increase in CM from both model systems, except that MMP-10 was increased 
significantly only in CM from R37-S100P and R37-S100A4 cells, but not in S100P-
induced HeLa-A3 cells (Appendix 2). To undertake a more specific investigation based 
on function of the MMPs, zymography was undertaken in the cell culture models. 
These experiments were confined to rat cells, since the induced doxycycline in HeLa 
cells can at higher concentrations inhibit MMPs (Stechmiller et al., 2010) and more 
MMPs were significantly increased in the rat cells than in HeLa cells. The array 
produced only qualitative results and hence Zymography and Western blots were 





Figure 3.2. Multi-screening MMP array in S100P-induced HeLa-A3, stably 
transfected rat mammary Rama 37-S100P and Rama-S100A4 cell lines. 
 (A) Human MMP antibody array membranes represent levels of 7 MMPs and 3 TIMPs in CM 
from noninduced S100P HeLa-A3 or induced S100P HeLa-A3 cells. Membranes were probed 
with CM from S100P-noninduced HeLa-A3 (control) and S100P-induced HeLa-A3 cells 
(induced). (B) Histogram of 3 experiments from A showed the mean fold increase in band 
intensity for MMP-2, 9 and 13 in S100P-induced HeLa-A3 compared to their noninduced 
control. (C) Human MMP antibody array membranes represent levels of 7 MMPs and 3 TIMPs 
in CM from R37 empty vector (E.V), R37-S100P (S100P) and R37-S100A4 (S100A4) cells. 
Membranes were probed with CM from Rama 37 empty vector (E.V.), Rama 37-S100P 
(S100P) and Rama 37-S100A4 (S100A4) cells. (D & E) Histograms of 3 experiments from C 
showed mean fold increase in band intensities for MMP-2 and 9 were increased, but not 
significantly (Student’s t-test, P>0.05), whilst that for MMP-13 was increased significantly in 
Rama 37-S100P and Rama 37-S100A4 cell lines (P=0.002 and P˂0.001, respectively). 
Abbreviations: Matrix metalloproteinase (MMP). Tissue inhibitor of metalloproteinase 




3.2.3 Functional activity assay for MMPs using zymography 
 
The zymography technique was used as a second method to help confirm the 
functional activity of MMPs in conditioned media (CM) from R37 empty vector 
control, R37-S100P and R37-S100A4 cell lines. The CM was concentrated and 
normalized for total cell lysate protein determined by BCA (Section 2.4 and 2.5). The 
volumes of CM corresponding to the proportion of cell lysate proteins were loaded 
onto the zymography gels. SDS gels containing gelatine were used for MMP-2 and 
MMP-9 investigations (gelatine-zymography) (Section 2.12.3) and all the various 
forms of the proteases, both inactive and active, were chemically activated after the 
gel had been run (Section 2.12.3). Using gelatine-zymography the CM samples 
showed distinct bands of cleared area which corresponded in size to both forms of 
recombinant human MMP-2 (rhMMP-2), the proform rhMMP-2 (68kDa) and active 
form rhMMP-2 (62 kDa)(da Silva et al., 2014; Shimokawa Ki et al., 2002) (Figure 
3.3.A1), or one form of recombinant human MMP-9 (rhMMP-9), the proform 
rhMMP-9 (92 kDa) (Nair et al., 2006) (Figure 3.3.B1). Moreover, by visual inspection 
there were no cleared bands corresponding to the molecular weights of other 
members of the MMP family which may show gelatinolytic activity, including MMP-
10. From the literature proteolytic activity of MMP-10 (stromelysin-2) has been 
tested also using gelatine-zymography (Wu et al., 2012). The latter study showed that 
MMP-10 has gelatinolytic activity for two forms, proform at 58 kDa and active form 
at 44 kDa in CM from gastric cancer cell lines. In our gelatine-zymography study, no 




The gelatinolytic activity of MMP-2 in CM from the R37-S100P cell line showed 
the following results: proform MMP-2 was significantly decreased by 3-fold (mean±SE 
with respect to empty vector cells set at 1: 3.0±0.4, n =7, Student’s t-test, P˂0.0001). 
Active form MMP-2 showed a significant increase by about 2-fold (1.9±0.2, n =7, 
P=0.008) over empty vector controls. Moreover, gelatinolytic activity of MMP-2 in 
CM from the R37-S100A4 cell line showed the following results: proform MMP-2 was 
significantly decreased by 2.5-fold (mean±SE with respect to empty vector cells set at 
1: 2.5±0.1, n=7, Student’s t-test, P˂0.0001). In contrast, active form MMP-2 was 
significantly increased by 2.4-fold (2.4±0.2, n=7, P˂0.0001) over empty vector 
controls (Figure 3.3.A2).  
Gelatinolytic activity of MMP-9 showed only proform MMP-9 in CM samples 
from both R37-S100P and R37-S100A4 cell lines. The proform MMP-9 was 
significantly increased by 1.9-fold (mean±SE with respect to empty vector cells set at 
1: 1.94±0.16, n=7, Student’s t-test, P˂0.0001) in CM from R37-S100P, and by 2.3-fold 
(2.31±0.17, n=7, P˂0.0001) in CM from R37-S100A4 cell lines over that in empty 
vector cells (Figure 3.3.B2). 
Casein-zymography was used to identify the proteolytic activity of MMP-13, 
since its single cut in its target collagen I is not readily detectable by collagen-
zymography (Chung et al., 2004; Van Doren, 2015). Caseinolytic activity of MMP-13 
on casein gels showed distinct clear bands for proform MMP-13 (60 kDa) and active 
form MMP-13 (52 kDa) (Figure 3.3.C1). The CM from R37-S100P and R37-S100A4 cell 
lines showed significant decreases in proform MMP-13 of 2-fold (mean±SE with 
respect to empty vector cells set at 1: 1.96±0.05, n=3, Student’s t-test, P=0.031) and 
1.4-fold (1.4±0.02, n=3, P=0.001), respectively over empty vector cells. The active 
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form MMP-13 was significantly increased by 5.3-fold (5.26±0.25, n=3, P=0.001) in CM 
from R37-S100P and by 2.2-fold (2.16±0.06, n=3, P˂0.0001) in CM from R37-S100A4 
(Figure 3.3.C2) over empty vector cells. The MMPs identified by zymography were 








Figure 3.3. Gelatin- and casein-zymography for MMP’s activity in conditioned media 
of rat mammary cell lines. 
 (A1) A representative gelatine gel showed proform (pro) MMP-2 (68 kDa) and active (act) 
form MMP-2 (62 kDa) in the CM of Rama 37 empty vector (E.V.), Rama 37-S100P (S100P) and 
Rama 37-S100A4 (S100A4) cells, which corresponded in size to both forms of a recombinant 
human MMP-2 (rhMMP-2). The bands appeared as a clear zone in the gelatine gel. The 
scanner setting was changed to show a negative film image to display the best possible 
contrast of the bands. (A2) Histogram of 7 experiments from A1 showed the proform MMP-
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2 in the CM of Rama 37-S100P was significantly decreased by 3.0±0.4-fold (Student t-test, 
P˂0.0001), but active form MMP-2 was significantly increased by 1.9±0.2-fold (P=0.008) 
compared to E.V. control cells. Proform MMP-2 in the CM of Rama 37-S100A4 was 
significantly decreased by 2.5±0.14-fold (P˂0.0001), but active form MMP-2 was significantly 
increased by 2.3±0.2-fold (P˂0.0001). (B1) A representative gelatine gel showed only proform 
(pro) MMP-9 (92 kDa) in the CM from Rama 37 empty vector (E.V.), Rama 37-S100P (S100P) 
and Rama 37-S100A4 (S100A4) cells, which corresponded in size to a recombinant human 
MMP-9 (rhMMP-9). As above the scanner setting was changed to show a negative film image 
to display the best possible contrast of the bands. The rhMMP-9 was overloaded and hence 
produced an artificial tail in the gel.  (B2) Histogram of 7 experiments from B1 showed 
proform MMP-9 in the CM from Rama 37-S100P and Rama 37-S100A4 was significantly 
increased by 1.9±0.2-fold (P˂0.0001) and by 2.3±0.2-fold (P˂0.0001), respectively, over that 
in empty vector cells. (C1) A representative casein gel showed proform (pro) MMP-13 (60 
kDa) and active (act) form MMP-13 (52 kDa) in the CM of Rama 37 empty vector (E.V.), Rama 
37-S100P (S100P) and Rama 37-S100A4 (S100A4) cells. The bands appeared as a clear zone 
in the gelatin gel when recorded as a positive image. (C2) Histogram of 3 experiments from 
C1 showed proform MMP-13 in the CM of Rama 37-S100P was significantly decreased by 
1.96±0.05-fold (P=0.031), but active form MMP-13 was significantly increased by 5.3±0.2-
fold (P=0.001). Proform MMP-13 in the CM of Rama 37-S100A4 was significantly decreased 
by 1.4±0.02-fold (P=0.001), but active form MMP-13 was significantly increased by 2.2±0.06-
fold (P˂0.0001). E.V. was different for empty vector control for R37-S100P and for R37-
S100A4 cells (Section 2.2.2). 
 
3.2.4 Western blot analysis to confirm identities of MMPs 
 
A specific antibody for each of these MMPs was used in Western blotting as a 
third method to confirm the identities of MMP-2, -9 and -13 and to measure more 
accurately the levels of expressed protein. Cell lysate (CL) and conditioned media 
(CM) from the R37 empty vector, R37-S100P and R37-S100A4 cell lines were collected 
and normalized (Section 2.5). The definitions used of precursor form, proform and 
active form of MMPs detected in this study using Western blotting are as follows. 
Precursor form is the intracellular form of MMP which is detected inside the cell in 
the cell lysate (CL). Proform and active form are the extracellular forms of MMP which 




  When Western blotting was used, the measured apparent molecular weight 
of the MMP-2 precursor in the CL and the MMP-2 proform and active forms in the 
CM were 72, 68 and 62 kDa, respectively, consistent with molecular weights reported  
previously (da Silva et al., 2014; Roomi et al., 2010; Takino et al., 1995). The levels of 
MMP-2 were changed significantly in both the CL and CM from R37-S100P and R37-
S100A4 compared to R37 empty vector control cell lines. When Western blot was 
used on CL, the ratio of band intensity for the precursor MMP-2 at 72 kDa (precursor 
MMP-2/GAPDH ratio) was significantly increased by 1.6-fold (fold mean±SE: 
1.57±0.068, n=3, Student’s t-test, P=0.004) in the CL from R37-S100P and about 1.8-
fold (1.81±0.079, n=3, P=0.004) in CL from R37-S100A4 compared to R37 empty 
vector control cell lines (Figure 3.4.A1 & A2). Moreover, both proform and active 
forms of MMP-2 in the CM from these cell lines were detected using Western 
blotting. The proform MMP-2 at 68 kDa was significantly decreased over empty 
vector by 3.8-fold (mean±SE with respect to empty vector cells set at 1: 3.8±0.07, 
n=7, P˂0.0001) in the CM from R37-S100P and 1.2-fold (1.2±0.02, n=7, P˂0.0001 with 
respect to empty vector cells set at 1) in the CM from R37-S100A4. In contrast, the 
active MMP-2 at 62 kDa was significantly increased by about 1.8-fold (1.83±0.03, 
n=7, P˂0.0001) in the CM from R37-S100P and about 2.5-fold (2.47±0.06, n=7, 
P˂0.0001) in the CM from R37-S100A4 over that in empty vector cells (Figure 3.4.B1 
& B2).  
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3.2.4.2  MMP-9 
The CL and CM from these cell lines showed only one form of MMP-9, a 
precursor/proform at 92 kDa, consistent with that reported previously (Orgaz et al., 
2014) and no active MMP-9 reported molecular weight of 82 kDa (Zeng et al., 1999) 
was observed. The former finding confirmed the results for extracellular MMP-9 
using gelatin-zymography (Figure 3.3.B1). The levels of MMP-9 were changed 
significantly in the CL and CM from R37-S100P and R37-S100A4 compared to R37 
empty vector control cell lines when Western blot was used. Thus, the ratio of band 
intensity for the precursor MMP-9 at 92 kDa (precursor MMP-9/GAPDH ratio) was 
significantly increased in CL from R37-S100P and R37-S100A4 by 1.7-fold (fold 
mean±SE: 1.71±0.03, n=3, Student’s t-test, P=0.035), and 2.5-fold (2.52±0.14, n=3, 
P=0.001), respectively, compared to empty vector control cell lines (Figure 3.5. A1 & 
A2). Moreover, the level of proform MMP-9 at 92 kDa was significantly increased by 
1.6-fold (1.62±0.05, n=7, P˂0.0001) in the CM from R37-S100P and 2.7-fold (2.7±0.2, 
n=7, P˂0.0001) in the CM from R37-S100A4 compared to R37 empty vector control 
cell lines (Figure 3.5. B1 & B2).  
3.2.4.3 MMP-13 
When Western blotting was used for MMP-13, the measured apparent 
molecular weight of the MMP-13 precursor in the CL and the MMP-13 proform and 
active forms in the CM were 50, 60 and 52 kDa, respectively, consistent with those 
reported previously (Peeters-Joris et al., 1998; Schröpfer et al., 2010). The levels of 
MMP-13 were changed significantly in the CL and CM from R37-S100P and R37-
S100A4 compared to R37 empty vector control cell lines. When Western blot was 
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used on CL, the ratio of band intensity for the precursor MMP-13 at 50 kDa 
(precursor MMP-13/GAPDH ratio) was significantly increased by 3.6-fold (fold 
mean±SE: 3.64±0.14, n=3, Student’s t-test, P=0.001) in the CL from R37-S100P and 
2.9-fold (2.92±0.21, n=3, P=0.005) in the CL from R37-S100A4 compared to R37 
empty vector control cell lines (Figure 3.6. A1 & A2). Moreover, the CM from R37-
S100P, R37-S100A4 and R37 empty vector control cell lines all showed expression of 
2 forms of MMP-13, the proform at 60 kDa and active form at 52 kDa. The 60 kDa 
proform MMP-13 was significantly decreased by 2.8-fold (mean±SE with respect to 
empty vector cells set at 1: 2.8±0.07, n=3, Student’s t-test, P=0.004) in the CM from 
R37-S100P and by 8.4-fold (8.4±0.2, n=3, P˂0.0001) in the CM from R37-S100A4. In 
contrast, the 52 kDa active MMP-13 was significantly increased by about 5.3-fold 
(5.27±0.29, n=3, P<0.0001) in the CM from R37-S100P and by 1.6-fold (1.6±0.005, 
n=3, P=0.012) in the CM from R37-S100A4 compared to R37 empty vector control cell 






Figure 3.4. Western blot for MMP-2 forms in the cell lysate (CL) and conditioned 
media (CM) from rat mammary cell lines.  
Ten micrograms (10 µg) of protein for CL or 10 µL volume for CM were loaded on 10 % (w/v) 
SDS-PAGE gels. The total protein concentrations were quantified using BCA. The quantities 
of CM loaded were adjusted according to the amount of protein in the CL estimated by BCA 
(Section 2.5) (A1:CL) Representative Western blot showed the precursor MMP-2 (preMMP-
2) at 72 kDa in the cell lysate (CL) from R37 empty vector (E.V.), R37-S100P (S100P) and R37-
S100A4 (S100A4) cell lines. (A2) Histogram of three independent experiments of A1 showing 
that the level of preMMP-2 (precursor) was increased significantly in the CL from R37-S100P 
and from R37-S100A4 by 1.57±0.06-fold (Student’s t-test, P=0.004) and by 1.81±0.07-fold 
(P=0.004), respectively, compared to their E.V. control cell lines. (B1:CM) Representative 
Western blot showed the proform MMP-2 (proMMP-2) at 68 kDa and active MMP-2 
(actMMP-2) at 62 kDa in the CM from R37 empty vector (E.V.), R37-S100P (S100P) and R37-
S100A4 (S100A4) cell lines. (B2) Histogram of three independent experiments from B1 
showed proMMP-2 (proform) was significantly decreased by 3.8±0.07-fold (P˂0.0001), but 
actMMP-2 (active form) was increased significantly by 1.83±0.03-fold (P˂0.0001)   in the CM 
from R37-S100P over that in empty vector control cell line. The CM from R37-S100A4 cell line 
showed proMMP-2 (proform) was also decreased significantly by 1.14±0.02-fold (P˂0.0001), 
but actMMP-2 (active form) was increased significantly by 2.47±0.06-fold (P˂0.0001) over 
that in empty vector control cell line. There is a band observed at 90 kDa which only appeared 
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during longer exposures with ECL Select Reagent but did not correspond to any seen by 
zymography. Therefore, it was excluded in reporting quantitative results for MMP-2. E.V. was 




   
Figure 3.5. Western blot for MMP-9 forms in the cell lysate (CL) and conditioned 
media (CM) from rat mammary cell lines.  
Ten micrograms (10 µg) of protein for CL or 10 µL for CM was loaded on 10 % (w/v) SDS-PAGE 
gels. The total protein concentrations in CL were quantified using BCA.  The quantity of CM 
loaded was adjusted according to the amount of protein in the CL estimated by BCA (Section 
2.5). (A1:CL) Representative Western blot showed the precursor MMP-9 (preMMP-2) as a 
double band at 92 kDa in the cell lysate (CL) from R37 empty vector (E.V.), R37-S100P (S100P) 
and R37-S100A4 (S100A4) cell lines. (A2) Histogram of three independent experiments from 
A1 showing that the level of preMMP-9 (precursor) was increased significantly in the CL from 
R37-S100P and R-37-S100A4 cell lines by 1.7±0.03-fold (Student’s t-test, P=0.035) and about 
2.5±0.14-fold (P=0.001), respectively, compared to their E.V. control cell lines. (B1:CM) 
Representative Western blot shows the proform MMP-9 (proform) at 92 kDa in the CM from 
R37 empty vector (E.V.), R37-S100P (S100P) and R37-S100A4 (S100A4) cell lines. (B2) 
Histogram of three independent experiments from B1 showing that proform MMP-9 
(proform) was significantly increased by 1.62±0.05-fold (P˂0.0001) and by 2.75±0.17-fold 
(P˂0.0001) in the CM from R37-S100P and R37-S100A4 cell line, respectively, over empty 
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vector cells. E.V. was different for empty vector control for R37-S100P and for R37-S100A4 





Figure 3.6. Western blot for MMP-13 forms in the cell lysate (CL) and conditioned 
media (CM) from rat mammary cell lines. 
 Ten micrograms (10 µg) of protein for CL or 10 µL for CM were loaded on 10 % (w/v) SDS-
PAGE gels. The total protein concentrations were quantified using BCA.  The quantity of CM 
loaded was adjusted according to the amount of protein in the CL estimated by BCA. (A1:CL) 
Representative Western blot showed the precursor MMP-13 (preMMP-13) at 50 kDa in the 
cell lysate (CL) from R37 empty vector (E.V.), R37-S100P (S100P) and R37-S100A4 (S100A4) 
cell lines. (A2) Histogram of three independent experiments from A1 showing that the level 
of precursor MMP-13 (precursor) was increased significantly in the CL from R37-S100P and 
R37-S100A4 cell lines by 3.6±0.14-fold (Student’s t-test, P=0.001) and by 2.9±0.21-fold 
(P=0.005), respectively, compared to their E.V. control cell lines. (B1:CM) Representative 
Western blot showed the proform MMP-13 (proMMP-13) at 60 kDa and active MMP-13 
(actMMP-13) at 52 kDa in the CM from R37 empty vector (E.V.), R37-S100P (S100P) and R37-
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S100A4 (S100A4) cell lines. (B2) Histogram of three experiments from B1 showing that the 
proform MMP-13 (proform) was significantly decreased by 2.8±0.07-fold (Student’s t-test, 
P˂0.004), but active MMP-13 (active form) was increased significantly by 5.27±0.29-fold 
(P˂0.0001) in CM from the R37-S100P cell line. The CM from S100A4 cell line showed proform 
MMP-13 (proform) was also decreased significantly by 8.38±0.21-fold (P˂0.0001), while 
active MMP-13 (active form) was increased significantly by 1.6±0.005-fold (P=0.012) 
compared to empty vector cells. There was a band observed at 75 kDa which appeared only 
during longer exposures with ECL Select Reagent, but which did not correspond to any seen 
by zymography. Therefore, it was ignored in reporting quantitative results for MMP-13. E.V. 





The apparent molecular weights of intracellular S100P and S100A4 of 
(mean±SE) 7.4±0.2 and 8.5±0.3 kDa, respectively, were consistent with Wang et al., 
(2015) and Zhuang et al., (2016). S100A4 has a longer C-terminal region than S100P 
of 5 amino acid residues corresponding to an increase of about 1 kDa in apparent 
molecular weight (Gross et al., 2014). In addition, we detected S100P and S100A4 
proteins in the CM from the same transfected rat mammary cell lines. These proteins 
had the same molecular weights as those in the cytoplasm, but they showed very 
large increases of about (mean±SE) 34.3±3.0 and 76±13-fold, respectively, compared 
to their empty vector control cell lines (Figure 3.1. B2, D2). Although S100P can be 
detected extracellularly, whether they are secreted from living cells or released from 
floating, potentially dying cells in vitro is still debated (Bresnick et al., 2015; Donato 
et al., 2013; Leclerc, 2011). The amounts of S100P or S100A4 proteins inside cells (CL) 
were 16.6±3.8 ng or 18.1±0.5 ng per 20 µg CL and outside in the CM were 8.6±2.3 ng 
or 8.0±0.4 ng per 10 µL CM. Thus, approximately 14.4 % for S100P and 13.1 % for 
S100A4 was found in the conditioned media over the same time period. How these 
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S100 proteins were released from cells is unknown, since they contain no secretory 
signal sequence (Gross et al., 2014). 
 The human array used here can detected 7 MMPs and 3 TIMPs: MMP-1, -2, -
3, -8, -9, -10 & -13, and TIMP-1, -2 & 4. This experiment showed that all these MMPs 
were increased, but not significantly except for MMP-10 and MMP-13 in the CM from 
R37-S100P or R37-S100A4 cells over the empty vector cell lines (Figure 3.2, Appendix 
2). Moreover, the most common MMP proteins which showed an increase between 
S100P-induced HeLa-A3 and R37-S100P/A4 cells were MMP-2, -9, -10 and -13. The 
S100P-induced HeLa cells were included in case the antibodies showed preferential 
specificity for human MMPs. The results using zymography showed that CM from 
R37-S100P and S100A4, when chemically activated after running the gels, produced 
bands corresponding to only MMP-2 and MMP-9 on gelatin-gels and to only MMP-
13 on casein-gels, so eliminating MMP-10 as an activatable MMP (Wu et al., 2012) in 
the cell lines under study. The reason why overexpression of S100P and S100A4 
stimulated only MMP-2, -9 and -13, at least, in Rama 37 cells is unknown. 
 The measured molecular weights in the CM for the higher molecular weight 
forms of MMP-2 and -13 of 68 and 60 kDa and for the next lowest forms of 62 and 52 
kDa, respectively, are identical when detected by chemically-activated enzymatic 
activity (zymography) (Figures 3.3.A1, B1, C1) or by specific antibodies (Western 
blotting) (Figures 3.4.B1, 3.5.B1, 3.6.B1). These molecular weight forms correspond 
to the reported values for the activated forms and the proforms of the MMPs (da 
Silva et al., 2014; Nair et al., 2006; Orgaz et al., 2014; Peeters-Joris et al., 1998; Roomi 
et al., 2010; Schröpfer et al., 2010; Shimokawa Ki et al., 2002), except for MMP-9 
where our gels identified only that corresponding to the proform and not the 
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reported active form of 82 kDa (Zeng et al., 1999). Moreover, the molecular weights 
forms of  MMP-2, MMP-9 and MMP-13 identified by Western blot of CLs (cell lysates) 
of 72, 92 and 50 kDa, respectively, corresponded to those of the reported precursor 
forms which occur within cells (da Silva et al., 2014; Nair et al., 2006; Orgaz et al., 
2014; Peeters-Joris et al., 1998; Roomi et al., 2010; Schröpfer et al., 2010; Shimokawa 
Ki et al., 2002). Presumably preMMP-2 at 72 kDa is successively cleaved into 
proMMP-2 at 68 kDa and activated MMP-2 at 62 kDa (Takino et al., 1995); the 
cleavage pathway for MMP-9 (Orgaz et al., 2014) does not occur in our cells. In 
contrast, there is an increase in apparent molecular weight in going from preMMP-
13 at 50 kDa to proMMP-13 at 60 kDa and then a reduction to activate MMP-13 at 
52 kDa presumably due to post-translation modifications and zymogen activation, 
respectively (Boon et al., 2016; Knäuper et al., 1996).  
When the quantitative results are compared between those obtained by 
zymography and by Western blots, there is complete agreement of direction of 
change for all 3 MMPs in R37-S100P and R37-S100A4 cells (Table 3.1.). In the CM for 
MMP-2 and MMP-13 where cleavage occurs, the proform is significantly reduced and 
the activated form is significantly increased (Student’s t-test P≤0.004). Since no 
activated form of MMP-9 is produced, the proforms showed significant accumulation 
in the CM over the empty vector cell lines (P≤0.035) (Table 3.1). The production of 
precursors in the CL measured by Western blotting alone all showed an increase 
ranging from 1.6 to 3.6-fold and these increases were similar to the range of increases 
in activated forms for MMP-2 and MMP-13 of 1.6 to 5.3-fold, with individual paired 
fold changes showing similar differences (CL precursor vs CM active form in the R37-
S100P and S100A4 cells using Western blot) MMP-2: 1.6 vs 1.83 and 1.81 vs 2.47, and 
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MMP-13: 3.64 vs 5.27 and 2.92 vs 1.56, respectively. Since the input of both the CM 
and CL have been normalised to the total protein in the cell (section 2.5), these results 
suggested that all the increase seen in the active forms of MMP-2 and MMP-13 in the 
CM could be accounted for by the increase in production of the precursor forms 
within the cell, and even in the case of MMP-9 where no active form is produced, the 
increases in proMMP-9 in CM are not significantly different from those in precursor 
MMP-9 in the cells (CL vs CM: 1.71±0.035 vs 1.62±0.05; 2.52±0.14 vs 2.75±0.17 for 
S100P and S100A4-containing cells) (Table 3.1).  
 
Table 3.1. Conclusion of comparative changes in MMPs. 
 
 
a Matrix metalloproteinase (MMP): pre, precursor; pro, proform; act, active form. 
b Cell lysate (CL) or conditioned media (CM). 
c Mean fold changes in levels of MMPs in S100P/S100A4 either increased (+) or decreased (-
) ± standard error of mean (SE). 




Our results of increases in MMP-2, -9 and -13 in malignant over non-malignant 
cell lines are broadly in agreement with those previously published in different cell 
system (Johansson et al., 1999; Li et al., 2017). Thus in the breast cancer cell lines 
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MDA-MB-231 and MCF-7 there is an increase in MMP-2 mRNA or protein compared 
to the normal human breast Hs578Bst cell line (Li et al., 2017), although an earlier 
publication suggested that it was produced only in the stromal cells and not from the 
breast cancer cells in cell lines  and primary cultures from breast cancer  biopsies 
(Singer et al., 2002). For MMP-9 Mehner et al. (2014) showed that expression of 
MMP-9 mRNA was elevated in the media of the more malignant breast cancer MDA-
MB-435 cell line. A further study showed that more inactive proform of MMP-9 was 
produced in rounded-amoeboid melanoma cells than in elongated mesenchymal-like 
melanoma cells. More importantly, addition of inactive proform MMP-9 could 
enhance rounded-amoeboid cell migration in three dimensions due to an increase in 
actomyosin contractility triggered via the CD44 receptor (Orgaz et al., 2014). Thus, it 
is possible that overproduction and release of proform MMP-9 from R37-S100P/A4 
cells may still have a significant role in cell migration independent of its gelatinase 
activity. For MMP-13, it was found to be highly expressed as mRNA or protein in 
highly invasive MDA-MB-231 cells compared to other less invasive cell lines (Balduyck 
et al., 2000). Moreover, a study on specimens from breast cancer in vivo showed that 
the level of MMP-13 protein was significantly higher in breast cancer than in normal 
breast cells (Kotepui et al., 2016), confirming earlier reports in colorectal cancer (M. 
F. Leeman et al., 2002) and papillary thyroid carcinoma (Wang et al., 2013). Whether 
the increased levels of these MMPs play a biological role in the development of the 






 Summary  
 
Benign rat mammary (R37) cell lines previously transfected with expression 
vectors for S100P or S100A4 produced 22 to 128-fold more of these proteins inside 
cells in comparison with empty vector-containing R37 cells and for the first time were 
shown to secrete substantial amounts of 8.6 ng and 8.03 ng in 10 µL CM, respectively. 
When screened with antibody arrays these transfected and S100-overexpressing cell 
lines produced increased levels of MMPs in their CM, but on chemically-activated 
zymography only MMP-2, MMP-9 and MMP-13 showed significant increases in 
proteolytic activity on gelatin (MMP-2 and MMP-9) or casein (MMP-13) containing 
polyacrylamide gels. Western blotting confirmed significantly increased levels of 1.6 
to 5.3-fold of active forms of MMP-2 and MMP-13 in the CM were probably produced 
by similar increases of 1.6 to 3.6-fold in their precursors inside the cells (CL). MMP-9, 
in contrast, produced only its proform in the CM in 1.6 to 2.7-fold higher levels than 
that in empty vector-containing cells and these values were matched by a similar 










Chapter 4  
 
 
Role of specific MMPs in induction of migration and 
invasion in S100P/S100A4 overexpressing rat 




Among many proteins reported to be involved in breast cancer are S100P and 
S100A4, and their levels correlate significantly with poor outcome for breast cancer 
patients’ survival (Ismail et al., 2017; Rudland et al., 2000; Wang et al., 2006; Zhang 
et al., 2017). S100P and S100A4 have been shown to promote metastasis in breast 
cancer models (Ambartsumian et al., 1996; Davies et al., 1993, 1996; Wang et al., 
2006) by increasing cell motility and invasion (Du et al., 2012; Jenkinson et al., 2004). 
Degradation of the ECM is involved in both cell migration and cell invasion and both 
processes  are promoted by MMPs in tissue cultured cells (Maletzki et al., 2012). 
MMPs also can enhance cancer cell metastasis, presumably by stimulating cell 
migration and/or invasion (Mishra et al., 2012), possibly by cleavage of fibronectin 
and collagen I, respectively  (Sen et al., 2010). On particular example is when S100P 
inhibition is reduced in nasopharyngeal carcinoma cell lines a series of intracellular 
alterations are generated, these include suppression of expression of MMP-2 and 
MMP-9 (Liu et al., 2017). Moreover in the pancreatic carcinoma BxPC3 cell line, S100P 




In thyroid cancer and in rat C6 glioma cell lines, overexpression and 
suppression of the S100A4 gene intracellularly has led to increases and decreases, 
respectively, in the expression of MMP-9 (Jia et al., 2013; Takenaga and Kozlova, 
2006). Moreover, in MDA-MB-231 and MDA-MB-468 breast cancer cell lines, S100A4 
can induce epithelial-mesenchymal transition (EMT), in part, through increased 
expression of MMP-2 (Xu et al., 2016). Thus, in order to investigate the effects of 
MMPs on cell migration and invasion in vitro, we shall knock-down the selected 
MMPs identified in Chapter 3 in S100P/S100A4-overexpressing rat mammary cell 
lines and observe the resultant effects on cell migration and invasion in vitro. 
For knock-down experiments in mammalian cells, double stranded RNAs (21-
23 nucleotides), also called short or small interfering RNAs (siRNA), can be used to 
inhibit specific sequences in protein-coding genes (Elbashir et al., 2001). Thus, 
transient transfection of siRNAs into living cells can inhibit, for a short-term, specific 
gene expression, and hence the effect of this gene on cellular processes (Ameyar-
Zazoua et al., 2005). There are several examples of this type of experiment in cancer 
cells. Thus, when Badiga et al., (2011) inhibited MMP-2 expression using siRNA 
techniques, this caused a significant reduction in glioma cell migration, invasion, 
angiogenesis and tumour growth compared to non-inhibited control cells.  
To study cell migration, there are a number of methods, e.g., scratch or 
wound healing assays in 2D,transwell migration and invasion assays by squeezing 
through pores in membranes, 3D cell migration in gels in vitro and cell movement in 
organs in vivo (Moutasim et al., 2011; Su et al., 2017). These assays all have their own 
advantages and disadvantages. The most common method to study cancer cell 
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migration and invasion is through pores in membranes along a concentration 
gradient (Moutasim et al., 2011).  
4.1.1 Chapter aims 
 
To examine the transient effect of siRNAs directed against specific MMPs on the 
migration and invasion of S100P/A4 overexpressing cell lines. 
 Results 
4.2.1 Knock-down of MMP proteins 
 
The R37-S100P and R37-S100A4 cell lines were cultured routinely and then 
processed to knock-down MMP-2, MMP-9 and MMP-13 individually or a combination 
of all 3 MMPs as described in Materials and Methods (Section 2.15). 
4.2.1.1 Treatment with siRNA for MMP-2 
Upon transient transfection of siRNA directed at MMP-2 mRNA, the level of 
precursor intracellular MMP-2 at 72 kDa was significantly decreased in the R37-S100P 
and R37-S100A4 cell lines by 9-fold (mean±SE:9.02±0.19, n=3, Student’s t-test, 
P˂0.0001), and by 6.5-fold (6.5±1.6, n=3, P=0.020), respectively. The levels of 
intracellular precursor MMP-9 or MMP-13 were not significantly affected (P≤0.460) 
when MMP-2 alone was knocked-down by siRNA MMP-2 compared to si-scrambled 
control (Appendix 3). In addition, the R37-S100P and R37-S100A4 cells treated 
simultaneously with the combined siRNA to MMP-2, 9 and 13 showed a significant 
decrease in the level of MMP-2 by about 1.4-fold (1.4±0.01, n=3, P=0.014) and by 
about 3.8-fold (3.8±1.0, n=3, P=0.037), respectively (Figure 4.1). Since MMP-2 levels 
88 
 
failed to change between untreated R37-S100P (mean±SE, 0.321±0.04) or R37-
S100A4 (0.4±0.1) cells and treated R37-S100P (0.4±0.02) or R37-S100A4 (0.4±0.08) 
cells with scrambled siRNA (P≥0.51), there was no toxicity due to siRNA transfection.    
4.2.1.2 Treatment with siRNA for MMP-9 
When transiently transfected with siRNA to MMP-9, the R37-S100P and R37-
S100A4 cell lines showed a significant decline in the level of intracellular precursor 
MMP-9 at 92 kDa by about 5-fold (mean±SE:5.2±0.8, n=3, Student’s t-test, P=0.005), 
and by about 6-fold (5.8±0.2, n=3, P˂0.0001), respectively. Moreover, when the R37-
S100P and R37-S100A4 cells were simultaneously treated with siRNA to MMP-2, 9 
and 13 the level of MMP-9 was also significantly reduced by nearly 3.5-fold (3.5±0.7, 
n=3, P=0.011) and by nearly 2.6-fold (2.6±0.08, n=3, P˂0.0001), respectively (Figure 
4.2). The levels of intracellular precursor MMP-2 or MMP-13 were not obviously 
affected when MMP-9 alone was knocked-down by siRNA MMP-9 (data not shown). 
Since MMP-9 levels failed to change between untreated R37-S100P (mean±SE, 
0.55±0.14) or R37-S100A4 (0.14±0.004) cells and treated R37-S100P (0.38±0.05) or 
R37-S100A4 (0.13±0.002) cells with scrambled siRNA (P≥0.27), there was no toxicity 
due to siRNA transfection.    
4.2.1.3 Treatment with siRNA for MMP-13 
When both R37-S100P and R37-S100A4 cell lines were treated with siRNA to 
MMP-13, they showed a considerable decline in the level of intracellular precursor 
MMP-13 at 50 kDa by about 3.7-fold (mean±SE:3.7±0.2, n=3, Student’s t-test, 
P˂0.0001), and by nearly 3.6-fold (3.6±0.2, n=3, P=0.003), respectively. Additionally, 
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when R37-S100P and R37-S100A4 cell lines were simultaneously treated with siRNA 
to MMP-2, 9 and 13, they both showed a significant decrease in the level of MMP-13 
by about 1.7-fold (1.72±0.048, n=3, P˂0.0001) and about 1.9-fold (1.95±0.077, n=3, 
P=0.019), respectively (Figure 4.3). The levels of intracellular precursor MMP-2 or 
MMP-9 were not obviously affected when MMP-13 alone was knocked-down by 
siRNA MMP-13 (data not shown). Since MMP-13 levels failed to change between 
untreated R37-S100P (mean±SE, 0.83±0.01) or R37-S100A4 (0.22±0.03) cells and 
treated R37-S100P (0.70±0.01) or R37-S100A4 (0.21±0.02) cells with scrambled siRNA 




Figure 4.1. Western blots for MMP-2 in the R37-S100P and R37-S100A4 cell lines 
treated with siRNA to MMP-2 alone or siRNA to MMP-2, 9 and 13. 
 Ten µg of protein was loaded on 10 % (w/v) SDS-PAGE gels after total protein concentrations 
in cell lysates (CL) were quantified using BCA. (A1 & B1) Representative Western blots show 
the level of intracellular precursor MMP-2 (preMMP-2) at 72 kDa in the Rama 37-S100P (R37-
S100P) and in the Rama 37-S100A4 (R37-S100A4) cells after 72 h treatment with siRNA MMP-
2 (si-MMP-2) alone, siRNA MMP-2, 9 and 13 simultaneously (siMMP-2, 9 and 13), and siRNA 
scrambled control (si-scrambled). GAPDH was used as a loading control. The MMP-2 band 
chemiluminescence was detected using ECL Select Reagents, whilst that of GAPDH was 
detected using standard ECL Reagents (Materials and Methods). (A2) Histogram of the 
mean±SE of three independent experiments from A1 showing ratio precursor band intensity 
of MMP-2 to that of GAPDH in the R37-S100P cells treated with si-MMP-2 individually; si-
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MMP-2, 9 and 13 simultaneously; or si-scrambled control. Level of MMP-2 was significantly 
decreased in the R37-S100P cells treated with si-MMP-2 alone by 9-fold (Student’s t-test, 
P˂0.0001) and in R37-S100P cells treated with si-MMP-2, 9 and 13 simultaneously by 1.42-
fold (P=0.014) compared to si-scrambled control. (B2) Histogram of the mean±SE of three 
independent experiments from B1 showing ratio precursor band intensity of MMP-2 to that 
of GAPDH in the R37-S100A4 cells treated with si-MMP-2 individually, si-MMP-2, 9 and 13 
simultaneously, or si-scrambled control. Level of MMP-2 was also significantly decreased in 
R37-S100A4 cells treated with si-MMP-2 alone by 6.5-fold (P=0.020) and in R37-S100A4 cells 






















Figure 4.2. Western blots for MMP-9 in the Rama 37-S100P (R37-S100P) and Rama 
37-S100A4 (R37-S100A4) cell lines treated with siRNA to MMP-9 or MMP-2, 9 and 
13.  
Ten µg of protein was loaded on 10 % (w/v) SDS-PAGE gels after total protein concentrations 
in cell lysates (CL) were quantified using BCA. (A1 & B1) Representative Western blots 
showed the level of intracellular precursor MMP-9 (preMMP-9) at 92 kDa in R37-S100P or 
R37-S100A4 cell lines after 72 h treatment with siRNA MMP-9 (si-MMP-9) alone, siRNA MMP-
2, 9 and 13 simultaneously (siMMP-2, 9 and 13), or siRNA scrambled (si-scrambled) control. 
GAPDH was used as a loading control. The MMP-9 band chemiluminescence was detected 
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using ECL Select Reagents, whilst that of GAPDH was detected using standard ECL Reagents 
(Material and Methods). (A2) Histogram of the mean±SE of three independent experiments 
from A1 showing ratio precursor band intensity of MMP-9 to that of GAPDH in R37-S100P 
cells treated with si-MMP-9 alone; si-MMP-2, 9 and 13 simultaneously or si-scrambled 
control. Level of MMP-9 was significantly decreased in R37-S100P cells treated with si-MMP-
9 alone by 5-fold (Student’s t-test, P=0.005) and in R37-S100P cells treated with si-MMP-2, 9 
and 13 simultaneously by 3.5-fold (P=0.011) compared to si-scrambled control. (B2) 
Histogram of mean±SE of three independent experiments from B1 showing ratio precursor 
band intensity of MMP-9 to that of GAPDH in R37-S100A4 cells treated with si-MMP-9 alone, 
si-MMP-2, 9 and 13 simultaneously or si-scrambled control. Level of MMP-9 was also 
significantly decreased in R37-S100A4 cells treated with si-MMP-9 alone by 5.8-fold 
(P˂0.0001) and in R37-S100A4 cells treated with si-MMP-2, 9 and 13 simultaneously by 2.6-






Figure 4.3. Western blots for MMP-13 in Rama 37-S100P (R37-S100P) and Rama 37-
S100A4 (R37-S100A4) cell lines treated with siRNA to MMP-9 or siRNA to MMP-2, 
9 and 13 simultaneously.  
Ten µg of protein was loaded on 10 % (w/v) SDS-PAGE gels after total protein concentrations 
in cell lysates (CL) were quantified using BCA. (A1 & B1) Representative Western blots 
showed the level of intracellular precursor MMP-13 (preMMP-13) at 50 kDa in R37-S100P or 
R37-S100A4 cells after treatment for 72 h with siRNA MMP-13 (si-MMP-13) alone; siRNA 
MMP-2, 9 and 13 simultaneously (siMMP-2, 9 and 13); or siRNA scrambled (si-scrambled) 
control. The GAPDH was used as a loading control. The MMP-13 band chemiluminescence 
was detected using ECL Select Reagents, whilst GAPDH band chemiluminescence was 
detected using standard ECL Reagents. (A2) Histogram of mean±SE of three independent 
experiments from A1 showing that the ratio precursor band intensity of MMP-13 to that of 
GAPDH in R37-S100P cells treated with si-MMP-13 alone; si-MMP-2, 9 and 13 simultaneously, 
or si-scrambled control. Level of MMP-13 was significantly decreased in R37-S100P cells 
treated with the si-MMP-13 alone by 3.7-fold (Student’s t-test, P˂0.0001) and in R37-S100P 
cells treated with si-MMP-2, 9 and 13 simultaneously by 1.7-fold (P˂0.0001) compared to si-
scrambled control. (B2) Histogram of mean±SE of three independent experiments from B1 
showing ratio precursor band intensity of MMP-13 to that of GAPDH in R37-S100A4 cells 
treated with si-MMP-13 alone; si-MMP-2, 9 and 13 simultaneously, or si-scrambled control. 
Level of the MMP-13 was also significantly decreased in R37-S100A4 cells treated with si-
MMP-13 alone by 3.6-fold (P=0.003) and in R37-S100A4 cells treated with the si-MMP-2, 9 
and 13 simultaneously by 1.9-fold (P=0.019) compared to si-scrambled control. 
 
4.2.2 Migration and invasion assays in the Rama 37-S100P/S100A4 
cell lines 
 
For the R37-S100P and R37-S100A4 cell lines, 6 x 103 cells for the migration, 
and 12 x 103 cells for the invasion assays were seeded and grown for 24 h in Boyden 
chambers without or with membranes coated with Matrigel (Section 2.13 and 2.14) 
(Appendix Figure 4). Results from the migration assays showed that there was an 
increase of about 7-fold (mean±SE:7.4±0.7, n=3, Student’s t-test, P=0.006) in the R37-
S100P, and about 2-fold (2.1±0.2, n=3, P=0.006) in the R37-S100A4 cell line compared 
to the R37 empty vector control (Figure 4.4A). Moreover, results from the invasion 
assays showed even greater increases of about 20-fold (mean±SE:20.3±7.6, n=3, 
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Student’s t-test, P=0.014) in the R37-S100P, and about 3-fold (3.3±0.6, n=3, P=0.03) 
in the R37-S100A4 cell line compared to Rama 37 empty vector control (Figure 4.4B). 
 
Figure 4.4. Migration and invasion assays in the Rama 37-S100P (R37-S100P) and 
Rama 37-S100A4 (R37-S100A4) cell lines. 
 (A) Histogram shows the mean±SE increase in migrated cells for R37-S100P and R37-S100A4 
in comparison with the empty vector control cell lines. There was a significant increase of 
about 7-fold (Student’s t-test, P=0.006) and about 2-fold (P=0.006), respectively, compared 
to R37 empty vector control cells. (B) Histogram shows the mean±SE fold increase in invaded 
cells for R37-S100P and R37-S100A4 in comparison with the empty vector control cell lines. 
There was a significant increase of about 20-fold (P=0.014) and about 3-fold (P=0.034), 
respectively, compared to R37 empty vector control cells. Migration and invasion 
experiments were recorded from 3 wells repeated 3 times with different batches of 
cells (n=3). The Bars refer to mean±SE and the numbers above them refer to fold 
differences compared to empty vector control (R37 E.V.) cells. Micrographs of migration and 
invasion assays are recorded in Appendix 4.  
 
4.2.3 Effect of knock-down of MMPs on migration or invasion of 
S100P/S100A4 overexpressing rat mammary cells 
  
The R37-S100P or S100A4 cells were divided into 5 groups and then each 
group was treated with one of the following: siRNA to MMP-2; siRNA to MMP-9; 
siRNA to MMP-13; siRNAs to MMP-2, 9 and 13 simultaneously, or siRNA to scrambled 
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control (Section 2.15). After 48 h transfection time, all cells were removed and 
seeded in Boyden chambers without or with Matrigel (Sections 2.13 and 2.14) 
(Appendix 5). R37-S100P cells showed a significant decrease in cell migration for all 
knocked-down groups compared to siRNA scrambled control. Results were a 
decrease of 1.8-fold (mean±SE:1.82±0.05, n=2, Student’s t-test, P=0.001) in the siRNA 
MMP-2-treated group; 1.7-fold (1.72±0.10, n=2, P=0.008) in the group treated with 
siRNA MMP-9-treated group; 1.4-fold (1.44±0.07, n=2, P=0.010) in the siRNA MMP-
13-treated group; and 2.8-fold (2.75±0.07, n=2, P˂0.0001) in the siRNAs MMP-2, 9 
and 13 simultaneously-treated group. Moreover, R37-S100A4 cells after MMP’s 
knock-down also showed significant decreases in cell migration as follows: 2-fold 
(mean±SE: 2.1±0.05, n=2, Student’s t-test, P=0.002) in the siRNA MMP-2-treated 
group; 2-fold (2.5±0.01, n=2, P=0.002) in the siRNA MMP-9-treated group; 2-fold 
(2.4±0.02, n=2, P=0.002) in the MMP-13-treated group; and 2-fold (2.1±0.04, n=2, 
P=0.002) in the siRNAs MMP-2, 9 and 13 simultaneously-treated group compared to 
siRNA scrambled control groups (Figure 4.5A).  
Results for invasion were decreased even more significantly than those for 
migration in the R37-S100P cells after MMPs knock-down as follows: 3-fold 
(mean±SE: 3.3±0.2, n=2, Student’s t-test, P=0.002) in the siRNA MMP-2-treated 
group; 2-fold (2.3±0.1, n=2, P=0.004) in the siRNA MMP-9-treated group; 9-fold 
(9.4±0.7, n=2, P=0.001) in the siRNA MMP-13-treated group; and 5-fold (5.0±0.5, n=2, 
P=0.002) in the siRNA MMP-2, -9 and -13 simultaneously-treated group compared to 
siRNA-A scrambled control group. Moreover, results for knock-down of MMPs in R37-
S100A4 cells showed an even more significant decrease in invasion as follows: 21-fold 
(mean±SE: 21.17±0.54, n=2, Student’s t-test, P=0.009) in the siRNA MMP-2-treated 
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group; 11-fold (11.24±1.04, n=2, P=0.010) in the siRNA MMP-9-treated group; 18-fold 
(18.18±4.78, n=2, P=0.009) in the siRNA MMP-13-treated group; and 38-fold 
(37.95±3.21, n=2, P=0.009) in the siRNA MMP-2, -9 and -13 simultaneously-treated 
group in comparison with siRNA-A scrambled control (Figure 4.5B). 
 
Figure 4.5. Migration and invasion of S100P/S100A4 overexpressing rat mammary 
cell lines after knock-down by MMPs. 
 (A) Histogram shows mean±SE fold reduction in migrated cells for R37-S100P and R37-
S100A4 cell lines treated for 48 hours with siRNAs to different MMPs relative to scramble 
siRNA. R37-S100P cells showed significant decreases in cell migration after MMP’s knock-
down by the following: 1.8-fold (Student’s t-test, n=2, P=0.001) in the siRNA MMP-2 (si-MMP-
2)-treated group; 1.7-fold (P=0.008) in the siRNA MMP-9 (si-MMP-9)-treated group; 1.4-fold 
(P=0.010) in the siRNA MMP-13 (si-MMP-13)-treated group; and 2.7-fold (P<0.0001) in the 
siRNAs MMP-2, -9 and -13 simultaneously (si-MMP-2, -9 and -13 )-treated group compared 
to siRNA-A scrambled control. Moreover, R37-S100A4 cells showed a significant similar 
decrease in cell migration by 2-fold (Student’s t-test, n=2, P=0.002) in the siRNA MMP-2 (si-
MMP-2)-treated group; 2.3-fold (P=0.002) in the siRNA MMP-9 (si-MMP-9)-treated group; 
2.4-fold (P=0.002) in the siRNA MMP-13 (si-MMP-13)-treated group; and 2-fold (P=0.002) in 
the siRNAs MMP-2, -9 and -13 simultaneously (si-MMP-2, -9 and -13)-treated group 
compared to siRNA-A scramble control. (B2) Histogram shows mean±SE fold reduction in 
invaded cells for R37-S100P and R37-S100A4 cell lines treated for 48 hours with siRNA to 
different MMPs relative to scrambled siRNA. R37-S100P cells showed significant decreases 
in cell invasion after MMPs were knocked-down by the following: 3-fold (Student’s t-test, 
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n=2, P=0.002) in the siRNA MMP-2 (si-MMP-2)-treated group; 2.3-fold (P=0.004) in the siRNA 
MMP-9 (si-MMP-9)-treated group; 9-fold (P=0.001) in the siRNA MMP-13 (si-MMP-13)-
treated group; and 5-fold (P=0.002) in the siRNAs MMP-2, -9 and -13 simultaneously (si-
MMP-2, -9 and -13)-treated group compared to siRNA-A scramble control. Moreover, R37-
S100A4 cells showed even more significant differences than the R37-S100P cells in cell 
invasion after MMP’s knock-down by the following: 21-fold (Student’s t-test, n=2, P=0.009) 
in the siRNA MMP-2 (si-MMP-2)-treated group; 11-fold (P=0.01) in the siRNA MMP-9 (si-
MMP-9)-treated group; 18-fold (P=0.009) in the siRNA MMP-13 (si-MMP-13)-treated group; 
and 38-fold (P=0.009) in the siRNAs MMP-2, -9 and -13 simultaneously (si-MMP-2, -9 and -
13)-treated group compared to siRNA-A scramble control. Migration and invasion 
experiments were recorded from 3 wells repeated 2 times with different batches of 





S100P/S100A4 overexpressing rat mammary cell lines showed a significant 
decrease ranging from 3.6 to 9-fold (Student’s t-test, P≤0.02) (Table 4.1.) in protein 
expression of intracellular preMMP-2, -9 and -13 after separate treatment with each 
siRNA for MMP-2, -9 or -13 (Figure 4.1-3). Treatment of cell lines with the noncognate 
MMP siRNA showed no significant difference (P≥0.380) for MMP-9 or MMP-13 
(Appendix 3). Moreover, knock-down of MMP-2, -9 and -13 at the same time (i.e. 
simultaneously) showed a significant decrease ranging from 1.4 to 3.9-fold (Student’s 
t-test, P≤0.037) in the protein levels for these MMPs in R37-S100P/A4 cell lines as 
summarised in Table 4.1. A possible reason for the lower fold decreases in the triple 
siRNA to single siRNA levels of individual MMPs is the fact that the input was 3.5 pmol 
for each MMP in the triple siRNA and 7 pmol for each MMP in the single siRNA 
(Section 2.15.5). The siRNA depletion was specific for its target MMP, since there was 
no effect on unrelated MMPs (Appendix 3). Moreover, siRNA caused no reduction in 
the control protein GAPDH which showed that such house-keeping proteins are 
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unaffected. Although, both cell lines showed a reduction in specific MMP when 
transfected with its cognate siRNA and a concomitant reduction in both cell migration 
and cell invasion, there was no simple linear relationship between level of MMP and 
cell migration/invasion. However, the fold decreases in cell migration were usually 
less than those in cell invasion (Table 4.1 and 4.2). These results suggest that the 
major effect of the MMPs was in promoting cell invasion, probably by digesting the 
ECM in Matrigel, predominantly collagen I, and that they exerted a smaller effect on 
cell migration possibly by digesting proteins connected to focal adhesions (e.g. 
fibronectin) (Sen et al., 2010). This conclusion is consistent with that obtained in the 
R37-S100P and R37-S100A4 transfected cell lines where fold increases in invasion 
were invariably greater than fold increases in migration over those of the empty 
vector transfected control cell lines (Figure 4.4). The results are also consistent with 
these MMPs being one of the effectors of S100P/A4. 
 
Table 4.1. Effect of MMP knock-down on MMP protein levels in S100P/A4 
overexpressing rat mammary cell lines. 
 
 
a Mean fold decrease±SE, n=3, Student’s t-test, P value. 
b Matrix metalloproteinase-2. 
c Cell line transfected with particular siRNA to MMP (7 pmol). 




Migratory and invasive potential of malignant R37-S100P/S100A4 cells have 
been previously reported (Lloyd et al., 1998; Wang et al., 2006). Our data for R37-
S100P and R37-S100A4 cell migration showed significant increases by 7.4- and 2-fold 
(Student’s t-test, n=3, P≤0.006), respectively, over the non-malignant R37 empty 
vector control cell line. However, the difference between the two empty vector 
controls in the migration assay (Figure 4.4A) is of the order of 7-fold. This highlights 
the potential problem of using clonal cell lines for biological assays; these clones may 
at times exhibit substantial differences from the original cell population from which 
they were derived. Therefore, the differences between the results of transfectants 
and their respective empty vector controls may also include effects (positive or 
negative) due to their clonal origin. 
 In addition, the malignant S100P/S100A4 overexpressing cell lines showed 
even higher increases of 20- and 3-fold (P≤0.03), respectively, over non-malignant 
empty vector control cell lines, these results are in agreement with those previously 
reported for S100P or S100A4 transfected rat mammary cell lines (Du et al., 2012; 
Gross et al., 2014; Jenkinson et al., 2004).  
 When MMPs in malignant, overexpressing S100P or S100A4 rat mammary 
cells were knocked-down, they showed a significant decrease in the number of cells 
migrating ranging from 1.4- to 2.8-fold (P≤0.01) and 2.1- to 2.4-fold (P≤0.002), 
respectively, and an even greater fold reduction in invading cells ranging from 2.3- to 
9.4-fold and 11.2- to 38-fold, respectively (Table 4.2), since siRNA transfection 





Table 4.2. Conclusion of MMP knock-down and effect on R37-S100P/A4 cell 
migration and invasion. 
 
 
a Mean fold decrease±SE after transient transfection of siRNAs to different MMPs in relation 
to scrambled siRNA controls. 
b Probability P of difference from scrambled controls (Student’s t-test, n=2). 
 
 
The R37-S100P cell line showed higher fold increases in migrating and 
invading cells (7.4- and 20-fold) (Figure 4.4), respectively, than that for knock-down 
by various siRNA MMPs (1.4 to 2.8 and 2.3 to 9.4-fold decreases, respectively) (Table 
4.2) over the R37 empty vector control cells. Assuming siRNA inhibition is complete, 
this result suggests that there are additional changes induced by S100P which 
contribute to the S100P-induced increase in migration and invasion other than those 
produced by MMP-2, MMP-9 and MMP-13. One example could be increases in 
plasminogen activator/plasmin (Clarke et al., 2017). In contrast, the lower increases 
induced by S100A4 (2 and 3-fold) (Figure 4.4) are largely matched (2-fold in 
migration) or even exceeded (11- to 38-fold in invasion) (Table 4.2) by the decreases 
caused by siRNA MMPs in R37-S100A4 cells. Thus, it would seem that no extra 
changes need to be suggested to account for the increase in cell migration and 
invasion in R37-S100A4 cells.  
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Moreover, knocking-down MMP-2, -9 and -13 simultaneously in R37-S100P 
cells showed higher fold decreases in number of migrating cells by 2.8-fold (P<0.0001) 
compared to knock-down of MMPs individually which showed decreases ranging 
from 1.4- to 1.8-fold. In contrast, R37-S100A4 showed almost similar impacts on cell 
migration when siRNAs to MMPs were added either individually or when added 
simultaneously, producing decreases ranging from 2.1- to 2.4-fold. Since roughly 
equal amounts of total single and triple siRNA were added (Materials and Methods), 
it may be that there is a requirement for more than one MMP to be active in 
promoting cell migration in R37-S100P, but not in R37-S100A4 cells.   
The relative effect on cell invasion of individually knocking-down MMPs in the 
R37-S100P cells showed that the most effective siRNA was that due to MMP-13. This 
result may due to the requirement of MMP-13 for stimulation and activation of MMP-
2 and/or MMP-9 (Knauper et al., 1997, 1996; Leeman et al., 2002), as described in 
Section 1.3.2. This conclusion would suggest that more than one MMP is required to 
promote invasion effectively in R37-S100P cells, similar to the conclusion reached for 
migration. In contrast, siRNA to MMP-2 was the most effective in decreasing invasion 
of R37-S100A4 cells followed by siRNA to MMP-13. These results suggest that the 
collagen IV/collagen I matrix laid down by R37-S100P and R37-S100A4 cells may be 
slightly different requiring different MMPs to digest it successfully (Warburton et al., 
1987a, 1987b), and thereby allow cells to pass through the pores in the membrane.  
The results from knocking-down MMP-2 and MMP-13 on cell migration and 
invasion in both cell lines are consistent with their significant activities observed using 
zymography (Section 3.2.3). The stronger effect of siRNA to MMP-2 in R37-S100A4 
over R37-S100P cells may be because the level of precursor MMP-2 (in CL) and active 
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form MMP-2 (in CM) is always higher in the R37-S100A4 compared to the R37-S100P 
cells over empty vector control cell lines.  
The knock-down of R37-S100P/S100A4 cells with siRNA to MMP-9 showed 
that MMP-9 has more effect on cell migration and invasion in the R37-S100A4 
compared to the R37-S100P cell lines. This difference may due to the fact that MMP-
9’s levels in the CL and CM were higher in the R37-S100A4 compared to the R37-
S100P cells over empty vector control cell lies. Although, MMP-9 appeared only as its 
proform in CM of both cell lines using zymography (Section 3.2.3), it still showed a 
highly significant effect on the cells’ migration or invasion in both cell lines. Since 
MMP-9 appeared incapable of proteolytic digestion in our systems, it must produce 
its effects via another system or pathway. One suggested alternative is for proMMP-
9 to regulate the actomyosin cytoskeleton, thereby increasing cell migration via CD44 
receptors and eventually cell invasion via remodelling of the ECM via gelatinases and 
collagenases, such as MMP2/MMP-9 and MMP-13  (Orgaz et al., 2014). 
Intracellularly-overexpressed S100P has been found in many types of cultured 
cancer cell lines, such as those from breast (Guerreiro Da Silva et al., 2000), colon 
(Dong et al., 2014), pancreas (Dong et al., 2014) and lung (Dong et al., 2014). These 
cell lines have been usually manipulated by knockout experiments to demonstrate 
the crucial role of S100P in enhancing metastasis. These results in vitro are consistent 
with the finding in this thesis and that of others (Arumugam and Logsdon, 2011; Gross 
et al., 2014) that overexpression of S100P in rat mammary cell lines caused a 
significant increase in migration and invasion. Similarly, overexpression of S100A4 in 
our rat mammary cells shows enhanced cell migration and invasion, a result 
consistent with many previous reports in cancer cell lines from breast, colorectal, 
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pancreas, and lung (Bowers et al., 2012; Chen et al., 2012; Goh Then Sin et al., 2011; 
Huang et al., 2012; Jenkinson et al., 2004; Li et al., 2012; Sack et al., 2011; Wang et 
al., 2012; Zhang et al., 2012). In contrast, a study on brain white matter showed that 
siRNA depletion of S100A4 in cultured astrocytes caused increased cell migration 
(Takenaga and Kozlova, 2006). However, astrocytes are themselves migratory in the 
brain white matter, and it may be that suppression of S100A4 can interfere with the 
normal machinery of this cell to cause a stimulation of cell migration. Moreover, 
when a nasopharyngeal carcinoma C666-1 cell line was transfected with siRNA to 
S100P, this led to inhibition of cell migration and wound healing via suppression of 
MMP-2 and MMP-9 expression, downregulation of epidermal growth factor, cluster 
of  differentiation CD 44 and RAGE receptor expression (Liu et al., 2017). When 
prostate cancer cell lines overexpressed S100P or suppressed expression of S100P, 
this led to increases or decrease, respectively, in cell growth and expression of several 
genes related to proliferation and angiogenesis including MMP-13 by (3.7-fold) 
compared to control cells in vitro (Basu et al., 2008). When anaplastic thyroid 8505C 
and SW1736 cell lines were transfected with siRNA to TGF-β (transforming growth 
factor-beta), the resultant cells coordinately downregulated S100A4, MMP-2 and 
MMP-9 which, in turn, caused an inhibition of cell migration and invasion. 
Furthermore, when siRNA to S100A4 was transfected into the same parental cells, 
this experiment produced a significant reduction in MMP-2 and MMP-9 which, in 
turn, inhibited migration and invasion in these cell lines. Finally, when MMP-2 and 
MMP-9 were blocked with BB-94 MMP inhibitors (Batimastat), these same cells 
showed a significant reduction in mRNA and protein for S100A4 either with or 
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without  treatment by TGF- β (Zhang et al., 2016). These conclusions suggest the 
complex way that S100 proteins and MMPs may interact. 
Similar types of results were obtained in the breast cancer cell line MDA-MB-
231 (Wang et al., 2012). When they were transfected with cDNA for S100A4, the cells 
upregulated MMP-13 expression and caused an increase in cell migration. When 
transfected with siRNA to S100A4, these cells had a reduced level of MMP-13, cell 
migration and angiogenesis. Moreover, when MMP-13 was blocked with specific 
antibodies, the levels of cell migration and angiogenesis were reduced in these 
S100A4 expressing MDA-MB-231 cells (Wang et al., 2012). These results connected 
S100A4, MMP-13, cell migration and angiogenesis. Thus, our own results and those 
in the literature have established a causal link between elevated intracellular levels 
of two S100 proteins, S100P and S100A4, three MMPs: MMP-2, -9, -13 and an 
increase in cell migration and invasion in tissue cultured cells. However, whether the 
S100 proteins act inside the cell to induce these biological changes or whether they 
can act outside the cell in a paracrine fashion is still not yet clear, and will provide the 
focus for the next chapter.   
 Summary  
 
The malignant R37-S100P/S100A4 cell lines showed increases in cell migration 
and invasion in Boyden chambers without and with Matrigel, respectively, compared 
to their empty vector-transfected control cell lines. The R37-S100P and S100A4 cell 
lines demonstrated reductions in levels of specific MMPs after transient transfections 
with siRNA to MMP-2, MMP-9 or MMP-13 individually or simultaneously all together, 
compared to scrambled transfected control cells. These transient knocked-down cells 
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showed significant decreases in cell migration and even more in cell invasion. siRNA 
silencing of MMP-2 reduced cell migration and invasion more in R37-S100A4 cells and 
silencing MMP-13 relatively more in R37-S100P cells. These data suggest that the two 
S100 proteins target different MMPs, and that these three MMPs simultaneously can 






Chapter 5  
 
 
Effect of exogenously-added S100P/S100A4 on MMPs 




Despite being widely involved in broad intracellular signalling pathways that 
promote metastasis in many types of cancer cells, metastasis-inducing proteins 
S100P/S100A4 have also been reported to enhance metastasis in different types of 
cancer cells through extracellular functions (Leclerc and Vetter, 2015). Thus, addition 
of extracellular S100P can stimulate proliferation of pancreatic carcinoma BxPC3 cell 
line via phosphorylation of IκBα and activation MMP-9 (Dakhel et al., 2014), can 
contribute to the development of lung adenocarcinoma through its interaction with 
the receptor for advanced glycation end-products (RAGE) (Rehbein et al., 2008), and 
can stimulate cultured human colon cancer cell invasion through activation of RAGE 
(Mercado-Pimentel et al., 2015). In addition, direct binding between the V domain of 
RAGE and S100P was found to require Ca+2 ions and to lie in the micromolar range (Kd 
of ~6µM) (Penumutchu et al., 2014). 
Moreover, addition of extracellular S100A4 has also been reported to 
stimulate invasive growth and angiogenesis of mouse microvascular endothelial cells 
via MMP-13 production and activation (Schmidt-Hansen et al., 2004), and 
prometastatic activation of human melanoma cell line A375 via interaction with RAGE 
(Herwig et al., 2016). Downregulation of S100A4 in osteosarcoma cultured cells 
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resulted in reduced expression and activation of MMP-2 which led to diminished cell 
migration (Bjornland et al., 1999). Finally, addition of S100A4 to chondrocytes, 
synovial fibroblasts or endothelial cells enhanced cell invasion through elevated 
levels and activation of MMP-13 (Boye and Maelandsmo, 2010). In summary, 
although S100P/A4 are involved in many intracellular signalling pathways which 
promote tumour motility, when added extracellularly it seems that the RAGE 
receptor is the most frequent target employed to transduce the signal inside the cell.  
RAGE receptors have been reported to interact with a variety of ligands 
including some of the S100 protein family (Heizmann et al., 2007), as already outlined 
in Section 1.5. RAGE has been reported to be overexpressed in several cancer types 
and its signalling pathway may help to drive tumorigenesis and metastasis in multiple 
cancers including breast cancer (Kalea et al., 2010; Kang et al., 2010; Kwak et al., 
2017; Taguchi et al., 2000). When detected by immunohistochemistry, RAGE protein 
is highly expressed in breast (63%) and lung (47%) cancer, whereas low or no RAGE 
expression was observed in brain, lymphoma, prostate, ovarian, melanoma and colon 
cancers (Hsieh et al., 2003). Moreover, immunostaining, Western blot or RT-PCR 
showed that RAGE protein is expressed in breast adenocarcinoma MDA-MB-231 and 
lung cancer cell lines, but at higher levels in breast cancer than in lung cancer cells  
(Hsieh et al., 2003). A study on breast cancer showed that RAGE protein was 
expressed at a higher level in the aggressively malignant human triple negative breast 
cancer (TNBC) cell lines than in the weakly metastatic breast cancer cell lines such as 
MCF-7, T47D and BT474. Moreover, RAGE was also expressed at a significantly higher 
level in basal type human breast cancer (majorly TNBC) than in non-basal type 
tumours (majority ERα+) (Nasser et al., 2015). Also, the latter study showed that when 
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highly metastatic MDA-MB-231 cell lines were injected intracardially into nude mice 
and RAGE activity was blocked with neutralising antibody, there was a significant 
reduction in the metastatic potential of these cells compared to IgG control-treated 
mice (Nasser et al., 2015). In addition, when RAGE -/- model mice were injected with 
TNBC cells, they showed a significant inhibition in tumour growth compared to RAGE 
+/+ model mice. To show the signalling molecules involved, this study found that 
MMP-2 and MMP-9 immunofluorescent expression  was also decreased in TNBC cells 
obtained from RAGE -/- mice compared to tissue obtained from RAGE +/+ mice (Nasser 
et al., 2015). Silencing RAGE or its ligands such as S100P, S100A4 and high-mobility 
group box 1 (HMGB-1) led to inhibition of growth and migration of pancreatic ductal 
adenocarcinoma (PDAC) cells in vitro (Arumugam et al., 2012). Moreover, blocking 
RAGE contributes to a reduction in expression of MMPs such as MMP-2 /-9 and in 
carcinogenic properties of C6 glioma cell line in vitro (Taguchi et al., 2000). In parallel 
studies, antiallergic drugs such as olopatadine, amlexanox and cromolyn which can 
bind to S100 proteins such as S100A1, S100A12, S100A13 and an 8 kDa unknown 
protein, have been shown to inhibit the IgE-mediated degranulation of immune cells 
such as mast cells (Okada et al., 2002; Oyama et al., 1997). Moreover, the anti-allergic 
drug cromolyn can bind to S100P, prevent RAGE activation and can inhibit pancreatic 
tumour growth in vivo when pancreatic cancer cells are injected into mouse models 
(Arumugam et al., 2006), but how specific cromolyn was for inhibition of S100P was 
not determined. Cromolyn has a broad activity which appears to inhibit activities 
associated with RAGE activation (Arumugam et al., 2006) 
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5.1.1 Chapter aims 
 
To examine the effect of exogenously-added S100P/S100A4 on specific MMPs and 
migration/invasion of the parental rat mammary cell lines. 
 Results 
5.2.1 Effect of adding S100P to parental Rama 37 wild type cells on 
level of MMP-9 protein  
 
Recombinant S100P protein at different concentrations (0, 0.001, 0.01, 0.1, 1, 
5 µM) was added to the conditioned medium of the parental S100P/A4-negative rat 
mammary wild type cells (R37 wt) to study its effect on intracellular precursor MMP-
9) and extracellular proform MMP-9 production. The level of intracellular precursor 
MMP-9 (preMMP-9) was increased dramatically, initially in a dose-dependent manner 
(Figure 5.1). Thus, preMMP-9 showed a significant increase no addition when set at 
1.0 (mean fold±SE, n=3, one-way ANOVA, with overall P<0.0001) of 1.3±0.10, 4.6±0.3, 
5.6±0.2, 6.8±0.2 and 6.4±0.1-fold after addition of 0.001, 0.01, 0.1, 1 and 5 µM S100P, 
respectively.  The maximal response was achieved at 1 µM and plateaued out at 5 
µM, since there was no further significant increase (One-way ANOVA, 1 µM vs 5 µM 
P=99). Similar dose-dependent increases were seen in the level of extracellular 
proform MMP-9 (proMMP-9) in the CM when the proMMP-9 level for 0 µM set at 1.0 
(mean fold±SE, n=3, one-way ANOVA, with overall P<0.0001) of 2.1±0.08, 4.36±0.13, 
4.99±0.18, 6.07±0.11 and 5.28±0.17-fold after extracellular addition of 0.001, 0.01, 
0.1, 1 and 5 µM S100P, respectively, plateauing out at 1 µM (Student’s t-test, 1 µM vs 




Figure 5.1. Effect of adding extracellularly different doses of S100P on the level of 
intracellular and extracellular MMP-9.  
Different doses of recombinant S100P protein yielding the final concentrations shown were 
added to the medium of Rama 37 wild type cells which were then incubated for a further 24 
h. Ten micrograms (10 µg) of protein for CL or suitably adjusted µL for CM were loaded on 10 
% (w/v) SDS-PAGE gels. The total protein concentrations in CL were quantified using a BCA 
assay.  The quantity of CM loaded was adjusted according to the amount of protein in the CL 
estimated by BCA (Section 2.5) (A1:CL) Representative Western blot showing the precursor 
MMP-9 (preMMP-9) as a double band at 92 kDa in the cell lysate (CL) from R37 wt cells. 
GAPDH was used as a loading control. The preMMP-9 bands were detected using ECL Select 
Reagents, while GAPDH bands were detected used standard ECL Reagents. (A2) Histogram 
of three independent experiments from A1 showing that the level of preMMP-9 increased 
dramatically up to 6.85-fold for 1 µM S100P, and then plateaued at 5 µM S100P. (B1:CM) 
Representative Western blot shows the proMMP-9 (proform MMP-9) at 92 kDa in the CM 
from R37 wt cells. (B2) Histogram of three independent experiments from B1 showing that 
proMMP-9 (proform MMP-9) in the CM also increased dramatically up to 6.07-fold for 1 µM 
S100P, while its level started to fall to 5.28-fold with 5 µM S100P. Dose response in a log scale 




5.2.2 Effect of adding fixed concentrations of S100P or S100A4 to 
Rama 37 wild type cells on levels of MMP-2, MMP-9 and MMP-
13 
 
The dose-response experiment above showed that 1µM S100P when added 
extracellularly to R37 wt cells was saturating for the production of MMP-9. Therefore, 
in subsequent experiments 1µM S100P or S100A4 was added extracellularly to R37 
wt cells and its effects on levels of MMP-2, -9 and -13 in the CL and CM was measured 
by Western blotting. 
5.2.2.1 MMP-2 
When recombinant S100P or S100A4 were separately added to R37 cells to 
a final concentration of 1µM, precursor MMP-2 inside the cells was significantly 
increased by 2.8-fold (mean fold±SE: 2.75±0.05, n=2, Student’s t-test, P=0.007) and 
by 2.5-fold (2.5±0.02, P=0.001), respectively, over its level inside the cells without 
adding S100 proteins (Figure 5.2A). Moreover, the pro and active forms of MMP-2 
outside the cells were also increased significantly after addition of 1µM S100P or 
S100A4 by 7.5-fold (mean fold±SE: 7.5±0.12, n=2, Student’s t-test, P<0.0001) and by 
6.9-fold (6.87±0.57, P=0.005), respectively (Figure 5.2B). 
5.2.2.2 MMP-9 
Levels of MMP-9 were increased significantly for both intracellular precursor 
MMP-9 and extracellular proform MMP-9. Adding 1µM S100P or S100A4 
extracellularly to the R37 wt cells caused the level of precursor MMP-9 to increase 
significantly by 2.6-fold (mean fold±SE: 2.58±0.03, n=2, Student’s t-test, P=0.026) and 
3-fold (3.2±0.01, P=0.004), respectively inside cells (Figure 5.3A). The extracellular 
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form of MMP-9 protein showed only proform MMP-9 consistent with our previous 
result in Figure 5.1. Adding 1µM of S100P or S100A4 to the R37 wt cells caused a 
significant increase in proform MMP-9 by 3.6-fold (mean fold±SE: 3.57±0.18, n=2, 
Student’s t-test, P=0.003) and by 4-fold (4.1±0.22, P=0.002), respectively (Figure 
5.3B) outside the cells. 
5.2.2.3 MMP-13 
One micromolar of S100P or S100A4 added extracellularly to the R37 wt cells 
caused the levels of precursor MMP-13 to increase significantly by 3-fold (mean 
fold±SE: 3.1±0.02, n=2, Student’s t-test, P=0.003) and by 3.4-fold (3.38±0.003, 
P=0.001), respectively (Figure 5.4A) inside the cells. MMP-13 occurred outside the 
cells in both pro and active forms. When 1µM S100P or S100A4 was added to the R37 
wt cells, the levels of both pro and active forms of MMP-13 increased by 3-fold (mean 
fold±SE: 3.1±0.27, n=2, Student’s t-test, P=0.006) and by 5.7-fold (5.66±0.65, 




Figure 5.2. Effect of adding 1 µM S100P or S100A4 to R37 wt cells on levels of 
intracellular and extracellular MMP-2.  
Ten µg of CL proteins or suitably adjusted µL for CM were loaded on 10 % (w/v) SDS-PAGE 
gels. The total protein concentrations in CL were quantified using BCA. The quantity of CM 
loaded was adjusted according to the amount of protein in the CL estimated by BCA (Section 
2.5) (A1:CL) Representative Western blot shows the intracellular precursor MMP-2 
(preMMP-2) at 72 kDa in R37 wild type cells (R37 wt) treated with 1µM S100P (R37 wt + 
S100P) or S100A4 (R37 wt + S100A4) compared to R37 wt untreated control cells. MMP-2 
bands were detected using ECL Select Reagents, while GAPDH bands were detected using 
standard ECL Reagents. (A2) Histogram of two independent experiments from A1 showing 
the preMMP-2 band intensity firstly ratioed to GAPDH in the S100P or S100A4-treated R37 
wt cells and then compared to that in R37 wt untreated control which has been set at 1.0. 
The preMMP-2 level inside cells was increased significantly by 2.8-fold or 2.5-fold (Student’s 
t-test, P≤0.007) when 1 µM S100P or S100A4, respectively, were added to the R37 wt cells. 
(B1:CM) Representative Western blot shows both the pro (at 68 kDa) and active (at 62 kDa) 
forms of MMP-2 in the CM of untreated R37 wt or cells treated with 1 µM S100P or S100A4. 
(B2) Histogram of two independent experiments from B1 showing the combined fold changes 
in pro and active MMP-2 band intensities in the CM of R37 wt cells treated with 1 µM S100P 
or S100A4 compared to those in R37 wt cells untreated control which has been set at 1.0. 
The levels of both forms of MMP-2 increased significantly by 7.5-fold or 6.9-fold (P≤0.005) in 
115 
 
the CM of R37 wt cells treated with 1 µM S100P or S100A4, respectively, compared to 




Figure 5.3. Effect of adding 1 µM S100P or S100A4 to R37 wt cells on levels of 
intracellular and extracellular MMP-9.  
Ten µg of CL proteins or suitably adjusted µL for CM were loaded on 10 % (w/v) SDS-PAGE 
gels. The total protein concentrations in CL were quantified using BCA. The quantity of CM 
loaded was adjusted according to the amount of protein in the CL estimated by BCA (Section 
2.5) (A1:CL) Representative Western blot shows the intracellular precursor MMP-9 
(preMMP-9) at 92 kDa in R37 wild type (R37 wt) treated with 1µM S100P (R37 wt + S100P) 
or S100A4 (R37 wt + S100A4) compared to R37 wt untreated control cells. MMP-9 bands 
were detected using ECL Select Reagents, while GAPDH bands were detected using standard 
ECL Reagents. (A2) Histogram of two independent experiments from A1 showing the 
preMMP-9 band intensity ratioed to GAPDH in the S100P or S100A4-treated R37 wt cells and 
then compared to that in R37 wt untreated control, which has been set at 1.0. The preMMP-
9 level inside cells was increased significantly by 2.8-fold or 2.5-fold (Student’s t-test, 
P≤0.007) when 1µM S100P or S100A4, respectively, was added to the R37 wt cells. (B1:CM) 
Representative Western blot shows only the proform MMP-9 (proMMP-9) at 92 kDa in the 
CM of untreated R37 wt or cells treated with 1 µM S100P or S100A4. (B2) Histogram of two 
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independent experiments from B1 showing the ratio of proMMP-9 band intensities in the 
CM of R37 wt cells treated with 1 µM S100P or S100A4 compared to those in R37 wt 
untreated control, which has been set at 1.0. The levels of proMMP-9 increased significantly 
by 3.6-fold or 4-fold (P≤0.003) in the CM of R37 wt cells treated with 1 µM S100P or S100A4, 




Figure 5.4. Effect of adding 1 µM S100P or S100A4 to R37 wt cells on levels of 
intracellular and extracellular MMP-13.  
Ten µg of CL proteins or suitably adjusted µL for CM were loaded on 10 % (w/v) SDS-PAGE 
gels. The total protein concentrations in CL were quantified using BCA. The quantity of CM 
loaded was adjusted according to the amount of protein in the CL estimated by BCA (Section 
2.5) (A1:CL) Representative Western blot shows the intracellular precursor MMP-13 
(preMMP-13) at 50 kDa in the R37 wild type (R37 wt) treated with 1µM S100P (R37 wt + 
S100P) or S100A4 (R37 wt + S100A4) compared to R37 wt untreated control cells. MMP-13 
bands were detected using ECL Select Reagents, while GAPDH bands were detected used 
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standard ECL Reagents. (A2) Histogram of two independent experiments from A1 showing 
preMMP-13 band intensity ratioed to GAPDH in the S100P or S100A4-treated R37 wt cells 
and then compared to that in R37 wt untreated control, which has been set at 1.0. The 
preMMP-13 level inside the cells was increased significantly by 3-fold or 3.4-fold (Student’s 
t-test, P≤0.003) when 1µM S100P or S100A4, respectively, was added to the R37 wt cells. 
(B1:CM) Representative Western blot shows both the pro (at 60 kDa) and active (at 52 kDa) 
forms of MMP-13 in the CM of untreated R37 wt or cells treated with 1 µM S100P or S100A4. 
(B2) Histogram of two independent experiments from B1 showing the ratio of combined pro 
and active MMP-13 band intensities in the CM of R37 wt cells treated with 1 µM S100P or 
S100A4 compared to that in R37 wt untreated control, which has been set at 1.0. The 
combined levels of both forms of MMP-13 were increased significantly by 3-fold or 5.7-fold 
(P≤0.007) in the CM of R37 wt cells treated with 1 µM S100P or S100A4, respectively, 
compared to untreated R37 wt cells.  The two bands at 73 and 64 kDa were considered to be 
nonspecific and unrelated to MMP-13, since they appeared with only one batch of MMP-13 
antibody and were not observed in our previous blots in zymography or Western blotting for 
pro and actMMP-13.  
 
5.2.3 RAGE receptor levels in the S100P or S100A4 overexpressing rat 
mammary cell lines 
 
Several reports have suggested that extracellular S100P/A4 can interact with 
the Receptor for Advanced Glycation End Products (RAGE) in the plasma membrane 
(Arumugam et al., 2004; Boye et al., 2008; Herwig et al., 2016; Penumutchu et al., 
2014; Zhu et al., 2013), which could be consistent with our results in Figure 5.1. We 
investigated whether this receptor was present in the Rama 37 cells using a specific 
antibody directed at the RAGE receptor. RAGE protein was detected in the cell lysates 
(CL) of Rama 37 wild type (R37 wt), Rama 37-S100P (R37-S100P) and Rama 37-S100A4 
(R37-S100A4) cells using Western blotting. The apparent molecular weight of 45 kDa 
is consistent with reports in other system (Taguchi et al., 2000). The lower molecular 
weight band observed at 39 kDa (Figure 5.5) is thought to be nonspecific and 
unrelated to RAGE because it was not blocked by immunizing peptide (Section 2.17). 
The level of RAGE receptor was increased significantly by 2.2-fold (mean fold±SE: 
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2.18±0.07, n=3, Student’s t-test, P=0.015) and by 1.7-fold (1.65±0.04, P=0.027) in the 
CL of R37-S100P and R37-S100A4 cells, respectively, over the R37 wt control cell line 




Figure 5.5. Detection of RAGE in cell lysates of Rama 37 wild type and 
S100P/S100A4 overexpressing cell lines.  
Total protein concentrations in cell lysates (CL) were quantified using BCA and 10 µg of CL 
proteins were loaded on 10 % (w/v) SDS-PAGE gels. (A)Representative Western blot shows 
the level of RAGE at 45 kDa in the CL of Rama 37 wild type (R37 wt), Rama 37-S100P (R37-
S100P) and Rama 37-S100A4 (R37-S100A4) cell lines. A band at 39 kDa was considered to be 
nonspecific as describe in Section 2.17. GAPDH at 37 kDa was used as a loading control. RAGE 
and GAPDH bands were detected using standard ECL Reagents.  (B) Histogram of three 
independent experiments showing RAGE band intensities in the CL of R37 wt, R37-S100P and 
R37-S100A4 ratioed to that in GAPDH and normalized to that in R37 wt. which was set at 1. 
The levels of RAGE receptor were increased significantly by 2-fold or 1.7-fold (Student’s t-
test, P≤0.027) in the CL of R37-S100P or R37-S100A4 cell lines, respectively, compared to that 
in R37 wt control cell line. 
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5.2.4 Effect of adding S100P or S100A4 on migration and invasion 
activities of parental rat mammary wild type cells 
 
The Rama 37 wild type (R37 wt) are benign tumour cells, which migrate and 
invade at low frequency (Jenkinson et al., 2004). In this experiment 1 µM of S100P or 
S100A4 was added extracellularly to Rama 37 wt cells (Section 2.17.2) growing in 
three Boyden migration chambers or three Matrigel invasion chambers for each set 
of additions and each experiment was repeated twice. When 1 µM S100P or S100A4 
was added to R37 wt cells, the cells showed a significant increase in migration of 2.5-
fold (mean fold± SE: 2.49±0.23, n=2, Student’s t-test, P=0.03) or by 2.1-fold 
(2.07±0.05, P=0.017), respectively, compared to control R37 wt cells without any 
additions (Figure 5.6A). Higher increases were observed in cell invasion. Thus, when 
1µM S100P or S100A4 was added extracellularly to R37 wt cells, their invasion was 
significant increased by about 4-fold for both S100 proteins (S100P; mean fold ±SE: 
4.06±2.38, n=2, Student’s t-test, P=0.025 and S100A4; 4.33±0.016, P=0.005) 
compared to R37 wt cells without any additions (Figure 5.6B).  
The amount of S100P or S100A4 (1 µM) was estimated from a dose response 
curve of addition of S100P to stimulate production of MMP-9 and this was found to 
saturate at 1 µM (Figure 5.1). Therefore, 1 µM was used throughout on the 
assumption that additions of S100 proteins and production of other MMPs were the 








Figure 5.6. Effect of addition of S100P and S100A4 on migration and invasion of 
benign Rama 37 wild type cells. 
 (A) Histogram of two independent experiments showing the ability of benign Rama 37 wild 
type (R37 wt) cells to migrate through Boyden migration chambers. The migration rates of 
R37 wt cells were significantly increased after extracellular addition of 1µM S100P or S100A4 
by 2.5-fold (mean fold±SE: 2.49±0.23, n=2, Student’s t-test, P=0.03) or by 2-fold (2.07±0.05, 
P=0.017) over R37 wt control cells without additions. (B) Histogram of two independent 
experiments showing the ability of benign R37 wt cells to invade through Matrigel invasion 
chambers. The invasion rates of R37 wt cells were significantly increased after extracellular 
addition of 1µM S100P or S100A4 by about 4-fold for both S100P (mean fold±SE: 4.06±2.38, 
n=2, P=0.02) or S100A4 (4.33±0.016, P=0.005) over R37 wt control cells without additions. 
Invasion experiments were recorded from 3 wells repeated 2 times with different 
batches of cells (n=2). The Bars refer to mean±SE and the numbers above them refer to 
fold differences compared to empty vector control (R37 E.V.) cells.   
 
 
5.2.5 Effect of adding S100P/S100A4 with RAGE inhibitors on invasion 
of parental rat mammary cells 
 
To investigate whether the biological effects of S100P/A4 was exerted 
through RAGE, two of its inhibitors were also added to R37 wt cells. The two inhibitors 
used were a RAGE neutralising antibody (Namba et al., 2009) and the anti-allergy 
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drug, Cromolyn, which can  bind to members of the S100 protein family such as S100P 
at the site of the S100P-RAGE interaction (Arumugam et al., 2006; Penumutchu et al., 
2014).   
Firstly, we tested the effects of adding RAGE inhibitors extracellularly alone 
on the invasive ability of R37 wt cells using concentrations reported to be completely 
inhibitory in a human gastric carcinoma cell line (Namba et al., 2009). Rama 37 wild 
type (R37 wt) cells were divided into three groups: Group 1: R37 wt cells were seeded 
alone inside the Matrigel chambers as a negative control. Group 2: R37 wt with 1/200 
diluted anti-RAGE antibody inside and outside the Matrigel chambers. Groupe 3: 
R37wt with 100 µM Cromolyn inside and outside the Matrigel chambers (Section 
2.17.3). The results showed that at the concentrations of inhibitors used, the RAGE 
antibody or Cromolyn alone had no significant effect on invasive ability of R37 wt cells 
compared to R37 wt control without additions (mean fold decrease±SE: 1.16±0.25, 
n=2, Student’s t-test, P=0.456 and 0.92±0.05, P=0.219, respectively) (Figure 5.7A). 
Secondly, The Rama 37 wild type (R37 wt) cells were divided into three 
groups: Group 1: R37 wt with final concentration of 1 µM S100P or S100A4 inside and 
outside the Matrigel chamber. Group 2: R37 wt with final concentration of 1 µM 
S100P or S100A4 and 1/200 µL anti-RAGE antibody inside and outside the Matrigel 
chamber. Groupe 3: R37 wt with 1 µM S100P or S100A4 and 100 µM Cromolyn inside 
and outside the Matrigel chamber (Section 2.17.4). The results showed that addition 
of RAGE antibody or Cromolyn with S100P to R37 wt cells significantly decreased their 
rate of invasion by 4-fold (mean fold decrease±SE: 3.96±0.13, n=2, Student’s t-test, 
P=0.02) or by 2.5-fold (2.51±0.09, P=0.03), respectively, compared to R37 wt cells 
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with only S100P (Figure 5.7B). Indeed, the inhibitions were able to reduce the 
invasion of the cells to at least below basal levels (Figures 5.7A, B). 
Moreover, the results showed that addition of RAGE antibody or Cromolyn 
with S100A4 to R37 wt cells also significantly decreased their rate of invasion by 1.9-
fold (mean fold decrease±SE: 1.88±0.13, n=2, Student’s t-test, P=0.037) or by 2-fold 
(2.04±0.104, P=0.03), respectively, over the R37 wt cells with only S100A4 (Figure 
5.7C). In contrast to S100P-stimulated cells, the 2-fold reduction in invasion in 
S100A4-stimulated cells remained well above basal levels (Figures 5.7A, C). 
 
 
Figure 5.7. Effect of addition of S100P/S100A4 and RAGE inhibitors on invasion of 
Rama 37 wild type cells.  
(A) Histogram of two independent experiments of 3 chambers each shows that 1/200 diluted 
RAGE antibody or 100 µM Cromolyn drug had no significant effect (RAGE Ab mean fold 
decrease±SE: 1.16±0.25, n=2, P=0.456; Cromolyn: 0.92±0.05, P=0.219) on rate of invasion of 
Rama 37 wild type (R37 wt) compared to R37 wt cells alone (control). (B) Histogram of two 
independent experiments of 3 chambers each shows that the R37 wt with 1 µM S100P and 
1/200 diluted RAGE antibody (RAGE Ab.) or 100 µM Cromolyn produced significant decreases 
in R37 wt cells rate of invasion by 4-fold (mean fold decrease: 3.96±0.13, n=2, P=0.02) or 2.5-
fold (2.51±0.09, n=2, P=0.03), respectively, compared to R37 wt cells with 1 µM S100P 
(control). (C) Histogram of two independent experiments of 3 chambers each showing that 
R37 wt with 1 µM S100A4 and 1/200 diluted RAGE antibody (RAGE Ab.) or 100 µM Cromolyn 
produced significant decreases in R37 wt cells rate of invasion by 1.9-fold (mean fold 
decrease: 1.88±0.13, n=2, P=0.037) or 2-fold (2.04±0.104, n=2, P=0.03), respectively, 
compared to R37 wt cells with 1 µM S100A4 (control). Invasion experiments were 
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recorded from 3 wells repeated 2 times with different batches of cells (n=2). The Bars 
refer to mean±SE and the numbers above them refer to fold differences compared to empty 
vector control (R37 E.V.) cells.      
 
5.2.6 Effect of adding RAGE inhibitors on invasion of S100P/S100A4 
overexpressing rat mammary cells 
 
RAGE inhibitors were added to the Rama 37-S100P and Rama 37-S100A4 cells 
to observe their effects on the rate of invasion, when the S100 proteins were 
expressed inside the cells. Both cell lines were divided into three groups: Group 1: 
R37-S100P or R37-S100A4 cells alone (control). Group 2: R37-S100P or S100A4 cells 
with 1/200 diluted anti-RAGE antibody inside and outside the Matrigel chamber. 
Groupe 3: R37-S100P or S100A4 with 100 µM Cromolyn inside and outside the 
Matrigel chamber (Section 2.17.5). The results showed that addition of RAGE 
antibody or Cromolyn to R37-S100P cells significantly decreased their rate of invasion 
by 1.6-fold (mean fold decrease±SE: 1.60±0.02, n=2, Student’s t-test, P=0.003) or by 
1.5-fold (1.49±0.06, P=0.007), respectively, compared to R37-S100P cells alone 
(control) (Figure 5.8A). However, inhibition was still 2-3 fold above basal levels 
showing that the inhibition was incomplete (Figure 5.8A, 4.4B). Moreover, the results 
showed that addition of 1/200 diluted RAGE antibody or 100 µM Cromolyn to R37-
S100A4 cells significantly decreased their rate of invasion by 3-fold (mean fold 
decrease±SE: 2.99±0.55, n=2, Student’s t-test, P=0.006) or by 2.4-fold (2.44±0.12, 
P=0.005), respectively, over the R37-S100A4 cells alone (control) (Figure 5.8B). The 
3-fold reduction in invasion in R37-S100A4 cells approached basal levels showing that 





Figure 5.8. Effect of addition of RAGE inhibitors on invasion of Rama 37-
S100P/S100A4 cells.  
(A) Histogram of two independent experiments of 3 chambers each shows that R37-S100P 
with 1/200 diluted RAGE antibody (RAGE Ab.) or 100 µM Cromolyn produced a significant 
decrease in their rate of invasion by 1.6-fold (mean fold decrease±SE: 1.60±0.02, n=2, 
P=0.003) or 1.5-fold (1.49±0.06, P=0.007), respectively, compared to R37-S100P cells alone 
(control). (B) Histogram of two independent experiments of 3 chambers each shows that 
R37-S100A4 with 1/200 diluted RAGE antibody (RAGE Ab.) or 100 µM Cromolyn produced 
significant decrease in their rate of invasion by 3-fold (mean fold decrease±SE: 2.99±0.55, 
n=2, Student’s t-test, P=0.006) or by 2.4-fold (2.44±0.12, P=0.005), respectively, compared to 
R37-S100P cells alone (control). Invasion experiments were recorded from 3 wells 
repeated 2 times with different batches of cells (n=2). The Bars refer to mean±SE and 
the numbers above them refer to fold differences compared to empty vector control (R37 






When S100P or S100A4 was added to R37 wt cells the same molecular weight 
forms of MMP-2 (intracellular at 72 kDa, extracellular at 68 kDa and 62 kDa), MMP-9 
(intracellular and extracellular at 92 kDa) and MMP-13 (intracellular at 50 kDa, 
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extracellular at 60 kDa and 52 kDa) were seen as in parental R37 wt and 
S100P/S100A4-transfected cells and hence the same designations of pre/pro and 
active forms of each of the MMPs can be utilised in this chapter as in chapter 3.  
Our data showed that addition of S100P resulted in a gradual increase in the 
level of MMP-9 in a dose-dependent manner, both inside and outside the R37 wt cells 
and then plateaued off. These points lie on sigmoidal curves with initial slopes 
approximating to straight lines and the response plateaus off at 100 nM 
corresponding to an increase of roughly 6-fold for preMMP-9 and 5.6-fold for 
proMMP-9. The initial slopes occurred between 1 and 10 nM, plateau values at 100M, 
and half maximal effective concentration (EC50) at 4.33 nM for intracellular preMMP-




Figure 5.9. Effect of adding increasing concentrations of S100P to R37 wt cells on 
fold increase in MMP-9.  
(A) Dose-response of addition of S100P that stimulates fold increase in intracellular precursor 
MMP-9 (preMMP-9). The effective concentration at half maximum stimulation EC50 = 4.335. 
(B) Dose-response of addition of S100P that stimulates fold increases in extracellular proform 
MMP-9 (proMMP-9). The effective concentration at half maximum stimulation EC50 = 3.984. 
These graphs were plotted using GraphPad Prism software version 6.00 (GraphPad, San 




The simplest interpretation of the results is that S100P was binding to 
saturable receptors with EC50 of about 4 nM. This value is consistent with that of 
Arumugam et al. (2004), which showed that addition of S100P to NIH3T3 cells (mouse 
embryo fibroblasts) stimulated NFkB, ERKs and cell proliferation, over a wide range 
of concentrations from 0.01 to 100nM with EC50 of roughly 4 nM. However,  Boye et 
al., (2008), showed that addition of S100A4 to the human osteosarcoma cell line (II-
11b)  stimulated NFκB activation, angiogenesis, reduced cell death and increased cell 
invasion also in a dose-dependent manner, but this activation showed an EC50 of 
about 1 µM, suggesting a weaker binding for S100A4. 
These results also suggest that the increase in MMP-9 outside was matched 
by its increase inside the cells. This result is consistent with little or no processing of 
the protein and suggests that the binding of S100P to its receptors stimulates 
increased expression of intracellular preMMP-9, which governs the level of this 
protein outside the cells. Since 1 µM S100P was well in excess of saturating 
concentrations for production of maximum MMP-9 in R37 wt cells, this concentration 
was adopted for all subsequent experiments investigating levels of MMPs and their 
biological effects on R37 wt cells. 
Our results show that addition of S100P or S100A4 to the outside of R37 wt 
cells produced increases in all three MMPs and in cell migration and invasion. There 
were no increases in a standard housekeeping protein GAPDH showing that the 
increases were restricted to specific proteins. However, the results show slightly 
different fold changes in MMP-9 between cells of different passage number e.g 
MMP-9 production yielded a 6.85-fold increase in CL and a 6.07-fold increase in CM 
in Figure 5.1 compared to 3 and 4-fold increases, respectively, in Figure 5.3. This may 
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reflect the stem cell nature of the parental R37 wt cells, since the cuboidal epithelial 
cells produce at low frequency (< 1 %) more-elongated, myoepithelial-like cells the 
proportion of which can increase with passage number (Dunnington et al., 1983). 
These myoepithelial-like cells produce considerably more S100A4 than  the R37 wt 
cells (Barraclough et al., 1984) and hence increases in these cells with increased 
passage number would lead to increases in the overall basal levels of MMP-9 in the 
cell population (Chapter 3: Figure 3.3B and 3.5)  
Although, S100P and S100A4 increased all three MMPs by similar folds inside 
the cells (2.5 to 3.4-fold), MMP-2 outside the cells was increased by higher levels to 
7.5-fold and 6.9-fold, respectively, and similarly levels of MMP-13 were increased by 
5.7-fold for addition of S100A4, but not S100P (3.1-fold). In the case of MMP-2, the 
actMMP-2 at 62 kDa was relatively increased much more than proMMP-2 at 68 kDa 
over the non-stimulated R37 wt cells (Figure 5.2B).   In the case of MMP-13, the active 
form at 52 kDa was increased relatively much more for addition of S100A4 than 
addition of S100P (Figure 5.4B). These results suggest that although both S100P/A4 
increase production of all three MMPs, they have different effects on MMP 
processing, and these can even be different between S100P and S100A4 in processing 
the same MMP, in this case MMP-13. Thus, although there have been several reports 
of addition of S100P/A4 to cells causing increases in certain MMPs (Dakhel et al., 
2014; Schmidt-Hansen et al., 2004), this is the first report of differential effects on 
particular MMPs and by different S100 proteins.   
In addition to effects on MMPs, addition of 1µM S100P or S100A4 significantly 
increased the migration of R37 wt cells by 2.5- or 2-fold (P≤0.03), respectively, and 
invasion by 4-folds (P≤0.025). The fold increases in migration were less than the 
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general fold increases in MMPs, but the fold increases in invasion were higher than 
in migration and more similar to the fold increases in intracellular MMPs. These 
results suggest that there is a closer link between MMPs and cell invasion than with 
cell migration when S100 proteins are added to cells, consistent with previous reports 
(Dakhel et al., 2014; Schmidt-Hansen et al., 2004).  
Since we had identified saturation effects of addition of S100P to R37 wt cells 
on both intracellular and extracellular MMP-9 production, we investigated whether 
the most widely reported cell surface receptor linked to S100 proteins, RAGE (Herwig 
et al., 2016; Rehbein et al., 2008) could play a role in promoting the  effects of 
S100P/A4 on R37 wt cells. Our experiments showed that addition of 1 µM S100P or 
S100A4 with neutralising antibody to RAGE caused significant decreases by 3.96-fold 
(P=0.02) or 1.88-fold (P=0.03), respectively. Furthermore, addition of Cromolyn, 
which inhibits S100P binding to the RAGE receptor, also caused significant decreases 
by 2.5-fold (P=0.03) or 2.04-fold (P=0.03), respectively. There were no significant 
effects of either inhibitor alone on R37 wt cells showing that inhibition was specific 
to the stimulation produced by S100 proteins (Figure 5.7). The overall effect of both 
inhibitors on cell invasion was to suppress the approximate 4-fold stimulatory effect 
of the S100 proteins by just over a half (2.6-fold). Although, it is possible that these 
partial inhibitory effects could be due to use of too low a concentration of inhibitors, 
this is unlikely, since we used the optimum recommended 5 µg/mL dilution of anti-
RAGE (Arumugam et al., 2006; Taguchi et al., 2000) and 100 µM of Cromolyn. Even 
when RAGE neutralizing antibody was used at higher concentrations of 10 µg/mL 
(Nasser et al., 2015) or 20 µg/mL (L. Zhou et al., 2012), there was still only about a 50 
% reduction in invasion. Moreover, 100 µM Cromolyn caused inhibition of cell 
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invasion stimulated by S100P by a variable amount of 50 % or more in different cell 
lines (Arumugam et al., 2006; Weng et al., 2012). Taken at face value, this result 
suggests that not all the effects of the S100 proteins on cell invasion involves RAGE 
and that the S100P/A4 could interact with other targets, presumably still on the 
surface of the cell. One such reported target is Annexin II (Liu et al., 2015). When we 
used the same inhibitors on the stably-transfected R37-S100P or R37-S100A4 cell 
lines, the RAGE antibody significantly decreased invasion by 1.6-fold (P=0.003) or 
2.99-fold (P=0.006), respectively, and Cromolyn by 1.5-fold (P=0.007) or 2.44-fold 
(P=0.005), respectively. These results suggest that the original overall 11-fold 
stimulation for R37-S100P and R37-S100A4 (Chapter 4) caused by intracellularly 
produced S100 proteins on cell invasion was suppressed overall by about a half (2.2-
fold) and hence once again, other interactions could also play a role.  
If we compare the fold increases for production of MMP-9 after addition of 
different concentrations of S100P to R37 wt cells with the published binding of S100P 
to the RAGE-V domain (~6µM) (Penumutchu et al., 2014), there are differences of at 
least three orders of magnitude. Thus, even if all the effects of S100P on MMP-9 could 
have been inhibited by neutralising antibody, the large difference in these values 
would suggest that there are at least 2 forms of the RAGE receptor, either with 
different affinities like the epidermal growth factor receptor (EGFR) (McAndrew et 
al., 1994), or two different receptors as seen with the FGF dual receptor system with 
two different subunits synergising together to yield receptor binding of high affinity  
(Xu et al., 2013).    
Thus, we have shown that addition of extracellular S100P or S100A4 can 
stimulate cell migration and particularly cell invasion of benign rat mammary cells, in 
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part, via the RAGE receptor (Herwig et al., 2016; Mercado-Pimentel et al., 2015) 
probably by their ability to increase production and activation of certain MMPs, in 
general agreement with reports in other cell systems (Dakhel et al., 2014; Schmidt-
Hansen et al., 2004). The overall relevance of our finding to the human situation is 
discussed in Section 7. 
 Summary  
  
Our data showed that when S100P or S100A4 was added externally to Rama 
37 wild type cells (R37 wt), they increased production of intracellular MMP-2, MMP-
9 and MMP-13 by 2.5- to 3.4-fold, both increased extracellular MMP-2 by 7-fold, 
MMP-9 by only 3.5- to 4-fold, and S100A4 increased extracellular MMP-13 by about 
6-fold, whilst S100P increased it by only about 3-fold. These changes were 
accompanied by 2- to 2.5-fold increases in cell migration and 4-fold increases in cell 
invasion. Inhibition of these increases in invasion produced by S100 proteins with 
RAGE neutralizing antibody or Cromolyn caused a very approximate 50 % reduction 
in R37 wt cells with added S100P/A4 or in S100P/A4 transfected cells. These results 
suggest that S100P/A4 act in part through RAGE to stimulate MMP production and 
sometimes activation so as to increase invasion rates in these rat mammary cells. 
Whether changes in S100 proteins are related to changes in MMPs and death from 




Chapter 6  
 
 
Relationship of specific MMPs to S100P/A4 in primary 





The most common cause of cancer deaths amongst females in the Western 
and now Eastern world is breast cancer (Egeland et al., 2017; Makoukji et al., 2016). 
S100P and S100A4 are members of the S100 family  of Ca 2+ - binding proteins and 
have been reported to be associated with early patient death in many cancer types 
for example lung, prostate, colorectal, pancreas and breast cancer (Ambartsumian et 
al., 2001; Basu et al., 2008; Bresnick et al., 2015; Bulk et al., 2008; Dahlmann et al., 
2012; Dakhel et al., 2014; Ding et al., 2011; Gross et al., 2014; Jiang et al., 2011; 
Rudland et al., 2000; Salama et al., 2008; Siddique et al., 2013; Takenaga et al., 1997), 
presumably due to their propensity to induce metastasis, at least in experimental 
animals (Davies et al., 1993, 1996). Recent studies on breast cancer specimens with 
different histological grades (I, II & III) showed a significant increase in many mRNAs 
compared to non-tumour samples, including mRNAs for S100P and some MMPs, e.g 
MMP-13. Increases in S100P and MMP-13 mRNAs were correlated with reduced 
patient survival times (Makoukji et al., 2016). S100A4 has also been reported to be  
associated with MMPs, e.g. MMP-13,  and to encourage metastasis in many cancer 
types in vivo including those from breast cancer (Ambartsumian et al., 2001; Basu et 
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al., 2008; Bulk et al., 2008; Dahlmann et al., 2012; Dakhel et al., 2014; Ding et al., 
2011; Egeland et al., 2017; Fei et al., 2017; Gross et al., 2014; Jiang and Lai, 2011; 
Rudland et al., 2000; Salama et al., 2008; Siddique et al., 2013; Takenaga et al., 1997; 
Wang et al., 2012), MMPs have been reported to be associated with breast cancer 
patients’ survival times, either individually or in the presence of an S100 protein such 
as S100A4  in breast cancer specimens (Ismail et al., 2017). Moreover, protein levels 
and activities of MMP-2 and MMP-9 were increased in malignant tumours compared 
to normal breast tissues (Jinga et al., 2006). MMP-13 was also reported to be 
frequently detected in breast tumours, especially in lymph node metastases (Kotepui 
et al., 2016). Although, protein levels can be quantified using Western blots of whole 
specimens, they do not allow separate estimation of the important carcinoma cells 
from the reactive host stromal cells, which can be often 50% of the tumour mass 
(Rudland et al., 2000). For this aspect, immunohistochemical staining is undertaken 
and usually the percentage of stained tumour cells is related to the overall levels of 
the protein determined by Western blotting (Zhao et al., 2014). However, the 
detailed relationship between S100 proteins, MMPs and patient survival times in 
breast cancer has not yet been investigated.  
6.1.1 Chapter aims 
 
To examine the relationship between specific MMPs and S100P/A4 in primary 
tumours and their relationship to survival times of breast cancer patients using 





6.2.1 Immunohistochemistry (IHC) staining 
 
IHC was performed on 183 specimens of primary tumours from unselected 
breast cancer patients (Section 2.18.1). IHC staining with a single chromophore was 
used for monoclonal antibodies against S100P, S100A4, MMP-2, MMP-9 and MMP-
13, or double staining with antibodies directed against S100 proteins and directed 
against MMPs but with different chromophores for each family of proteins (Figure 
6.1). Histologically all sections showed lobules with some ducts. IHC staining for 
MMPs on 183 patients showed 32% to 67% with positively stained carcinoma cells 
(Figure 6.1). According to the IHC staining results of the carcinoma cells, the breast 
cancer specimens were divided into 5 staining categories: negative – (<1%), 
borderline ± (1-5%), intermediate + (5-25%), moderated ++ (25-50%) and strong +++ 
(>50%) staining groups (Section 2.18.2). IHC staining of the host stromal cells was 
ignored. Using Wilcoxon and Cox’s univariate analyses the most significant and 
greatest difference in relative risk (RR) of patients’ survival times between adjacent 
staining groups occurred between borderline (±) and moderately (+) staining 
categories for each of MMP-2, 9 and 13 (Ismail et al., 2017) (Table 6.1). Accordingly, 
we used a 5% cutoff to separate the patients into two categorical staining groups for 
ease of further statistical manipulations: the new negatively stained (- and ±) with 
about 19% to 26% of tumours and the overall positively stained group (+, ++ and +++) 
with about 15% to 47% of staining tumours (Ismail et al., 2017). 
Previously IHC staining of the same human breast cancer specimens for S100P 
or S100A4 showed highly significant reductions in patients’ survival times when 
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sections were positively stained for S100P or for S100A4 over those that were not 
stained (Rudland et al., 2000; Wang et al., 2006; de Silva Rudland et al., 2011; Ismail 
et al., 2017).  
 
 
Figure 6.1. Immunohistochemical staining of human breast carcinoma specimens 
for MMPs and S100 proteins.  
 (A, B and C) Monoclonal antibody staining against MMP-2, MMP-9 and MMP-13, 
respectively, showing brown staining of the carcinoma cell cytoplasm. (D and E) Monoclonal 
antibody staining for S100P or S100A4, respectively, showing bead-like, nuclear and mostly 
cytoplasmic brown staining. (F) Serial sections from the same tumour as in E stained for 
S100A4 (red) and for MMP-2 (brown). Most breast carcinoma cells were stained both red for 
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S100A4 and brown for MMP-2, but some cells were stained either red for S100A4 (arrow 
head) or brown for MMP-2 (arrow). Magnification x 180; scale bar 20 µM. Taken from Ismail 
et al., 2017.  
 
 
Table 6.1. Comparisons between pairwise IHC staining groups for MMPs to show 
the relative risk between each MMP group. 
 
 
a Staining group for each MMP, see Table 2.3. 
b Wilcoxon statistic X2. 
c Statistical significance from Wilcoxon-Gehan analysis.  
d Relative risk (RR) of survival from Cox’s univariate analysis. 
 
 
6.2.2 Association between MMPs and patients’ survival times  
 
The association between staining for each of MMP-2, -9 and -13 and patient 
survival times was checked by plotting Kaplan Meier survival curves for each of the 
staining groups in Table 2.3 followed by analysis using Wilcoxon and Cox’s univariate 
statistics, as described for S100A4 and S100P alone (de Silva Rudland et al., 2011). 
The most significant differences and greatest relative risks (RR) for all three MMPs 
occurred between the ± and + staining groups (Table 6.1). Therefore, for ease of 
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computation the staining groups were recategorized into two categorical staining 
groups of negative (-,±) and positive (+, ++, +++) groups using a 5 % cutoff of stained 
carcinoma cells to separate them (Section 2.18.2). When survival times for each of 
MMP-2, MMP-9 and MMP-13 or all 3 MMPs were compared between negative (-, ±) 
and positive (+, ++, +++) groups, there was a highly significant reduction in patient 
survival times for each of the 3 different MMPs or for their combination (Wilcoxon 
Gehan statistics, P<0.001) (Figure 6.2-3). In more individual detail for MMP-2, the 
cumulative proportion of patients surviving at the end for MMP-2 negative group (-, 
±) was 0.81 (number starting was 106 patients) and 0.11 (number starting was 77 
patients) for positive group (+, ++ and +++) with relative risk (RR) of 9.04 (Figure 6.2A). 
For MMP-9, the cumulative proportion surviving at the end for MMP-9 negative 
group (-, ±) was 0.58 (number starting was 156 patients) and 0.10 (number starting 
was 27 patients) for the positive group (+, ++ and +++) with relative risk (RR) of 4.7 
(Figure 6.2 B). For MMP-13, the cumulative proportion surviving at the end for MMP-
13 negative group (-, ±) was 0.75 (number starting was 96 patients) and 0.22 (number 
starting was 87 patients) for the positive group (+, ++ and +++) with relative risk (RR) 
of 4.9 (Figure 6.3 A). For the 3 MMPs together, the cumulative proportion surviving 
at the end for 3 MMPs combined negative group (-, ±) was 0.57 (number starting was 
160 patients) and 0.07 (number starting was 23 patients) for the positive group (+, ++ 








Figure 6.2. (A) MMP-2 or (B) MMP-9 survival curves. 
 Kaplan Meier plots to show the difference in survival time between patients with tumour (a) 
≤ 5% stained (-, ±) group and (b) ≥ 5% stained (+, ++ and +++) group for mAb to MMP-2 or 
MMP-9 (see Tables 2.3, 6.1 and Figure 6.1). The data from 183 patients with invasive breast 
carcinoma was collected every 12 months for 20 years. (A) The median survival time was 228 
months for (a) and 47.1 months for (b), there was a significant difference between the two 
groups (Wilcoxon Gehan statistic, P<0.001). (B) The median survival time was 228 months for 
(a) and 32.4 months for (b), there was a significant difference between the two groups 




Figure 6.3. (A) MMP-13 or (B) MMP-2, -9 and -13 together survival curves.  
Kaplan Meier plots to show the difference in survival time between patients with tumour (a) 
≤ 5% stained (-, ±) group and (b) ≥ 5% stained (+, ++ and +++) group for mAb to MMP-13 or 
mAbs for 3 MMPs together (see Tables 2.3, 6.1 and Figure 6.1). The data from 183 patients 
with invasive breast carcinoma was collected every 12 months for 20 years. (A) The median 
survival time was 228 months for (a) and 52.3 months for (b), there was a significant 
difference between the two groups (Wilcoxon Gehan statistic, P<0.001). (B) The median 
survival time was 228 months for (a) and 30 months for (b), there was a significant difference 




6.2.3 Association of IHC staining for MMPs with that for S100 proteins 
using cross-tabulations  
 
Comparisons of positive IHC staining of 183 patients for each one of MMP-2, 
-9 and -13 using 5% cutoffs with that for S100P or S100A4 from the same set of 
patients (Rudland et al., 2000; Wang et al., 2006) using cross-tabulations and 
significance computed by Fisher’s Exact test are shown in Table 6.2.  
Staining for each MMP and for the combination of all 3 MMPs was highly 
significantly associated with staining for either S100P or S100A4 (Fishers Exact test, 
P<0.001) (Table 6.2).  
 
Table 6.2. Cross-tabulations showing the association of IHC staining for MMPs with 
S100 proteins. 
 
 a S100 protein family members. 
b, c Patient number and percentage for classifying carcinoma cells IHC-stained negatively (-) 
or positively (+) for each of MMP-2 b, -9 b and -13 b or for all MMPs simultaneously c using 5% 
cutoff for each case. 







6.2.4 Relative probability of association of MMPs with S100 proteins 
using logistic regression 
 
Binary logistic regression analysis of 183 breast carcinoma specimens was 
performed to show the relative association (RA) of one variable with a set of other 
tumour variables in the same patients. Thus, in Set 1, when staining for S100P was 
tested with that for the MMPs, the association of S100P was only significant with 
MMP-2 (RA 3.31, P=0.004) and MMP-13 (RA 3.45, P=0.002), but not with MMP-9 (RA 
1.836, P=0.341) or all 3 MMPs together (RA<0.001, P=1.0). Similarly staining for 
S100A4 was only significantly associated with that for MMP-2 (RA 4.21, P<0.001) and 
borderline associated with MMP-13 (RA 2.17, P=0.051), but not with MMP-9 (P=0.11) 
nor all three MMPs (P=0.31) (Table 6.3). 
When the converse testing was undertaken for an individual staining MMP, 
with that for S100P and S100A4 together, then MMP-2 was more strongly associated 
with S100A4 (RA 5.18, P<0.001) than S100P (RA 3.71, P=0.001). MMP-9 was similarly 
more strongly associated with S100A4 (RA 4.52, P=0.006) than S100P (RA 3.4, 
P=0.049). MMP-13, in contrast to MMP-2 and MMP-9, was more strongly associated 
with S100P (RA 4.22, P<0.001) than with S100A4 (RA 3.56, P=0.002). Staining for all 3 
MMPs was only significantly associated with that for S100A4 (RA 5.16, P=0.005) and 








Table 6.3. Relative association between test variable and other tumour variables. 
 
a Test variable, Set 1, staining for S100P or S100A4 compared with the staining for each one 
of the three MMPs. Set 2, staining for each one of the 3 MMPs compared with staining for 
both S100P and S100A4 together. 
b Other variables; Set1: MMPs and Set 2: S100 proteins. 
c Logistic Regression statistic X2.  
d Standard error in binary Logistic Regression. 
e P from Logistic Regression statistic X2. 








6.2.5 Association of patient survival times with MMPs without and 
with S100 proteins 
 
Cox’s univariate analyses were performed on the 183 patients to determine 
whether staining for each one of MMP-2, -9, -13, S100P and S100A4 has a separate 
effect on patient survival times (Table 6.4, Set 1). Moreover, to determine whether 
staining for each of MMP-2, -9, -13 or for 3 MMPs simultaneously were significantly 
independent of staining for S100P or for S100A4 when related to patient survival 
times, Cox’s bivariate analyses were conducted (Table 6.4, Set 2 and 3).  
Data analysis showed that the individual risk of death significantly (P≤0.002) 
increased with staining for MMP-2, -9, -13, S100P or S100A4 when treated separately 
(univariate analysis). The relative risk (RR) of patient death was highly significant for 
all variables (P<0.001) and greater for patients with breast cancer stained for S100A4 
(9.961) than stained for S100P (7.076). The RR of positive staining for each MMP on 
patient death was also highly significant (P<0.001) for all MMPs and greater for 
staining for MMP-2 (9.041), followed by staining for MMP-13 (4.870) and then for 
MMP-9 (4.694) (Table 6.4, Set 1).    
When analyses with staining for one MMP and one S100 protein were 
conducted together (bivariate analysis), staining for MMP-2 with that for S100P or 
for S100A4 remained the greatest RR (6.5 or 5.1, respectively) compared to that for 
MMP-9 or MMP-13, the latter two MMPs had similar RRs in the presence of S100P or 
S100A4. These results may suggest that the pathway to patient death for MMP-2 
overlap those of S100P and S100A4 less well than those of MMP-9 and MMP-13. 




Table 6.4. Cox’s bivariate analyses to show whether MMPs are significantly 
independent of S100 proteins when related to patient survival times. 
 
a Set 1: Set of stains for one tumour variable using cutoff of 5% carcinoma cells stained to 
separate the two categorical groups. Set 2 and Set 3: Set of stains for two tumour variables. 
To test their simultaneous effects on patient survival times, the calculations involved entering 
2 variables into Cox’s Multiple Regression Analysis in order to compare their individual 
contribution to patient survival times in the presence of the other variable. 
b Cox’s statistic X2. 
c Standard error (SE) of X2. 
d P value, df = 1 in each case. 
e Relative risk (RR). 
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 In addition, when serial sections from three breast carcinomas strongly-
staining for MMP2 were doubly IHC-stained for S100A4 (red) and for MMP2 (brown) 
on the same section, there were (mean ± SE) 80.2% ± 2.2% doubly stained cells, 6.9% 
± 0.9% cells stained red for S100A4, 2.9% ± 0.4% cells stained brown for MMP2 and 
9.1% ± 1.5% unstained cells (ANOVA, F = 669.3, 3 df, P<0.001) (Figure 6.1). Thus, 
S100A4 is associated with and partially confounded for patient survival by the three 
MMPs to varying degrees (Ismail et al., 2017). 
 Discussion 
  
IHC staining for both S100 proteins, S100P and S100A4 and for all three MMPs 
was located both in the carcinoma cells as well as in the host cells of the primary 
tumours. Here we considered only staining of the carcinoma cells, since the 
percentage of stained carcinoma cells has previously been shown to be directly 
related to the level of particular proteins in the primary tumour (Rudland et al., 2002, 
2000). That our antibodies recognized the correct proteins is shown by the fact that 
the same antibodies used in Western blots in Chapter 3, yielded the correct size 
bands on SDS-containing polyacrylamide gels. Moreover, prior incubation of the 
specific antibodies with the correct immunizing peptide/protein for both the S100 
proteins (Rudland et al., 2002, 2000) and the MMPs (Ismail et al., 2017) abolished 
completely all the immunohistochemical staining. 
Staining for the S100 proteins in previous publications (Ismail et al., 2010; 
Wang et al., 2006), and for each of the three MMPs as well as that for the combined 
set of MMPs (Figure 6.2 and 6.3) showed a highly significant association with reduced 
patient survival times. Our results for the MMPs and patient survival times with 
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breast cancer are consistent with those previously reported for only one of MMP-2 
(Chen et al., 2015; Li et al., 2017), for MMP-9 (Li et al., 2017) and for MMP-13 (Zhang 
et al., 2008). 
That staining for the MMPs usually occurred in the same tumours as that for 
either of the two S100 proteins can be inferred from the high level of significance of 
association determined from Fisher’s Exact tests of the relevant paired cross 
tabulations (Table 6.2).  Moreover, in at least one case where antibodies for S100A4 
and to MMP-2 were labelled with different chromophores, most of the carcinoma 
cells were doubly stained by both antibodies, whereas relatively few were stained by 
only one or the other antibody (Figure 6.1F). This result demonstrated that S100A4 
and MMP-2 were produced in the same cell, which is consistent with the idea that 
S100A4 triggered, either directly or indirectly the production of MMP-2 in the human 
cancer cells. 
The relative association of staining for one S100 protein was tested against 
staining for the 3 MMPs together and one MMP was tested against the two S100 
proteins together using logistic regression analysis (Table 6.3). Staining for S100A4 
showed a greater propensity to associate with that for MMP-2, whilst that for S100P 
showed a greater propensity to associate with MMP-13. Moreover, staining for 
MMP-9 associated significantly with that for S100A4 and S100P (Table 6.3). These 
results suggest that S100 proteins may target the induction of different combinations 
or even different MMPs and that both S100P and S100A4 may be required to induce 
effectively all 3 MMPs. This differential targeting of MMPs by S100P and S100A4 may 
be one reason for the finding that the occurrences of both S100P and S100A4 in a 
breast tumour significantly enhances the rate of patient death over those patients 
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with only one or the other of the S100 proteins present (Wang et al., 2006). 
Moreover, there would be a requirement for S100P to induce MMP-13 to initiate 
collagen I digestion before S100A4 was required to induce MMP-2 and/or MMP-9 so 
as to complete the digestion of collagen I (Section 1.3.2). If a major metastasis – 
inducing property of S100A4/P is to induce the MMPs, then it would be anticipated 
that S100P should be induced before S100A4 in the development of metastatic breast 
cancer. Preliminary results of immunohistochemical staining for X-ray detected 
premalignant and malignant breast cancer lesions suggest that this is indeed the case 
(Mr. J. Winstanley and Prof. P. S. Rudland, unpublished results). 
 Summary 
 
The effect of S100P and S100A4 on patient survival times was reduced the 
most by MMP-2 in both cases, but MMP-13 reduced the effect of S100P more than 
that of S100A4. The decrease in RR probably reflects the extent of overlap of 
pathways leading to patient death (Ismail et al., 2017). This result would then suggest 
that S100P and MMP-13 pathway overlap more than those of S100A4 and MMP-13 
consistent with the idea advanced in Chapter 3, that S100P and S100A4 promote 
some unique nonoverlapping pathways which lead to patient death and that both 
therefore could work synergistically in promoting patient demise.  
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 Insight and purpose of the Project  
 
The most common mortality amongst females caused by cancer is metastatic 
breast cancer (Egeland et al., 2017; Makoukji et al., 2016). Amongst the most 
common tumour markers in humans involved in stimulating cancer cells to 
metastasise in rodent models are S100P and S100A4 (Egeland et al., 2017; Fei et al., 
2017; Ismail et al., 2017; Makoukji et al., 2016). Cancer cells metastasise, in part, by 
passing though the extracellular matrix (ECM) by a combination of migration and 
invasion. The first component of the ECM encountered by the cancer cells is the 
basement membrane (collagen IV, laminin) and the remaining bulk is an insoluble 
interstitial matrix consisting of components such as collagen I, gelatin, proteoglycan 
and glycoproteins (McCuaig et al., 2017). Thus, cancer cells are required to recruit 
degradative systems to facilitate their passage through this insoluble barrier, these 
systems include degradative proteases such as serine, aspartic, cysteine, threonine 
and metalloproteinases (Brünner et al., 1994) (Chapter 1). Matrix metalloproteinases 
(MMPs) have been reported to be the most common proteases associated with and 
involved in human cancers (Mason and Joyce, 2011). Amongst the many members of 
the family of MMPs involved in cancer, the most commonly reported in breast cancer 
are MMP-2, -9 and -13. These have been reported to be expressed in either the host 
stromal cells of malignant tumours (Singer et al., 2002; Uría et al., 1997), or by the 
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malignant cancer cells themselves, both in vivo and in vitro (Li et al., 2017; Uría et al., 
1997).  
When expression of S100 metastasis-inducing proteins (e.g S100P) have been 
induced in rat mammary and human HeLa cells, their induction causes increased cell 
migration and invasion (Du et al., 2012). Moreover, when stromal cells such as 
fibroblasts have been incubated with conditioned medium from breast cancer cells 
such as MCF-7, they produce MMP-13 (Uría et al., 1997). These facts suggest that 
tumour factors such as S100P or S100A4 produced in breast cancer cells or in adjacent 
host stromal cells could stimulate expression of MMPs, either in the cancer cells 
themselves or in the adjacent stromal cells. The production of these MMPs, in turn, 
could assist the cancer cells to digest the basement membrane (mostly collagen IV) 
(Li, 2003; Yue, 2014) and ECM (mostly collagen I) to encourage cell migration and, 
particularly, cell invasion. Based on these considerations, we started our 
investigations to see whether breast cancer cells, which have raised levels of tumour 
factors like S100P/A4, could stimulate the production of MMPs to facilitate 
migration/invasion of carcinoma cells, as part of the overall process of metastasis.    
7.1.1 Selection of members of MMPs in vitro 
 
A human MMP antibody array was used to scan for MMP expression in R37-
S100P/A4 and S100P-induced HeLa-A3 cell lines. This array consisted of antibodies to 
7 MMPs (MMP-1, -2, -3, -8, -9, -10 and -13) and to 3 TIMPs (TIMP-1, -2 and -4). The 
first investigation showed that all MMPs tested were increased, but only MMP-10 
and MMP-13 were increased significantly in R37-S100P/A4 cell lines (Chapter 3). 
Zymography assay was then used to show which MMP had proteolytic function when 
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released outside the cells. This experiment showed that CM from R37-S100P/A4 cell 
lines produced only MMP-2, -9 and -13 in significantly higher amounts than empty 
vector control cells. Both MMP-2 and MMP-13 released both pro and active forms, 
whilst MMP-9 released only the proform into the culture medium (Chapter 3). Thus, 
from these two experiments, we confined our investigations to these three MMPs, 
MMP-2, MMP-9 and MMP-13, and their relationship with S100P/A4 in model cancer 
cells in vitro and in human breast cancer specimens in vivo.     
7.1.2 Comparison of the effect of intracellular or extracellular S100 
proteins on the expression of MMPs in vitro 
 
Both extracellular addition of or intracellularly-produced S100P/S100A4 
significantly stimulated the levels of MMP-2, -9 and -13 in CL and CM (Chapter 3 and 
5). Moreover, expression of MMP-2, -9 and -13 depended on the presence of S100P 
or S100A4 in our rat mammary cell lines (Chapter 5). Thus, levels of MMP-2, -9 and -
13 increased significantly (P≤0.026) when 1 µM of S100P or S100A4 was added 
extracellularly to these rat mammary cells. These results are consistent with our data 
in Chapter 3, which showed that levels of these MMPs in CL and CM were increased 
significantly (P≤0.035) when S100P/A4 was expressed inside the cells using suitably-
transfected R37-S100P or S100A4 cell lines (Table 7.1).  
The combination of both pro and active forms of MMP-13 or proform of 
MMP-9 showed greater increases under the influence of S100A4 when produced by 
the cells or added extracellularly than the influence of S100P. In contrast, the 
combination of both pro and active forms of MMP-2 showed greater increases under 
the influence of S100P produced from either intracellularly or added extracellular 
than those of S100A4 (Table 7.1). These results suggest firstly that earlier steps for 
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stimulation of production of MMPs by S100 proteins inside and outside cells are 
similar. Secondly, since there are different quantitative changes in the levels of the 3 
MMPs produced by either S100P or S100A4, these results suggest that particular 
S100 proteins can selectively stimulate production of different MMPs. Thus, the 
finding that S100P and S100A4 stimulate different quantitative changes in the MMPs 
in the same cell system represents a novel conclusion in the field.   
In the S100P and S100A4 overexpressing R37 cells (R37-S100P, R37-S100A4), 
the amount of S100P or S100A4 released was 0.215 µg or 0.203 µg, respectively into 
7 mL of CM /10 centimeter diameter dish. This represents concentrations of ~ 3 nM 
and 2.5 nM, respectively. Thus, the concentrations of S100 proteins released from 
R37 cells (Figure 3.1) are sufficient to stimulate appreciable production of MMPs 
reported in Table 7.1. Thus, even in this simple system, there is sufficient amount of 
S100P/A4 generated internally to produce an external effect on the increase in MMP 
production. 
 
Table 7.1. Influence of different sources of S100P/S100A4 on levels of MMP-2, -9 
and -13 in vitro. 
 
 
a Source of S100 proteins; either overexpression inside the R37 cells (intra S100P/A4) or 
added extracellularly to R37 wt cells (extra).  
b Matrix metalloproteinase-2, -9 or -13. 
c, d Fold increase for MMP protein level in cell lysate (CL)c and conditioned medium (CM)d 
compared to either control of R37 empty vector for intra S100P/A4 cell lines, or control of 
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R37 wild type without addition of S100P/A4 for extra S100P/A4 cell lines. All significantly 
different P≤0.035. 
 
7.1.3 Effect of MMPs on cell biological activity produced by S100 
proteins inside or added outside cells in vitro  
 
In this thesis, expression and activation of MMPs can be stimulated by the 
presence of S100P or S100A4 either from inside or added from outside the cells 
(Chapters 3 and 5). Moreover, the presence of S100P and S100A4 inside or added 
outside the R37 cells showed significant increases in cell migration and invasion with 
an approximate ratio of 1:2, respectively (Chapters 4 and 5). Since MMPs have been 
reported to be involved in controlling focal adhesion sites and thereby cell migration 
in vitro (Jessen and Jessen, 2017), one interpretation of this ratio may be that cancer 
cells use the MMPs more for degradation of Matrigel in invasion than use them to 
reduce the number of focal adhesion sites and hence reduce cell migration in vitro. 
Thus, since S100P and S100A4 can also interact directly with myosin-IIA to stimulate 
breast cell migration in culture (Du et al., 2012; Li and Bresnick, 2006), the stimulatory 
effect of either S100 protein is likely to be more pronounced on cell migration than 
that of the MMPs, in agreement with results obtained in Chapters 3 and 4.  
When MMPs were knocked-down in the R37-S100P or S100A4 cells, the 
resultant cells showed a significant reduction in both cell migration and invasion 
(Chapter 4). Similar to the S100 protein-overproducing cell lines, these knocked-
down cell lines showed a much higher fold reduction in cell invasion compared to 
that in cell migration (Figure 4.5), one again suggesting that the effect of the MMPs 
was greater on cell invasion than on cell migration. Knock-down of each MMP 
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individually in R37-S100P or R37-S100A4 cell lines showed reductions in cell invasion 
in the following order: MMP-13/MMP-2 and then MMP-9 (Figure 4.5).  
7.1.4 Association between staining for S100 proteins and MMPs on 
patients’ survival times in vivo and their link to MMPs with S100 
proteins in vitro 
 
In the immunohistochemically-stained breast cancer specimens the relative 
association (RA) of MMPs with S100 proteins was significant (Table 6.3, Set 2) and 
showed higher RAs of MMP-2 and MMP-9 with S100A4, whilst RA of MMP-13 was 
higher with S100P. Our data in Chapter 3 (Table 3.1) showed that the active form of 
MMP-2 and proform for MMP-9 were higher in overexpressing S100A4 cells than in 
overexpressing S100P cells, whilst the active form of MMP-13 showed higher levels 
in overexpressing S100P cells than in overexpressing S100A4 cells. These results for 
the overlapping of expression of S100P or A4 with that of individual MMPs are similar 
in the in vivo and in vitro systems and showed that S100A4 overlaps predominantly 
with MMP-2 and MMP-9 and that S100P overlaps predominantly with MMP-13 in 
either system.  
The relative risk (RR) of patient survival for S100 proteins and MMPs taken 
together in vivo using a series of Cox’s bivariate analyses showed significant 
reductions in patient survival times for all MMP/S100 paired combinations (Table 
6.4). These confounding results showed that individual pathways leading to patient 
death for such pairings overlapped somewhat, but the extent of their overlap varied 
according to the identity of the pair. Thus, a comparison of RRs between anyone of 
MMP-2, MMP-9 and MMP-13 alone with that in the presence of either S100P or 
S100A4 showed that S100A4 had a greater confounding effect and hence overlap 
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than S100P on all 3 MMPs’ pathways leading to patient death (Table 7.2). This 
conclusion is consistent with that obtained on cell invasion in the cell line studies, in 
that knock-down of any one MMP caused a greater reduction in cell invasion 
stimulated by S100A4 than by S100P (Table 4.5). Moreover, the RR for MMP-13 was 
confounded the most in the presence of S100P, and that for MMP-2 the most in the 
presence of S100A4 (Table 7.2), consistent with the knock-down studies on cell 
invasion in vitro (Figure 4.5). The consistency of results obtained on patient survival 
in vivo and cell invasion in vitro for the effect of S100 proteins on MMPs suggest that 
the two biological processes are strongly linked. Thus, a simple interpretation would 
be that a major rate–limiting step in patient death is indeed that of cell invasion, at 
least for the 5 molecules studied here.    
 
Table 7.2. Decrease in relative risk of patient survival for each MMP with one or the 
other S100 protein. 
 
a Percentage reduction in relative risk (RR) for patient survival time of a particular MMP when 
calculated in the presence of S100P or S100A4. Taken from Table 6.4. 
b Matrix metalloproteinase: MMP-2, MMP-9 or MMP-13.  






7.1.5 Role of RAGE receptor in mediating S100 protein interaction 
with MMPs 
 
The most common cell surface receptor reported to be involved with S100 
proteins and their cell signalling is RAGE (Section 1.5.2). When different doses of 
S100P were added to R37 wt cells, they showed a corresponding response in MMP-9 
in the range 0 – 1 µM with half maximum at 4 nM (Figure 5.9). These results raised 
the possibility that a cell surface receptor was involved, and it was found that R37-
S100P or -S100A4 expressed significantly higher levels of RAGE than the still 
appreciable levels found in R37 wt cells (Figure 5.5). The reasons for this increase are 
unknown. When the RAGE receptor was inhibited by its neutralizing antibody, the 
S100P/A4 stimulatory effect on cell invasion was reduced somewhat, either when the 
S100 proteins were produced intracellularly or added extracellularly to the R37 
transfectant or wt cells, respectively (Figure 5.7 and 5.8). This result suggested that 
the RAGE receptor was partially responsible for the S100-induced system that leads 
to increased cell invasion, either when the S100 proteins were produced 
intracellularly or added from the outside. When the RAGE receptor was inhibited in 
the R37 cells with S100P or S100A4 being added externally, cell invasion was reduced 
by about 80 % and 45 %, respectively (Figure 5.6 and 5.7). However, when the RAGE 
receptor was inhibited in stably transfected R37-S100P and R37-S100A4 cells, cell 
invasion was reduced by about 8 % and 83 %, respectively (Figure 4.5 and 5.8). These 
results suggested that the extent of interaction of RAGE with the S100 proteins was 
not the same for S100P and S100A4, and that the source of the S100 proteins was 
important in generating the increase in cell invasion. In general, the RAGE-S100A4 
interaction was a stronger influence on cell invasion than that of RAGE-S100P, either 
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when the S100 proteins were added extracellularly or expressed inside the cells. The 
exception was the comparative lack of effect of the antibody to RAGE on R37-S100P 
cells, producing only an 8 % reduction in cell invasion. These results may suggest that 
intracellular S100A4 works via the RAGE receptor in stimulating cell invasion, but 
intracellular S100P does not. How intracellular S100P/A4 can stimulate the cell 
surface RAGE receptor is unknown. Moreover, since neutralising antibodies only 
suppress the effect of extracellularly-added S100 proteins on cell invasion by 45-80%, 
it is possible that certain S100 proteins can utilize other cell surface receptors to 
generate the extra signals required for maximum cell invasion (e.g. Annexin II; Liu et 
al., 2015).  
 Novel conclusions 
 
 In vitro we demonstrated that MMP-2, -9 and -13 were the only MMPs 
expressed which showed activatable proteolytic activity in the R37 rat mammary cell 
lines. The elevated levels of these MMPs were dependent on S100P/A4 being 
present. MMPs were capable, at least in part, of controlling the migratory and 
invasive abilities of these cultured cells. Both intracellularly synthesised and 
extracellularly-added S100P/A4 could be partially inhibited by anti-RAGE sera in their 
effect on cell invasion. This result suggests that the RAGE receptor was involved, as 
reported previously (Section 1.5), to vary degrees in delivering the intracellular 
signals for cell invasion. In primary breast tumours S100P/A4 and these 3 MMPs were 
individually associated with a higher risk of death of the breast cancer patients. The 
associations between individual S100 proteins and MMPs established in cultured cells 
was largely replicated in clinical specimens in vivo. The new confounding effect of 
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S100P/A4 on RR of individual MMPs suggested that the pathways associated with 
patient death for MMP-13 overlapped more with S100P and those for MMP-2 more 
with S100A4, consistent with MMP knock-down experiments on cell invasion in our 
cultured cells (Chapter 5). Since MMP-13 works more to unwind collagen I before the 
other MMPs can digest it further (eg. MMP-2 and MMP-9) (Sections 1.3.2and 3.1), 
there may be a requirement for both types of MMP in human breast cancer, 
consistent with the synergistic effect of S100P and S100A4 on enhancing premature 


















 Future work 
 
 Tubulin target in Cos-7 cells  
Since the major intracellular target for S100P/A4 proteins is nonmuscle 
myosin IIA (NMIIA) (Du et al., 2012; Kiss et al., 2016), it is not clear if S100P/A4 can 
initiate the changes in MMPs inside and even outside the cells, either in whole or 
in part, by binding solely to this component. To investigate whether this is a 
necessary first step, a monkey kidney Cos-7 cell line devoid of NMIIA will be 
utilised (Rai et al., 2017). In the past the S100P-NMIIA interaction has been studied 
in vitro using the inducible HeLa-A3 and R37-T25 cell lines (Du et al., 2012). In these 
systems, overexpression of S100P was shown to lead to a reduction in polymerised 
NMIIA (actomyosin fibers) and focal adhesions which, in turn, increased their 
ability to reduce anchoring forces and increase cell migration and invasion. 
Recently the equivalent S100P-inducible cell line has been produced from these 
NMIIA-deficient Cos-7 cells (Du et al., 2015). In these cells, S100P has been shown 
to interact with tubulin and to alter its dynamics of polymerisation, as well as 
stimulating cell migration (Du et al., 2015). The interaction between tubulin and 
S100P can be blocked by a specific peptide in the test tube. When this peptide is 
attached to a suitable signal sequence, it can penetrate these cells and inhibit cell 
migration, so demonstrating the importance of the S100P-tubulin interaction in 
promoting cell migration, independently of NMIIA, in these Cos-7 cells (Du et al., 
2015).   
My aim would be: firstly, to see if the same MMPs and cell invasion, as 
described in my thesis for the rat mammary cell line, are induced in these S100P-
inducible Cos-7 cells. Secondly, to use the S100P-tubulin inhibitory peptide to 
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test whether both MMP production and cell invasion are inhibited. Thirdly, to 
see if addition of S100P/A4 extracellularly to Cos-7 parental cells also stimulates 
MMP production and invasion, and whether these events can be inhibited by the 
same tubulin-blocking peptide. If successful, these results should identify the 
same or different MMPs induced by S100P in the Cos-7 monkey kidney cells, and 
link them to cell invasion, so as to generalise my results obtained from rat 
mammary cells. Secondly, they would demonstrate that intracellular S100P can 
interact with tubulin rather than NMIIA, to induce MMPs and cell invasion in the 
Cos-7 cells. Thirdly, when applied from the outside to investigate whether 
S100P/A4 can still stimulate, or not as the case may be, induction of MMPs and 
cell invasion, and if they do, whether the extracellular addition of S100P/A4 still 
requires their binding to the cytoskeletal component, tubulin inside the cell, at 
least in Cos-7 cells.  
In this way I should be able to dissect out in more detail S100P/A4-induced 
intracellular pathways that may lead to increases in MMPs and in cell invasion in 
Cos-7 cells. With further experimentation along similar lines in the original rat 
mammary cells, I should then be able to define the relative contribution of 
differing pathways involving NMIIA, tubulin, RAGE and indeed any other receptor 
which may further the S100P/A4 induction of MMPs and cell invasion, all in one 
cell system. In this way I should be able to clarify what are completely confusing 
studies reported in the literature at present regarding a plethora of targets for 





 Stromal-epithelial interactions 
At a more general level, the abnormal tumour microenvironment (TME) 
which surrounds growing tumours can facilitate their development, progress and 
even their drug resistance (McCuaig et al., 2017). However, how these 
mechanisms work is still largely unknown (McCuaig et al., 2017). Moreover, 
patient profiling strategies for cancer-drug treatments, immunotherapy and the 
use of biomarkers requires a thorough understanding of both compartments of 
the tumour: the epithelial tissue and the TME, and how they interact in the 
development of the cancer. The TME contains cells of mesenchymal and 
haematopoietic origin, as well as noncellular components. Most mesenchymal 
cells in the TME are fibroblasts-myofibroblasts and the noncellular insoluble 
component is the extracellular matrix (ECM), largely consisting of collagens and 
to a lesser extent of proteoglycans and glycoproteins.  
The purpose of possible future work would be to investigate the interactions 
between the surrounding TME and the carcinoma cells and how they facilitate 
cell invasion. I have recently been introduced to the chick embryo model, 
whereby cancer cells can be implanted on the chick chorioallantoic membrane 
and allowed to grow into a tumour and invade, while the embryo itself develops 
in a relatively immune-supressed environment (Ribatti, 2016). This could be an 
ideal model to study a reconstituted host cell and cancer cell interaction, since 
the development of the tumour as it invades can be followed for up to 14 days 
in the egg, using a variety of detection systems.     
For example, I could transplant fibroblasts from different sources e.g. 
fibroblasts from normal breast tissue and myofibroblasts from breast cancer 
160 
 
(Chatterjee et al., 2018) with breast cancer cell lines, with the aim of determining 
whether the source of fibroblasts alters invasive capacity of the carcinoma cells. 
Once I have identified that there were differences in the fibroblasts from 
different sources as already recorded by others (Chatterjee et al., 2018), I could 
then screen for differentially-expressed mRNAs using standard high-through-put 
nucleotide-sequencing systems. I could then select those differentially expressed 
genes, that seemed appropriate for further study; in my case perhaps focussing 
on the degradative proteinases. By a combination of knock-in and knock-out 
experiments, I could then go on to identify invasion-enhancing genes for the 
carcinoma cells, first of all screening in a Matrigel/Boyden chamber assay, and 
then in the chick embryo system. In this way I should be able to identify invasion-
stimulatory factors in the cancer fibroblasts, hopefully relating to collagen-
degradative enzymes of the ECM, like the MMPs. A similar series of experiments 
could then identify the agents produced by the cancer cells that impinge on the 
fibroblasts to stimulate their release of invasion-stimulating factors like the 
MMPs. Since S100 proteins are some of the most abundant proteins produced 
by cancer cells (Bresnick et al., 2015), it is possible that their release from the 
carcinoma cell, may be the trigger, in turn, for the fibroblasts to release MMPs. 
In this way I may be able to identify some of the cross-talk necessary at the 
molecular level between the ECM and the carcinoma cells for cancer invasion 
that my studies of the extracellular effects of S100P/A4 on MMPs and cell 
invasion have suggested in the homogeneous rat mammary epithelial cell system 
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Appendix  1. Full length gel for overexpression of S100P and S100A4 proteins in 
transfected rat mammary cell lines.  
(A) Cell lysate (CL) from stably transfected Rama 37 with empty vector (R37 E.V.) or from 
Rama 37 with S100P (R37-S100P) cell lines. (B) Cell lysates (CL) from R37 E.V. or from R37-
S100A4 cell lines were run on similar SDS-PAGE gels. In controls, recombinant 5 or 10 ng 





Appendix  2. MMP array for the rest of the MMPs: MMP-1, MMP-3, MMP-8 and 




a Matrix metalloproteinase. 
b Fold increase over control cells (mean±SE, n=3) with corresponding P value (Student’s t-test, 
2-tailed). 
c S100P-Induced human cervical cancer cell line. 
d S100P cDNA stably transfected rat mammary cell line. 













Appendix  3. Knockdown of MMP-2 with siRNA for MMP-2 (si-MMP-2) or scrambled 
(si-scrambled) for 48 and 72 hours (h). 
 Western blots for MMP-2, MMP-9 and MMP-13 from the same intracellular sample of the 
R37-S100P cell line are shown. Results show that preMMP-2 (72 kDa) was knocked down 
almost completely by 72 h (P≤0.02) (Section 4.2.1.1 and Figure 4.1). In contrast, preMMP-9 
(92 kDa) and preMMP-13 (50 kDa) were not significantly (P≥0.380) affected for the mean of 





Appendix  4. Micrographs of migration and invasion assays for the Rama 37-S100P 
(R37-S100P), Rama 37-S100A4 (R37-S100A4) and Rama 37 empty vector (R37 E.V.) 
control cell lines. 
 (A & B) Representative images showing (A) Boyden chambers for cell migration and (B) 
Matrigel chambers for cell invasion assays, after culturing for 24 hours. Underside of 
membranes were photographed with a light microscope using a 4 x objective. Red bar = 100 
µm. Three chambers for each group were used for migration or invasion assays and each 
experiment was performed three times (Sections 2.13 and 2.14). Quantitative details are 








Appendix 5. Micrographs of migration and invasion assays of S100P/S100A4 
overexpressing rat mammary cell lines after siRNA knock-down of different MMPs. 
(A & B) Representative images showing (A) Boyden chambers for cell migration and (B) 
Matrigel chambers for cell invasion assays, after culturing for 24 hours. Undersides of 
membranes were photographed with a light microscope using a 4 x objective. Red bar = 100 
µm. Three chambers for each group were used for migration or invasion assays and each 
experiment was performed three times (Sections 2.13 and 2.14). Quantitative details are 
shown in Figure 4.5.  
Abbreviations of cell lines and procedures used: P (R37-S100P cells), A4 (R37-S100A4 cells), 
si (siRNA), 2 (against MMP-2), 9 (against MMP-9), 13 (against MMP-13), all (against MMP-2, 







Appendix  6. Data for IHC staining of S100 proteins and MMPs in patients’ specimens. 
AnonNosa MMP2b MMP2at5%c MMP9d MMP9at5%e MMP13f MMP13at5%g S100A4h 
 
S100A4at5%i S100Pj S100Pat5%k SurvMonthsl 
286 1 0 1 0 1 0 1 0   231.37 
4 2 0 1 0 1 0 5 1   166.62 
6 1 0 2 0 4 1 3 1 2 0 226.22 
289 4 1 3 1 2 0 2 0 5 1 224.54 
290 2 0 1 0 1 0 2 0 2 0 72.08 
291 1 0 1 0 1 0 3 1 4 1 91.59 
9 3 1 2 0 3 1 3 1 2 0 36.37 
11 2 0 1 0 1 0 5 1 1 0 219.97 
12 1 0 2 0 1 0 1 0 1 0 219.74 
294 1 0 1 0 1 0 3 1 4 1 76.77 
295 3 1 1 0 3 1 3 1   43.73 
297 1 0 1 0 1 0 1 0 1 0 218.3 
13 1 0 2 0 2 0 1 0   217.87 
298 1 0 1 0 1 0 1 0 2 0 167.94 
15 2 0 2 0 1 0 1 0 3 1 104.47 
16 3 1 2 0 3 1 5 1 5 1 99.9 
18 4 1 3 1 4 1 3 1 3 1 19.12 
19 2 0 1 0 1 0 4 1 3 1 85.61 
20 2 0 1 0 1 0 1 0 2 0 106.83 
301 1 0 1 0 1 0 1 0 2 0 214.82 
302 3 1 1 0 1 0 2 0 3 1 166.92 
24 2 0 1 0 4 1 1 0 1 0 212.39 
303 4 1 1 0 4 1 4 1 3 1 191.06 
25 2 0 1 0 2 0 1 0 1 0 212.06 
199 
 
26 2 0 2 0 3 1 1 0 3 1 41.62 
304 1 0 1 0 1 0 1 0 1 0 211.89 
27 3 1 2 0 2 0 3 1   78.02 
305 5 1 1 0 3 1 3 1 3 1 53.25 
307 3 1 4 1 3 1 2 0 2 0 96.68 
308 2 0 2 0 1 0 1 0 1 0 143.82 
310 1 0 1 0 1 0 3 1 2 0 79.7 
311 1 0 1 0 1 0 1 0 1 0 207.52 
32 1 0 2 0 4 1 1 0 3 1 207.33 
99 4 1 3 1 4 1 3 1 5 1 46.71 
34 3 1 1 0 4 1 4 1   48.82 
71 1 0 1 0 1 0 1 0 1 0 206.64 
72 1 0 1 0 1 0 1 0   206.6 
100 2 0 3 1 5 1 3 1 4 1 46.06 
73 1 0 1 0 1 0 1 0 1 0 206.41 
312 4 1 1 0 2 0 3 1 1 0 48.59 
35 5 1 2 0 4 1 4 1 4 1 76.31 
36 2 0 1 0 1 0 1 0 3 1 206.34 
74 1 0 2 0 1 0 1 0 1 0 206.11 
38 2 0 3 1 3 1 3 1 3 1 33.9 
313 3 1 1 0 1 0 2 0 4 1 74.31 
314 1 0 1 0 1 0 1 0 1 0 204.99 
75 1 0 1 0 2 0 1 0 2 0 204.96 
40 5 1 5 1 5 1 3 1 3 1 50.95 
317 5 1 1 0 3 1 2 0 5 1 106.44 
41 2 0 1 0 1 0 1 0 2 0 203.42 
76 4 1 1 0 4 1 3 1 3 1 64.45 
200 
 
43 1 0 1 0 1 0 1 0 1 0 202.96 
321 1 0 1 0 2 0 2 0 2 0 1.97 
45 1 0 2 0 1 0 3 1   89.49 
46 3 1 2 0 4 1 1 0 5 1 91.03 
103 5 1 3 1 5 1 4 1 4 1 21.65 
104 4 1 3 1 5 1 3 1 5 1 91.72 
107 5 1 1 0 5 1 1 0   51.31 
77 5 1 1 0 2 0 3 1   53.32 
322 1 0 1 0 1 0 1 0 1 0 55.32 
78 2 0 1 0 1 0 3 1 3 1 54.5 
79 2 0 1 0 1 0 1 0 3 1 43.43 
80 2 0 2 0 2 0 1 0 3 1 44.91 
108 4 1 2 0 3 1 3 1 3 1 4.24 
109 5 1 3 1 5 1 2 0 5 1 10.15 
110 2 0 1 0 3 1 1 0   52.37 
113 2 0 1 0 3 1 2 0 5 1 104.57 
114 2 0 1 0 5 1 2 0 5 1 44.58 
325 5 1 1 0 3 1 2 0 3 1 151.77 
326 5 1 5 1 5 1 3 1 5 1 25.49 
115 1 0 2 0 3 1 4 1   3.25 
81 4 1 1 0 1 0 2 0 2 0 21.71 
48 3 1 1 0 2 0 3 1 5 1 21.25 
330 1 0 1 0 1 0 1 0 1 0 43.63 
82 1 0 1 0 1 0 1 0 1 0 198.75 
117 3 1 4 1 5 1 3 1 5 1 7.33 
122 5 1 3 1 5 1 3 1 5 1 51.38 
331 1 0 1 0 1 0 1 0 1 0 209.79 
201 
 
123 1 0 1 0 3 1 1 0 3 1 51.71 
125 2 0 1 0 3 1 1 0 4 1 42.12 
126 3 1 1 0 3 1 1 0 2 0 197.21 
128 5 1 2 0 4 1 2 0 5 1 139.95 
129 4 1 2 0 4 1 2 0 4 1 28.42 
130 2 0 1 0 4 1 1 0 5 1 63.63 
52 1 0 1 0 1 0 3 1 2 0 197.54 
131 3 1 4 1 3 1 3 1 4 1 36.07 
133 5 1 3 1 4 1 3 1 5 1 16.26 
83 1 0 1 0 1 0 1 0   196.22 
334 1 0 1 0 1 0 1 0 1 0 117.97 
335 1 0 1 0 1 0 1 0 2 0 146.19 
84 4 1 4 1 4 1 2 0 5 1 162.32 
337 1 0 1 0 1 0 1 0 2 0 193.99 
339 3 1 1 0 4 1 2 0 4 1 26.54 
340 1 0 1 0 2 0 1 0 1 0 193.76 
56 1 0 1 0 1 0 1 0 1 0 12.98 
57 1 0 1 0 1 0 1 0 1 0 83.25 
58 2 0 2 0 1 0 3 1 3 1 57.65 
59 1 0 1 0 1 0 2 0 3 1 40.11 
85 4 1 1 0 3 1 3 1 2 0 36.79 
86 3 1 3 1 4 1 3 1 3 1 9.49 
342 1 0 1 0 1 0 2 0 3 1 33.28 
140 2 0 1 0 2 0 1 0 2 0 191.92 
141 5 1 1 0 4 1 3 1 5 1 35.81 
60 3 1 1 0 2 0 1 0 4 1 41.39 
343 2 0 1 0 1 0 1 0 2 0 55.16 
202 
 
146 2 0 2 0 3 1 1 0 2 0 190.08 
147 3 1 2 0 2 0 3 1 4 1 50.85 
149 1 0 1 0 3 1 1 0 2 0 189.85 
152 2 0 1 0 1 0 1 0 2 0 189.82 
61 5 1 2 0 1 0 4 1 3 1 32.42 
92 4 1 1 0 2 0 3 1 4 1 22.83 
154 5 1 3 1 4 1 4 1 3 1 43.4 
156 4 1 1 0 4 1 3 1 4 1 64.22 
93 1 0 1 0 1 0 1 0   100.33 
157 1 0 1 0 3 1 3 1 2 0 109.82 
94 2 0 1 0 1 0 1 0 1 0 188.7 
158 3 1 2 0 4 1 4 1 5 1 5.72 
161 2 0 1 0 4 1 3 1 4 1 27.5 
162 1 0 1 0 2 0 1 0 2 0 188.4 
163 5 1 4 1 5 1 3 1 4 1 12.58 
346 1 0 1 0 1 0 1 0 1 0 188.01 
96 5 1 4 1 5 1 2 0 2 0 6.18 
347 3 1 1 0 4 1 3 1 4 1 34.86 
348 2 0 2 0 1 0 1 0 2 0 187.48 
97 2 0 1 0 1 0 1 0 2 0 187.09 
175 1 0 1 0 1 0 1 0 1 0 186.86 
350 2 0 1 0 2 0 1 0   186.83 
64 2 0 2 0 2 0 3 1   23.69 
65 1 0 1 0 1 0 1 0 2 0 186.4 
98 4 1 2 0 3 1 3 1 3 1 3.94 
182 2 0 1 0 4 1 1 0 4 1 30.12 
183 2 0 1 0 2 0 1 0 3 1 107.88 
203 
 
351 2 0 3 1 4 1 3 1   25.49 
184 3 1 1 0 2 0 2 0 3 1 185.28 
185 4 1 2 0 4 1 3 1 4 1 170.07 
186 1 0 1 0 2 0 1 0 2 0 185.25 
188 1 0 1 0 2 0 1 0 2 0 185.18 
189 2 0 1 0 2 0 1 0 4 1 29.63 
352 4 1 1 0 1 0 3 1 4 1 32.23 
353 3 1 1 0 3 1 3 1 3 1 37.22 
354 1 0 1 0 2 0 1 0 1 0 184.56 
69 2 0 1 0 3 1 3 1 5 1 28.84 
202 3 1 1 0 3 1 1 0 4 1 87.65 
355 1 0 1 0 1 0 4 1   56.67 
205 5 1 1 0 4 1 3 1 4 1 105.49 
206 4 1 2 0 5 1 5 1 5 1 82.85 
207 2 0 1 0 2 0 1 0 1 0 182.65 
210 4 1 3 1 4 1 2 0 2 0 182.26 
211 2 0 1 0 2 0 1 0 2 0 182.16 
212 1 0 1 0 1 0 1 0 2 0 182.06 
218 2 0 1 0 2 0 3 1 3 1 181.04 
222 2 0 1 0 2 0 1 0 2 0 180.19 
223 1 0 1 0 3 1 2 0 4 1 180.19 
224 1 0 1 0 2 0 1 0 1 0 179.4 
227 1 0 2 0 3 1 1 0 1 0 179.04 
235 3 1 2 0 2 0 1 0 1 0 176.02 
236 1 0 1 0 2 0 1 0 2 0 175.99 
237 2 0 1 0 3 1 1 0 3 1 175.82 
239 1 0 1 0 3 1 1 0 2 0 174.41 
204 
 
240 2 0 1 0 3 1 1 0 1 0 173.75 
241 2 0 1 0 2 0 1 0   173.55 
242 1 0 1 0 2 0 1 0 2 0 172.5 
243 3 1 3 1 5 1 3 1 5 1 53.48 
244 2 0 1 0 2 0 1 0 1 0 172.14 
245 1 0 1 0 1 0 1 0 1 0 185.71 
247 3 1 3 1 4 1 3 1 3 1 12.84 
248 4 1 1 0 5 1 4 1 5 1 41.03 
252 3 1 3 1 4 1 3 1 3 1 32.33 
255 3 1 2 0 4 1 3 1 4 1 29.43 
357 4 1 1 0 4 1 1 0 1 0 179.63 
259 3 1 2 0 4 1 3 1 2 0 16.06 
262 4 1 1 0 4 1 2 0 2 0 18.82 
264 2 0 1 0 5 1 3 1 5 1 80.72 
267 1 0 2 0 2 0 1 0 2 0 176.31 
268 5 1 1 0 5 1 2 0 2 0 1.48 
269 3 1 1 0 5 1 3 1 3 1 48.06 
270 5 1 3 1 3 1 3 1 4 1 7.03 
272 5 1 1 0 2 0 2 0 2 0 15.34 
275 5 1 4 1 4 1 3 1 2 0 27.53 
276 1 0 1 0 2 0 1 0 2 0 173.52 
279 3 1 1 0 3 1 1 0 1 0 221.78 
281 3 1 1 0 4 1 3 1   21.68 
282 5 1 1 0 4 1 3 1 2 0 53.35 
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a Anonymised case number. 
b Staining for MMP2 (1-5 staining categories: 1= -, 2= +/-, 3= +, 4= ++, 5= +++). 
c Two staining categories: 0= - or <5% positive staining, 1= + or >5% positive staining. 
d MMP9 = MMP9 (1-5 staining categories). 
e Two staining categories: 0= - or <5% positive staining, 1= + or >5% positive staining. 
f Staining for MMP13 (1-5 staining categories). 
g Two staining categories: 0= - or <5% positive staining, 1= + or >5% positive staining. 
h Staining for S100A4 (1-5 staining categories). 
i Two staining categories: 0= - or <5% positive staining, 1= + or >5% positive staining. 
j Staining for S100P (1-5 staining categories). 
k Two staining categories: 0= - or <5% positive staining, 1= + or >5% positive staining. 
l Patient survival time in months. 
 
